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ABSTRACT 
 
Structural Insights into the Enzymes of the Serine and Biotin Biosynthetic Pathways in  
Mycobacterium tuberculosis. (August 2008) 
Sanghamitra Dey, B.S.; M.S., Nagpur University, India 
Chair of Advisory Committee: Dr. James C. Sacchettini 
 
Mycobacterium tuberculosis (Mtb) utilizes different metabolic pathways for its 
survival during infection. Enzymes of these pathways are often targets for antibiotic 
development. Genetic studies indicate the importance of the serine and biotin 
biosynthetic pathways for Mtb survival. In this study, enzymes from these pathways 
were characterized using X-ray crystallographic and biochemical studies.  
 D-3-phosphoglycerate dehydrogenase (PGDH) catalyzes the first step of 
phosphorylated serine biosynthesis. In comparison to other forms of PGDH, the Mtb 
enzyme has an insertion near its C-terminus. This insertion results in two different 
conformations of the subunits in the tetramer, leading to two different environments for 
cofactor binding. This intervening domain might provide a second binding site for 
hydroxypyruvic acid phosphate (HPAP) that is responsible for substrate inhibition. 
Analysis of the HPAP-bound Mtb PGDH active site reveals the residues (Arg52, 
Arg131, and Arg233) involved in substrate interaction and provides insights into a 
possible enzyme mechanism. Mtb PGDH is feedback inhibited by the end product L-
serine. Examination of the serine-bound PGDH structure elucidates the key players 
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(Tyr461, Asp463, and Asn481) involved in this allosteric inhibition, as well as the 
resultant conformational changes at the regulatory domain interface.  
Preliminary biochemical studies of the first enzyme in Mtb biotin biosynthesis, 7-
keto-8-aminopelargonic acid (KAPA) synthase show that it exists as a dimer in solution 
and has higher substrate affinity than the E. coli enzyme.  
The second enzyme, 7, 8-diaminopelargonic acid synthase (DAPAS) uses S-
adenosyl methionine and KAPA as substrates in a bi-bi ping-pong mechanism. A 
comparison of the substrate analog sinefungin-bound Mtb DAPAS structure with a 
KAPA-bound DAPAS model provides a basis for the dual-substrate recognition. Tyr25 
is a key player in the substrate specificity in DAPAS; this was confirmed by mutation 
studies. In certain Bacillus species, a Phe replaces this Tyr. The KAPA-bound B. subtilis 
DAPAS structure shows an alteration in the KAPA binding mode. 
Substrate and product bound structures of the third enzyme, dethiobiotin 
synthetase (DTBS) in Mtb reveal the important residues involved in its catalysis and 
provide framework for a possible enzyme mechanism. Comparison to the DTBS 
structures from E. coli and H. pylori reveals differences in local conformations. 
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NOMENCLATURE 
 
A Alanine 
ACT Aspartokinase - chorismate mutase – TyrA 
ADP Adenosine-5'-diphosphate 
Ala Alanine 
AMP-PCP Adenylylmethylenediphosphonate 
AMPSO N-(1,1-Dimethyl-2-hydroxyethyl)-3-amino-2-hydroxypropane 
sulfonic acid 
 
Arg Arginine 
ASU Asymmetric unit 
Asp Aspartate 
Asn Asparagine 
ATP Adenosine-5'-triphosphate 
CNS Crystallography & NMR system 
CoA Coenzyme A 
Cu Copper 
Cys Cysteine 
D Aspartate 
DAPA 7, 8-diaminopelargonic acid 
DAPAS 7, 8-diaminopelargonic acid synthase 
DNA Deoxyribonucleic acid 
DTB Dethiobiotin 
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DTBS Dethiobiotin synthetase 
DTT Dithiothreitol 
F Phenylalanine 
G Glycine 
Gln Glutamine 
Gly Glycine 
Glu Glutamate 
His Histidine 
HPAP Hydroxypyruvic acid phosphate 
HTS High throughput screening 
I Isoleucine 
Ile Isoleucine 
IPTG Isopropyl-1-thio β-D-galactopyranoside 
KAPA 7-keto, 8-aminopelargonic acid 
kDa Kilo Dalton 
kbps kilo base pairs 
LLG Log likelihood gain 
M Methionine 
MAD Multiple anomalous dispersion 
MES 2-(N-morpholino)ethanesulfonic acid 
Met Methionine 
Mg Magnesium 
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MIR Multiple isomorphous dispersion 
MR Molecular replacement 
Mtb Mycobacterium tuberculosis 
N Asparagine 
NAD Nicotinamide adenine dinucleotide 
NBD Nucleotide-binding domain 
NIP Nitrogenase iron protein 
PAGE Polyacrylamide gel electrophoresis 
PCR Polymerase chain reaction 
PDB Protein data bank 
PEP Phosphoenol pyruvate 
PGDH D-3-phosphoglycerate dehydrogenase 
Phe Phenylalanine 
PIPES Piperazine-1,4-bis(2-ethanesulfonic acid) 
Pi Inorganic phosphate 
PLP Pyridoxal-5′-phosphate 
PMP Pyridoxamine-5′-phosphate 
PMSF Phenyl methyl sulfonyl fluoride 
Pro Proline 
RD Regulatory domain 
R.M.S.D. Root mean square deviation 
SAD Single anomalous dispersion 
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SAH S-adenosyl homocysteine 
SAM S-adenosylmethionine  
SBD Substrate-binding domain 
SDS Sodium dodecyl sulphate 
SeMet Selenomethionine 
Ser Serine 
Sm Samarium 
TB Tuberculosis 
TCEP Tris (2-carboxyethyl) phosphine hydrochloride 
TEV Tobacco etch virus  
TLS Translation libration screw 
Trp Tryptophan 
Tyr Tyrosine 
V Valine 
Val Valine 
VS Virtual screening 
W Tryptophan 
Y Tyrosine  
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CHAPTER I 
INTRODUCTION 
 
The different stages of infection in Mycobacterium tuberculosis (Mtb) are poorly 
understood. Mtb causes the deadly disease tuberculosis in humans so it is very important 
to study the various stages of its infection as well as its mode of virulence. With the 
availability of the genome sequence of Mtb and several genetic approaches, we have 
been able to identify the importance of various genes involved in different metabolic 
pathways. Detailed knowledge of the enzymes of these pathways that are absent or have 
alternate mechanisms or regulation in humans will be helpful in the elimination of 
tuberculosis. Genetic studies show that enzymes of the serine and biotin biosynthetic 
pathways are crucial for mycobacterial survival. In this dissertation, we have 
characterized, biochemically as well as structurally, some of the enzymes of these 
pathways. X-ray crystal structures of these enzymes shed light on the overall folds and 
on the basis of substrate/inhibitor recognition. The kinetic and structural features of these 
enzymes can be further used in the development of potential inhibitors. 
 
 
 
_____________ 
This dissertation follows the style of Journal of Biological Chemistry. 
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General description of Mycobacterium tuberculosis 
Mycobacterium tuberculosis (Mtb) belongs to the class Actinomycetes and is, 
thus, closely associated with Corynebacterium and Nocardia species. Identified in 1882 
by Robert Koch, Mtb is a rod shaped, aerobic, non-spore forming bacterium that has a 
complex cell wall containing mycolic acid. This intracellular and intravacuolar pathogen 
is responsible for causing the deadly disease of tuberculosis in humans. Initially, tubercle 
bacilli are transmitted via nasal droplets, aerosolized in the form of a sneeze or cough by 
the infectious person. Most of these bacteria are generally killed by the host immune 
system. However, some of these mycobacteria can still escape the host’s defenses and 
start replicating inside the alveolar macrophages. During the process of infection, these 
acid-fast bacilli employ several different strategies for their survival. Mtb resides in the 
macrophages, avoiding phagosome - lysosome fusion through surface sulfatides (1) and 
impeding acidification or maturation of phagosomes by excluding vesicular proton-
ATPase (2). Mtb also tolerates the presence of reactive oxygen and nitrogen 
intermediates in macrophages by producing detoxifying enzymes like catalase and 
superoxide dismutase (3).  
Once adapted to the phagosomal environment, the bacteria continue to multiply 
exponentially in the vesicles, lysing the macrophage due to high bacterial population and 
subsequently being engulfed by the neighboring activated macrophages. This process of 
struggle between the host immune system and the mycobacterium ultimately leads to the 
formation of granulomas with the recruitment of host CD4+ T cells. In this way, the 
mycobacteria remain contained inside these granulomas and are no longer infectious. 
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This stage of infection is called the latent state of TB. With a strong host immune 
system, the granulomas can slowly heal, leaving mild abrasions in their place. However, 
any weakness in the host immune system due to HIV infection, malnutrition, aging or an 
immunosuppressant can lead to the breakdown of these granulomas. This breakdown 
results in the release of infectious bacteria which travels through the blood and 
lymphatic system to the lungs and other tissues. Under these conditions, a person 
becomes chronically infected and needs antibiotics to kill these bacteria. Sadly, there are 
as many as 200 million people with this latent stage infection who are prone to 
reactivation leading to chronic infection (4). 
Even though the morphology of the mycobacterium, its physiology in cell 
cultures, and the immune response of the host against the mycobacterial infection are 
well characterized, the lifecycle of Mtb during its pathogenesis is still not completely 
understood, especially not during the latent stage. Most of the currently effective drugs 
are futile against this stage of bacterial infection. However, a major achievement in TB 
research in this direction was the annotation of the whole genome of Mtb (lab strain 
H37Rv) in 1998 (5). The circular genome of this strain of Mtb has a high GC content of 
about 65% and encodes 4000 genes (5). Still, 14% of these genes, which might be 
essential, could not be assigned any function.  
In recent years, extensive research using different genetic approaches (high 
throughput mutagenesis with transposon insertion, microarray-based genomic and 
transcriptome profiling) has enlightened us, to some extent, about the lifecycle of 
mycobacterium during different stages of infection and about its diverse virulence 
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mechanisms (6, 7). Mutation studies have led to the identification of genes involved in 
various metabolic pathways, which are required at different stages of mycobacterial 
infection in macrophages (8) and in the mice (9). The microarray analyses allow us to 
analyze the pattern of gene expression in Mtb under different physiological conditions 
analogous to the host environment during pathogenesis. Genes that are upregulated or 
downregulated due to different environmental conditions are thought to be important for 
the survival of this mycobacterium. This valuable information, coupled with the 
knowledge of the human genome, makes it easier for us to pinpoint the metabolic 
pathways necessary at different stages of mycobacterial infection that will not be 
important or present in host cells. Such metabolic pathways of interest are lipid 
metabolism, amino acid metabolism, carbohydrate metabolism, vitamin, and cofactor 
metabolism. It is further anticipated that the inhibitors designed against enzymes of these 
pathways will result in quick bacterial clearance. Thus, it is worthwhile to study the 
biochemical and the structural features of the enzymes from mycobacterial metabolic 
pathways in order to possibly use them as templates in the search for better 
antimicrobials. 
To this end, the focus of this dissertation is on the biochemical and three-
dimensional structural analyses of enzymes involved in two different metabolic 
pathways: the serine and biotin biosynthetic pathways.  
Serine biosynthesis 
From the genome sequence analysis, it appears likely that mycobacteria have all 
the amino acid metabolic pathways common to other bacteria. However, differences may 
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lie in the mechanism of regulation of the metabolites either by feedback inhibition or by 
repression of the enzyme synthesis. L-serine is the predominant source of one-carbon 
units, in the metabolism of amino acids like methionine and histidine, and in the de novo 
synthesis of purines and pyrimidines (10). This reversible reaction of conversion of 
serine to one-carbon unit glycine is catalyzed by serine hydroxymethyl transferase 
(SHMT) (11). L-serine also serves as a precursor for the synthesis of other amino acids 
like D-serine, cysteine and its derivative taurine, as well as phospholipids. 
 Though serine is considered to be nonessential due to the presence of all the 
enzymes needed for its synthesis in the cell, sometimes it can not be produced at an 
adequate rate to satisfy the needs of the proliferating cells, thereby making it a 
"conditional essential" (12). Humans with a deficiency in serine biosynthesis show a 
marked decline in serine and glycine concentrations in plasma and cerebrospinal fluid. 
This deficiency is the cause of several neurological disorders like congenital 
microcephaly, dysmyelination, intractable seizures and psychomotor retardation (13-15). 
There are two common pathways by which serine can be synthesized: the 
phosphorylated and non-phosphorylated pathways. 
Phosphorylated pathway of serine biosynthesis 
L-serine can be synthesized from the glycolytic intermediate, D-3-
phosphoglycerate (3-PGA) through the phosphorylated pathway of serine biosynthesis. 
This pathway, first reported by Ichihara and Greenberg (16), is most commonly used by 
organisms for serine production. D-3-phosphoglycerate dehydrogenase (serA, PGDH, 
EC 1.1.1.95) catalyzes the first step of the oxidation of D-3-phosphoglycerate to 
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hydroxypyruvate phosphate (HPAP), utilizing NAD+ as a cofactor. Subsequently, HPAP 
is converted to phosphoserine by phosphoserine transaminase (serC, PSAT, EC 2.6.1.52) 
requiring pyridoxal-5′-phosphate (PLP) as a cofactor. This phosphoserine is further 
dephosphorylated into L-serine by phosphoserine phosphatase (serB, PSP, EC 3.1.3.3) 
(Figure 1.1). Annotation of the Mtb (H37Rv lab strain) genome shows the presence of all 
three genes (Rv2996c, Rv0884c, Rv0505c) of this pathway on different operons of this 
genome. However, very little was known about these enzymes in Mtb until we started 
exploring the first enzyme of this pathway. In early 2007, Baker et al. determined the 
crystal structure of the third enzyme of this pathway, phosphoserine aminotransferase 
(PDB code-2FYF) in Mtb but no further biochemical characterization of this enzyme has 
been reported. 
 
FIGURE 1.1. Phosphorylated pathway of serine biosynthesis 
Non-phosphorylated pathway of serine biosynthesis 
L-serine can also be synthesized in a non-phosphorylated pathway using D-
glycerate as the starting material, as studied in detail by H. J. Sallach (17, 18). D-
glycerate, acquired from D-2-phosphoglycerate of the glycolytic pathway, is further 
oxidized to hydroxypyruvate using NAD+-dependent D-glycerate dehydrogenase (GDH, 
EC 1.1.1.29). L-serine is then produced by serine pyruvate aminotransferase (SPT, EC 
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2.6.1.51) requiring PLP as a cofactor (Figure 1.2). This non-phosphorylated pathway has 
been found in mammals (19), plants (20, 21) and some microbes, such as the unicellular 
protozoan E. histolytica (22). However, there is no evidence which suggests the 
existence of these enzymes in Mtb. This pathway has been thought to be more involved 
in serine catabolism than its biosynthesis due to the presence of all the reversible steps, 
leading to gluconeogenesis (23, 24). 
 
 
 
FIGURE 1.2. Non-phosphorylated pathway of serine biosynthesis 
 
Other possible pathways for serine biosynthesis 
In plants, e.g. Arabidopsis thaliana, apart from the above mentioned serine 
biosynthetic pathways, serine can also be produced from the glycolate pathway (25). 
This pathway occurs in mitochondria of photosynthetic tissues and only functions in the 
presence of light. In contrast, the phosphorylated and non-phosphorylated pathways are 
functional in dark conditions in plastids of non-photosynthetic tissues of the plants. In 
yeast, serine can also be produced from glyoxylate using TCA cycle intermediates in the 
absence of glucose (26, 27). 
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Regulation of serine biosynthesis 
In organisms like Escherchia coli (E. coli), Bacillus subtilis (B. subtilis), and 
yeast, the phosphorylated pathway of serine biosynthesis is regulated by feedback 
inhibition of the first enzyme, PGDH, by the final product, L-serine. Detailed study of 
the allosteric serine inhibition of PGDH has been carried out in E. coli. However, PGDH 
from plants (20) and mammals (28, 29) does not demonstrate this feedback inhibition by 
serine. In the case of rat liver tissues, serine biosynthesis is regulated in response to 
dietary protein and hormonal (insulin, glucocorticoid) intake (30-32). Interestingly, the 
flux through the serine biosynthetic pathway in rat and rabbit liver is regulated at the 
level of phosphoserine phosphatase, which is the irreversible and rate limiting step in 
this case (33). In contrast to the classical feedback inhibition of the serine biosynthetic 
pathway, it seems that serine biosynthesis in plants and mammals is regulated at the last 
step by cellular demands for serine. Little is known about the regulation in the non-
phosphorylated pathway of serine biosynthesis.  
Biotin biosynthesis 
The second part of this dissertation focuses on the enzymes of the biotin 
biosynthetic pathway in Mtb. Biotin (vitamin H) is indispensible as a cofactor during 
carboxylation, transcarboxylation and decarboxylation reactions in certain important 
pathways like fatty acid biosynthesis, gluconeogenesis, and amino acid metabolism in 
both prokaryotes and eukaryotes. It functions as a carrier of active CO2. Like insulin, 
biotin also plays a role in transcriptional regulation of glucokinase and phosphoenol 
pyruvate carboxykinase - key enzymes of glucose metabolism in eukaryotes (34, 35). 
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Utilization of biotin in the food and cosmetics industries is also well known. Since the 
bioavailability of biotin is very low, it was first chemically synthesized in 1944 by Harris 
and his colleagues (36). However, this type of industrial scale production is not cost 
effective and the chemical wastes produced are an environmental hazard. Hence, there is 
need for more efficient biotechnological methods of biotin synthesis. A better 
understanding of the enzymes in this pathway, in general, would make it easier to 
manipulate these enzymes in microbes such as E. coli, B. subtilis, and B. sphaericus to 
synthesize a large quantity of biotin. Moreover, it is also of particular interest to study 
this biotin biosynthesis in pathogens like mycobacterium because of its role in various 
metabolic pathways, especially fatty acid metabolism, which is essential for the bacterial 
survival during chronic phase of infection (37). 
Biotin biosynthesis in Mycobacterium tuberculosis 
 Bioinformatics studies on the Mtb H37Rv genome reveal the presence of all four 
enzymes in biotin biosynthetic pathway needed for the conversion of pimeloyl-CoA to 
biotin (38). However, not all the genes are present on the same operon - bioAFD are in 
one operon and bioB is in another operon as shown in the figure below (Figure 1.3). 
 
 
 
 
FIGURE 1.3. Biotin operon in Mtb 
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The first step towards biotin biosynthesis is the decarboxylative condensation of 
L-alanine and pimeloyl-CoA into 7-keto-8-aminopelargonic acid (KAPA), catalyzed by 
KAPA synthase (bioF: Rv1569), a PLP-dependent enzyme. However, the source of the 
starting material, pimeloyl-CoA, in Mtb is not yet clear (more details in next paragraph). 
In the second step of biotin synthesis, KAPA is transaminated into 7, 8- 
diaminopelargonic acid (DAPA) by DAPA synthase (bioA: Rv1568), another PLP 
dependent aminotransferase, requiring S-adenosyl methionine (SAM) as the amino 
donor. The product of the second step, DAPA is further carboxylated into an ureido ring 
of dethiobiotin in an ATP and magnesium dependent manner. This penultimate reaction 
is catalyzed by dethiobiotin synthetase (bioD: Rv1570). Finally, dethiobiotin is 
converted to biotin with the introduction of a sulfur between C6 and C9 carbons of 
dethiobiotin by biotin synthase (bioB: Rv1589), requiring a FeS cluster and generating a 
free radical by the use of SAM (Figure 1.4). 
The source of pimeloyl-CoA has been extensively studied in Bacillus and E. coli. 
Each organism follows a different pathway for the synthesis. In B. subtilis and B. 
sphaericus, two additional genes, bioW and bioI, are present in the biotin operon that are 
involved in this process of pimeloyl-CoA synthesis. Characterization of the bioI gene 
product in B. subtilis suggests a function homologous to cytochrome P450 in cleaving 
carbon-carbon bonds in free fatty acids to produce pimelic acid (39-41). Uptake of this 
pimelate is thought to be through passive diffusion. Pimeloyl-CoA is synthesized from 
pimelic acid with the hydrolysis of ATP, catalyzed by pimeloyl-CoA synthetase (bioW 
gene) (42). Other organisms which possess the bioW gene and use pimelate as the 
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precursor are Staphylococcus aureus, Corynebacterium diphtheriae, Aquifex aeolicus 
and Methanococcus jannaschii. In contrast, E. coli cannot take up pimelate as confirmed 
by radioactivity studies (43). Pimeloyl-CoA is synthesized from L-alanine via acetyl-
CoA using proteins coded by bioH and bioC genes. Structural and biochemical studies 
on the BioH protein in E. coli suggest that it may act as an esterase as well as an 
acyltransferase, in transferring the pimeloyl unit from the bioC protein to coenzyme A to 
form pimeloyl-CoA (44, 45). The bioC protein, in turn, is thought to be a pimeloyl 
carrier protein (46). Even so, not all bacteria possessing the bioC gene contain the bioH 
gene in their genome but, rather, have various nonorthologous genes (like bioG in many 
proteobacteria or bioK in some cyanobacteria or bioZ in rhizobia like Agrobacterium 
tumefaciens) which can complement the E. coli bioH mutant. In Mtb, no homology was 
found with the genes related to the above two pathways.  
In the biotin biosynthetic pathway, preliminary biochemical analysis of different 
enzymes has been carried out in microbes like B. sphaericus (42, 47) and B. subtilis (48), 
lower eukaryotes like Saccharomyces cerevisiae (49), and in plants like Arabidopsis 
thaliana (50). However, extensive biochemical and structural studies of all four enzymes 
of this pathway have been performed in E. coli. Several inhibitors are available for these 
different enzymes in E. coli. In plants, numerous inhibitor trials on the enzymes of this 
pathway were also carried out in search of effective herbicides (51-54).  
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FIGURE 1.4. Biotin biosynthetic pathway in Mtb 
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Need for biotin biosynthetic pathway in Mtb 
In recent years, several genetic studies have indicated the importance of the 
biotin biosynthetic pathway in mycobacteria during in vitro growth as well as infection. 
TraSH (Transposon Site Hybridization) studies on Mtb H37Rv strain suggest that genes 
related to different metabolic pathways are needed at different stages of infection in mice 
(9). TraSH involves transposon insertion mutation of almost 97% of the 4000 Mtb genes, 
followed by microarray mapping of these mutants. In this study, mutations in most of the 
genes of the biotin biosynthetic pathway resulted in rapid clearance of the bacterium at 
the early stages of infection in the mouse model (9). Also, knockout of the bioF gene in 
mycobacterium (H37Rv) has resulted in its inability to grow in vitro in culture (55) as 
well as to establish infection in mice, resulting in rapid clearance during early stages of 
infection (9). This is not surprising since biotin auxotrophy has also resulted in the 
attenuation of virulence in other bacterial pathogens like Vibrio cholerae (56). A 
separate study on the bioA gene in Mycobacterium smegmatis (M. smegmatis), an 
experimental model for mycobacterial physiology, suggests that this gene is needed for 
the survival in as well as recovery from the latent phase in M. smegmatis (57). In this 
study, the bioA mutant strain also survived poorly in rich medium containing biotin, 
suggesting that de novo biosynthesis of biotin is required in this stationary phase. 
Probably, these cells were not able to take up biotin from the medium. Microarray 
analysis on mycobacterium gene expression under nutrient-starved conditions shows that 
the bioD gene gets upregulated (2.4 fold) after 96 hours (58). This study was carried out 
to mimic bacterial persistence in infected hosts (37).  
  
14
The biotin biosynthetic pathway in Mtb can be examined for potential 
antimicrobial development since only bacteria and plants have the enzymes for the 
synthesis of this vitamin, but mammals generally get the required biotin from their diet. 
This pathway came into the spotlight during antibiotic screening in the 1950's and 
1970's. Two natural compounds - amiclenomycin (MIC = 3.1 μg/ml) and acidomycin 
(MIC = 0.0625-0.125 μg/ml) from Streptomyces species were demonstrated to have 
good whole cell activity against mycobacterium (59, 60). Further studies have indicated 
that their inhibitory effect is targeted to the biotin biosynthetic pathway (61, 62). 
Amiclenomycin and acidomycin target the second and fourth enzymes of the pathway. 
Together, they had a synergistic effect against mycobacterium. However, the interest in 
this pathway faded due to the ineffectiveness of these antibiotics in vivo in animals. This 
was thought to be due to the ability of Mtb to take up sufficient biotin from the host. 
However, studies conducted at Abbott laboratories, North Chicago, Il, have shown that 
acidomycin possesses poor bioavailability (63), with 31% of acidomycin recovered from 
urine within the first hour of administration and the remainder of the dose inactivated by 
the liver, which might be the reason for its poor performance. Information regarding the 
bioavailability of amiclenomycin is not available. We still believe that these compounds 
can provide ideas for developing new inhibitors by modifying their chemical structures, 
resulting in better biological properties.  
In short, this dissertation deals with the characterization of the first enzyme of the 
serine biosynthesis as well as the first three enzymes of the biotin biosynthesis. These 
two metabolic pathways are critical in mycobacterium survival during infection. 
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Elucidation of these enzymes will be helpful in designing inhibitors against these 
enzymes for the eradication of tuberculosis. 
Overview of chapters 
Chapter II of this dissertation discusses the structure-function relationship of the 
first enzyme of the phosphorylated serine biosynthetic pathway, D-3 phosphoglycerate 
dehydrogenase in Mtb. Sequence alignment of PGDH from different organisms suggests 
that this enzyme in Mtb represents a unique form, with a long insertion near the C-
terminus, which has not been characterized earlier. X-ray crystallographic methods were 
used to elucidate the domain organization, role of this extended C-terminal region, mode 
of substrate binding and catalysis, and serine inhibition in this enzyme. Additionally, 
biochemical analysis of Mtb PGDH has been done in collaboration with Dr. Gregory A. 
Grant (Washington University School of Medicine, St. Louis, MO). The substrate-bound 
PGDH structure helps us in mapping the active site. Based on the ligand-bound human 
truncated PGDH structure, the resulting model of a closed active site provides us with a 
picture of the catalytic events in this enzyme. Kinetic studies have also indicated that this 
enzyme is allosterically regulated by L-serine (64), as is E. coli PGDH (65). Structural 
determination of effector-bound Mtb PGDH pinpoints the residues involved in the 
allosteric regulation and the resulting conformational changes. Human PGDH has the 
same form as Mtb PGDH, so chapter II also describes the cloning, protein 
overexpression and purification procedures for human PGDH, and characterizes and 
compares this enzyme with its Mtb counterpart. 
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 Chapter III deals with the biochemical and three-dimensional structure analyses 
of 7, 8-diaminopelargonic acid synthase (DAPAS, EC 2.6.1.62), an enzyme involved in 
the second step of biotin biosynthesis. A unique feature of this aminotransferase enzyme 
is its usage of SAM as the amino donor. Comparison of the substrate-bound Mtb 
DAPAS structures sheds light on the mode of dual-substrate recognition in this 
particular transaminase, which was not characterized to date. This chapter also reveals 
the variation in the mode of substrate binding at the DAPAS active site in certain 
Bacillus species and thermophiles using KAPA-bound B. subtilis structure. Following 
characterization of the Mtb DAPAS active site, virtual screening of commercially 
available drug-like compounds was carried out. In this process, the substrate-bound 
active site of Mtb DAPAS was used as a template and the resultant top hits were tested 
for inhibitor development using enzyme assays.  
Chapter IV elucidates the structural details of the penultimate enzyme in the 
biotin biosynthesis in Mtb, dethiobiotin synthetase (DTBS, EC 6.3.3.3). This study 
outlines the differences in overall structural conformations in comparison to the enzyme 
found in E. coli, as well as, in H. pylori. It further explains the mode of substrate 
recognition at the active site and the mechanism of this amidoligase reaction, based on 
the substrate and the product-bound DTBS structures.  
Chapter V of this dissertation discusses the cloning, protein overexpression and 
purification protocols, crystallization trials, and preliminary biochemical characterization 
of 7-keto, 8-aminopelargonic acid synthase (KAPAS, 2.3.1.47), an enzyme involved in 
the first step of the biotin biosynthetic pathway in Mtb. 
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CHAPTER II 
STRUCTURAL STUDIES ON D-3-PHOSPHOGLYCERATE 
DEHYDROGENASE IN Mycobacterium tuberculosis*  
 
Background 
D-3-phosphoglycerate dehydrogenase (PGDH) catalyzes the reversible reaction 
of oxidation of phosphoglycerate (PGA) to hydroxypyruvic acid phosphate (HPAP) in 
an NAD+ dependent manner (Figure 2.1). This is the first step in the serine biosynthetic 
pathway. This enzyme is a member of the 2-hydroxy acid dehydrogenase family that is 
specific for substrates with a D-configuration (66). It has sequence/structural homology 
with other members of this family, e.g. formate dehydrogenase (67), D-glycerate 
dehydrogenase (68), D-lactate dehydrogenase (69), and erythronate-4-phosphate 
dehydrogenase (70). PGDH is present in both prokaryotes and eukaryotes.  
 
 
 
 
* Part of this chapter is reproduced with permission from “Crystal Structure of 
Mycobacterium tuberculosis D-3-Phosphoglycerate Dehydrogenase: extreme asymmetry 
in a tetramer of identical subunits”, Dey, S., Grant, G.A., Sacchettini, J.C. (2005), The 
Journal of Biological Chemistry, 280, 14892-14899, Copyright 2005 by The American 
Society for Biochemistry and Molecular Biology, Inc. 
 
* Part of this chapter is reproduced with permission from “Structural Analysis of 
Substrate and Effector Binding in Mycobacterium tuberculosis D-3-Phosphoglycerate 
Dehydrogenase”, Dey, S., Burton, R.L., Grant, G.A., Sacchettini, J.C. (2008), 
Biochemistry, DOI 10.1021/bi800212b, Copyright 2008 by American Chemical Society. 
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FIGURE 2.1. Reversible enzymatic reaction catalyzed by PGDH.  
 
Different forms of PGDH 
Sequence alignment of PGDH protein from various species indicates that this 
enzyme exists in at least three different basic structural forms. None of which appear to 
be strictly specific for organism type (Figure 2.2). The simplest form, which is found in 
some bacteria including Clostridium and Pyrococcus, contains only two domains- the 
nucleotide-binding domain and the substrate-binding domain (Figure 2.3). The dimeric 
PGDH from the unicellular parasite Entamoeba histolytica (22) differs from other forms 
of PGDH in having a lysine residue rather than a histidine as one of the members of the 
catalytic dyad at the active site. The PGDH from some bacteria and lower eukaryotes 
such as Saccharomyces cerevisiae (71) and Leishmania major (72) shares similar motif 
with the E. coli enzyme. This enzyme has been extensively studied in E. coli, both 
biochemically (65, 73) as well as structurally (74, 75). In E. coli PGDH, in addition to 
the substrate and nucleotide binding domains, this enzyme possesses a C-terminal 
domain that is involved in regulation of enzyme activity through binding the effector, L-
serine (Figure 2.4). Other microbes such as Mycobacterium, Bacillus subtilis (76) and 
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Corynebacterium glutamicum, plants such as Arabidopsis thaliana (20), and higher 
order eukaryotes, including mammals, possess a large polypeptide insertion (~130-200 
amino acids) in their C-terminal segment between the substrate-binding and regulatory 
domains (Figure 2.5). 
Kinetic properties of Mtb PGDH 
The serA1 gene that codes for PGDH has been found to be an essential gene by 
Himar1-based transposon mutagenesis studies in Mtb H37Rv strain (77). This gene 
sequence in Mtb is also nearly identical to that in M. leprae (89.6%). Generally, only the 
essential genes are conserved in M. leprae because of its long generation time (11-13 
days in mice), thus, supporting the essentiality of serA1 gene in Mtb (12, 13). 
Furthermore, kinetic studies on Mtb PGDH provide a Km value of ~ 85 µM for substrate 
HPAP and a kcat/Km of ~ 5.6 x 106 M-1sec-1 (78) in comparison to the E. coli Km value of 
~ 40 µM for substrate HPAP and a kcat/Km of ~ 7 x 105 M-1sec-1 (64). In Mtb PGDH, the 
backward reaction from HPAP to PGA is the favored reaction. It has also been 
demonstrated that the activity of Mtb enzyme is greatly affected by the ionic strength of 
the reaction buffer (64). In addition, Mtb PGDH exhibits uncompetitive substrate 
inhibition at higher concentrations of HPAP (250 µM) (64) analogous to rat liver PGDH 
(29). This type of substrate inhibition has not been reported in E. coli PGDH. 
  
 20 
 
 
 
 
 
 
 
 
 
 
FIGURE 2.2. Three different forms in PGDH based on sequence alignment. The polypeptide arrangement of PGDH falls 
into three categories. (A) PGDH containing only two domains- substrate-binding and nucleotide-binding as in P. horikoshii, 
Clostridium, and E. histolytica. (B) PGDH containing a nucleotide-binding domain, a substrate-binding domain and an 
additional domain- regulatory domain as in E. coli, S. cerevisiae, and Leishmania. (C) PGDH with an insertion of ~130-200 
amino acids between the substrate-binding and regulatory domains as in human, rat liver, Mtb, and B. subtilis.
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FIGURE 2.3. Domain organizations of PGDH in Pyrococcus horikoshii. Ribbon 
diagram representation of (A) monomer (B) dimer of PGDH in P. horikoshii. The 
nucleotide-binding domain is colored green and the substrate-binding domain is colored 
pink. This PGDH exists as a homodimer as it lacks the regulatory domain. 
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FIGURE 2.4. Domain arrangements of the E. coli PGDH. Ribbon diagram representation of E. coli PGDH (PDB code-
1YBA). (A) monomer (B) tetramer. The nucleotide-binding domain is depicted in green, the substrate-binding domain in pink 
and the regulatory domain in violet.
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FIGURE 2.5. Alignment of PGDH sequences from human, rat liver, Mtb and E. coli. 
The residues colored in green are the conserved residues in all four PGDH sequence. 
Identical and similar residues are shown in yellow and cyan. This alignment is prepared 
using ClustalW (79). All the important residues involved in catalysis and allosteric 
regulation are marked with a red asterisk. The stretch of three glycine residues (316-318) 
in Mtb is highlighted with a box. 
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Serine inhibition of PGDH 
 The phosphorylated pathway of serine biosynthesis is mostly regulated by 
feedback inhibition of the first enzyme, PGDH, by the end product of the pathway, L-
serine. E. coli PGDH has been found to be strongly inhibited by L-serine (IC50 ~ 2-4 
μM) (80). B. subtilis PGDH is less sensitive to inhibition by L-serine (IC50 ~ 0.6 mM) 
and any sensitivity to L-serine appears to be lost under oxidizing conditions (76). The 
enzymes from E. coli and B. subtilis are the only homogeneous preparations of PGDH 
that have been reported to be inhibited by L-serine. While C. glutamicum PGDH has 
also been reported to be inhibited by L-serine, although at very high concentrations (IC50 
~ 10 mM). It has not been studied in homogeneous form (81). In addition, L-serine 
inhibition of both the B. subtilis and C. glutamicum PGDH require extensive pre-
incubation of the enzyme with the inhibitor before appreciable inhibition can be 
measured. In the pea (Pisum sativum), the sensitivity to L-serine has been reported to be 
cold labile (82). In crude extracts of wheat germ (83), PGDH activity appears to be 
inhibited by high concentrations of L-serine, but this sensitivity is lost upon incubation, 
since the purified wheat germ PGDH is not inhibited by L-serine. Interestingly, L-serine 
has been reported to have no effect on the activity of PGDH from rat liver (29) and 
chicken liver (28). Mtb PGDH, which belongs to the same form of PGDH as mammals, 
is inhibited by L-serine with an IC50 for L-serine of ~30 µM, making it the second most 
sensitive enzyme after E. coli PGDH, reported so far. Hence, it appears that there is a lot 
of variation in the serine inhibition of PGDH with insertion near the C-terminus. 
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Mtb PGDH is also a V-type enzyme (84) which affects the velocity of the enzyme 
reaction, similar to E. coli PGDH (65). It shows mixed noncompetitive inhibition (64).  
Some of the other enzymes which also show V-type allosteric regulation are fructose 1, 
6 bisphosphatase (85), glycerol kinase (86), carbamoyl phosphate synthetase (87), and 
pyruvate carboxylase (88).  
In this chapter, the crystal structures of PGDH from Mtb in its apo form, as well 
as, in complex with its substrate HPAP, and with the inhibitor L-serine will be discussed. 
We also discuss the cloning and protein purification procedures of different constructs of 
Mtb PGDH. This PGDH structure represents the enzyme with an extended motif near the 
C-terminus. The apostructure sheds light on how this 130 amino acid insertion affects 
the domain organization and also provides an image of the effect of this insertion on the 
overall structure of this PGDH which still maintains the tetrameric form. Remarkably, 
although the tetramer is composed of symmetry related heterodimers, extreme 
asymmetry is seen in the tertiary structure of the subunits. The apostructure also hints at 
a possible role for this insertion as an alternative substrate-binding site, responsible for 
substrate inhibition of Mtb PGDH. 
Two other crystal structures of PGDH have been determined since the structure of 
Mtb PGDH apoenzyme was established. One is a truncated form of human PGDH, 
consisting of the nucleotide-binding and substrate-binding domains (PDB code- 2G76). 
Native human PGDH is similar to Mtb PGDH with the intervening and the regulatory 
domains. The other structure is from P. horikoshii (PDB code- 1WWK), which has the 
simplest form of PGDH, consisting only of nucleotide-binding and substrate-binding 
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domains. This PGDH exists as a dimer. Further biochemical characterization of PGDH 
from either human or pyrococcus has not been reported.  
Furthermore, the crystal structure of the binary complex of Mtb PGDH with the 
substrate HPAP aids us in identifying the residues involved in substrate binding at the 
active site. Modeling of the active site closure of Mtb PGDH on substrate binding 
provides us with an insight into the catalytic event occurring in this dehydrogenase. It 
will also be intriguing to understand the mechanism of serine inhibition in this particular 
form of PGDH which shows so much variation in serine inhibition. The serine-bound 
Mtb PGDH structure reveals the key players involved in this allosteric regulation as well 
as the conformational changes occurring on serine binding, both of which are quite 
different from those of E. coli PGDH.  
Human PGDH also belongs to the same form of PGDH as Mtb. In eukaryotes, 
the PGDH structure has not been well characterized. Hence, in this study, we will 
discuss the cloning and protein purification protocols of human PGDH in an effort to 
characterize and compare it with the Mtb PGDH. 
Methods 
Reagents 
Restriction enzymes for serA cloning were purchased from New England 
Biolabs. All the reagents for purification purposes were from Sigma. Selenomethionine 
was purchased from Acros. HPAP was synthesized from dimethylketal tri-
cyclohexylammonium salt (Sigma) using the protocol of Ballou (89). After the 
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hydrolysis of ketal to HPAP, aliquots of HPAP were stored at -20 ºC. NADH, NAD 
analog (3-acetyl pyridine dinucleotide) and L- serine were also purchased from Sigma. 
Cloning, protein overexpression and purification of Mtb PGDH 
His-tagged PGDH clone was obtained by amplifying serA1 gene from Mtb 
H37Rv (lab strain) genomic DNA and further ligating into pET28a vector (Novagen) 
using NdeI and HindIII restriction sites. The NdeI site contained the ATG start codon 
and the HindIII site was preceded immediately by a stop codon (TCA) following the C-
terminal residue of the enzyme, resulting in an N-terminus His-tag protein. 
  PGDH without a His-tag was obtained by cloning the Rv2996c gene into pET30b 
vector (Novagen) using NdeI and HindIII sites. Production of a selenomethionylated 
(SeMet) protein for MAD (Multiple Anomalous Dispersion) phasing was accomplished 
by mutation of Ile (ATC) at position 514 to Met (ATG). This mutant was constructed 
using the QuikChange site-directed mutagenesis kit (Stratagene) with pET30b-serA1 as 
a template. The mutated gene was cloned into the pET30b vector in the same way as the 
wild type. All the constructs were verified by DNA sequencing. The primers used in this 
study were: 
For the His-tagged Mtb PGDH 
Forward primer 
 
5'AGAGAAGCATATGGTGAGCCTGCCTGTTGTGTTGATCGCGAC3' 
 
Reverse primer 
5'CCCAAGCTTTCACGACAGATCGACAACCTCGAGCTTGTAGGCGT3' 
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For PGDH I514M mutant: 
Forward primer: 5' GCGGACGGCGATGGCGGCGGCGG 3' 
Reverse primer: 5' CCGCCGCCGCCATCGCCGTCCGC 3'  
The pET28a-serA1 as well as pET30b-serA1 clones were both transformed into 
the E. coli over-expression strain, BL21 (DE3) (Novagen). The cell culture was grown in 
LB media with kanamycin (50 μg/ml) at 37 °C until the A600  reached 0.6-0.8 and then 
induced with 1 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG) and grown at 18 °C 
overnight. For SeMet protein, the pET30b-serA1 (I514M) clone was transformed into E. 
coli B834 (DE3) (Novagen), a methionine auxotroph. Cells were grown in M9 minimal 
media with all the 19 standard amino acids except Met. Selenomethionine (50 mg/L) and 
kanamycin (50 μg/ml) were also added to the cell culture. Culture was induced with  
1 mM IPTG when A600 reached 0.8 and then grown overnight at 18 °C. The cells were 
harvested by centrifugation at 3000 rpm for 30 min and resuspended in buffer A 
(depending on the type of purification) supplemented with one tablet of Complete 
EDTA-free protease inhibitor cocktail (Roche) per cell pellet.  
For the His-tagged protein, the cell pellet was resuspended in 20 mM potassium 
phosphate buffer (pH 7.5), 500 mM NaCl (buffer A). The cells were then lysed using a 
French press (11,000 psi) and the cell debris was removed by centrifugation at 15,000 
rpm for 1 hr. The 0.22 μ filtered supernatant was loaded on a Hitrap Ni column (GE 
healthcare), pre-equilibrated with buffer A + 5 mM imidazole and then washed with 25 
mM imidazole containing buffer A to remove the contaminants. The protein was eluted 
with imidazole gradient of 25–400 mM. For untagged PGDH protein, the supernatant 
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was loaded onto a pre-equilibrated (20 mM potassium phosphate buffer (pH 7.5), 5 mM 
KCl) anion exchange Q sepharose Fast Flow column (GE healthcare) and the 
contaminants were washed till absorbance reached zero. The protein was eluted using a 
KCl gradient (50-800 mM). The fractions containing pure PGDH were pooled and 
concentrated using Centriprep (Millipore). This concentrated protein was applied to a 
Superdex 200 gel filtration column (GE healthcare) pre-equilibrated with 100 mM 
potassium phosphate buffer (pH 7.5), 1 mM DTT and 1 mM EDTA. The eluted protein 
was 98% pure as judged from the 4-12% gradient SDS-PAGE gel. The entire 
purification procedure was carried out at 4 ºC. 
Cloning, protein overexpression and purification of human PGDH 
 The pET30b-huserA clone was provided to us by Dr. G. A. Grant (Washington 
University School of Medicine, St. Louis). HuserA gene codes for human PGDH. The 
pET28b-huserA clone for N-terminal His-tagged PGDH protein with TEV cleavage site, 
as well as, N-terminal His-tagged truncated form of PGDH (Ser322-Phe530) was 
constructed, using the pET30b-huserA as a template with NdeI and HindIII restriction 
sites.  
The primers used for the N-terminal His-tagged protein, 
Forward primer: 5' AGAGAAGCATATGGCTTTTGCAAATCTGCGGAAAGTG 3' 
Reverse primer: 5' CCCAAGCTTTTAGAAGTGGAACTGGAAGG 3' 
For truncated form of human PGDH (323-532) (N-terminal His-tag), 
Forward primer: 5' AGAGAAGCATATGACCAAGCCTTGGATTGGTCTGGCA 3' 
Reverse primer: 5' CCCAAGCTTTTAGAAGTGGAACTGGAAGG 3' 
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All the constructs were further verified by DNA sequencing. 
All three clones were transformed into the E. coli over-expression strain, 
Rossetta (DE3) (Novagen). The cell culture was grown in LB media with kanamycin (50 
μg/ml) and chloramphenicol (34 μg/ml) at 37 °C until the A600  reached 0.6-0.8 and then 
induced with 1 mM IPTG and grown at 18 °C overnight. The cells were harvested by 
centrifugation at 3000 rpm for 30 min and resuspended in buffer A (depending on the 
type of purification) supplemented with one tablet of Complete EDTA-free protease 
inhibitor cocktail (Roche) per cell pellet.  
For the His-tagged human PGDH protein, the cell pellet was resuspended in 20 
mM potassium phosphate buffer (pH 7.5), 500 mM NaCl (buffer A). The cells were then 
lysed using a French press (11,000 psi) and the cell debris was removed by 
centrifugation at 15,000 rpm for 1 hr. The 0.22 μ filtered supernatant was loaded on a 
Hitrap Ni column (GE healthcare), pre-equilibrated with buffer A + 5 mM imidazole and 
washed with 25 mM imidazole containing buffer A to remove the contaminants. The 
protein was eluted with imidazole gradient of 25–400 mM. The His-tag was further 
cleaved using 1 mg TEV protease per 20 mg purified protein at 4 ºC in overnight dialysis 
against a buffer containing 20 mM phosphate buffer, 200 mM NaCl, 10% glycerol and 2 
mM DTT. The cleaved protein was reloaded on Ni column and was eluted as a flow 
through. 
For untagged human PGDH protein, the supernatant was loaded onto a pre-
equilibrated (20 mM potassium phosphate buffer (pH 7.5), 5 mM KCl) anion exchange 
Q sepharose Fast Flow column (GE healthcare) that was washed till absorbance 
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decreased to zero and, finally, the protein was eluted using a KCl gradient (50-800 mM). 
The fractions containing pure PGDH were pooled and concentrated by ultrafiltration 
using Centriprep (Millipore) and applied to a Superdex 200 gel filtration column (XK 
16/60, GE healthcare) pre-equilibrated with 100 mM potassium phosphate buffer (pH 
7.5), 100 mM NaCl, 10% glycerol, 1 mM DTT and 1 mM EDTA. 2ml fractions were 
collected at the rate of 0.5 ml/min. The protein was 98% pure as analyzed from a 4-12% 
gradient SDS-PAGE gel. The entire purification procedure was carried out at 4 ºC. 
Fluorescence studies of Mtb PGDH 
Mtb PGDH (5 μM) was excited at 280 nm and fluorescence emission spectra was 
scanned in the range of 300-450 nm on a LS 55 luminescence spectrometer (Perkin 
Elmer Instruments) with constant stirring. Further emission spectra were collected for 
the enzyme reaction with 200 μM NADH as well as with 0.5 mM HPAP in a 500 μl total 
reaction volume. All the experiments were carried out in buffer containing 50 mM 
potassium phosphate (pH 7.5) and 150 mM NaCl at room temperature. 
Crystallization of Mtb and human PGDH 
His-tagged Mtb PGDH protein was initially screened for the purpose of 
crystallization. Tiny rod shaped crystals in several precipitant conditions were obtained, 
but further optimization of these conditions did not lead to the improvement of the 
crystal quality. So crystallization of Mtb PGDH without any tag was attempted which 
eventually provided good quality crystals. Native and SeMet Mtb PGDH (13 mg/ml) 
were both crystallized in 1 M NaK tartrate, 0.1 M MES (pH 6.5) at 18 °C by the vapor 
diffusion method in hanging drop plates. This precipitant condition was found to 
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produce crystals of good diffraction quality after setting up a matrix screening with 
different kits (Hampton Crystal Screen and II, Wizard screen I and II from Emerald 
BioSystems). Crystals grew within 3-4 days in 4 μl hanging drops of 2 μl of PGDH (13 
mg/ml) and 2 μl of precipitant (Figure 2.6). For SeMet protein, crystals took more than a 
week to grow. The substrate HPAP-bound and inhibitor serine-bound PGDH crystals 
were obtained by cocrystallising PGDH (13 mg/ml) with 5 mM HPAP + 5 mM NAD 
analog (3-acetyl pyridine dinucleotide) and 5 mM L-serine + 5 mM NADH, respectively 
in the same precipitant condition. There were several other precipitant conditions which 
resulted in crystal formation in the same space group, but they all diffracted poorly. For 
data collection purposes, crystals were flash frozen in liquid nitrogen using 20% 
propylene glycol in mother liquor as the cryoprotectant. 
Full length human PGDH (10 mg/ml) and truncated human PGDH in complex 
with 5 mM NADH were also subjected to similar crystallization screening using 
different matrix screens. 
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FIGURE 2.6. Hexagonal rod shaped crystals of Mtb PGDH.  Crystals grew to 
dimensions of 50 μM × 50 μM × 200 μM in 1 M NaK tartrate, 0.1 M MES (pH 6.5) 
using hanging drop vapor-diffusion technique. 
 
Data collection and processing 
The initial native dataset for Mtb PGDH was collected to 2.8 Å resolution at 
beamline 14-BMC, Advanced Photon Source (APS), Argonne National Laboratory, 
Chicago. The diffraction dataset was processed and scaled using the HKL2000 suite 
(90). The space group was found to be P6522. Solvent content calculations using 
Mathews coefficient (91) indicated either a dimer (Vm = 3.9, Vs = 68.3%) or a trimer 
(Vm = 2.6, Vs = 52.4%) in the asymmetric unit. Phasing by molecular replacement was 
attempted using the E. coli PGDH monomer (PDB code-1PSD) or its nucleotide-binding 
domain (the largest domain) as a search model. No clear solution was obtained using 
various programs (AMoRe (92), MOLREP (93), PHASER (94)). Subsequently, several 
different compounds of heavy metals (mercury, platinum, iodine and neodynium) were 
tried, but they failed to produce an acceptable isomorphous or anomalous signal. SeMet 
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MAD (Multiple Anomalous Dispersion) phasing of PGDH was originally not possible as 
this 529 amino acid protein did not contain any methionine residues except the N-
terminal methionine which might be cleaved during expression. Based on sequence 
alignment with E. coli PGDH, a single methionine residue was introduced at position 
514. This mutation was sufficient to obtain complete and highly redundant Se MAD 
datasets for PGDH at 3.15 Å, collected at beamline 14-BMD, APS. High resolution 
datasets of apoenzyme, HPAP, and serine complexed PGDH at 2.3 Å, 2.4 Å, and 2.7 Å 
were also obtained at beamline 14-BMC, APS. All the datasets were processed and 
scaled using the HKL2000 package (90). Datasets collected at selenium peak (0.9794 Å) 
and inflection wavelengths (0.9796 Å), along with native data were enough to provide 
the phase information for Mtb PGDH apoenzyme. 
Basics of structure determination 
X-rays are electromagnetic waves that interact with the electrons and because of 
which the electrons oscillate with the same frequency as the incident wave acting as 
radiation scatters. The range of wavelength particularly useful for protein-crystal 
structure determination is 0.5-2.5 Å. For in-house source, the X-ray of Cu Kα 
wavelength (1.541 Å) can be generated by rotating anode generators. At synchrotron, 
particle storage rings are used to generate intense X-ray beam in a whole range of 
spectrum from 0.5-1.6 Å.  
Bragg’s law interprets X-ray diffraction by a crystal lattice as reflections from 
different planes of molecules/lattice points in the crystal.  
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For constructive interference, this can be written as the equation: 
2d sinθ = nλ, 
where d is the distance between each plane of molecules, θ is the angle of incidence of 
the X-ray beam, n is an integer and λ is the wavelength of the X-ray beam.  
The ultimate goal of protein crystallography is to determine the electron density 
(ρ) at every position (xyz) of the unit cell. The electron density map ρxyz can be obtained 
by Fourier transformation of structure factor Fhkl, 
ρxyz = 1/V Σ |Fhkl |e-2πi(hx + ky + lz) + iαhkl 
   
                                h k l  
 
where V is the volume of the unit cell. It is easy to derive the amplitude |Fhkl | from the 
experimental intensities as amplitude is square root of intensity, but the phase angle αhkl 
cannot be obtained directly from the diffraction pattern. There are three different 
methods by which this "phase problem" in protein crystallography can be solved. (1) 
Molecular replacement (MR) (2) Multiple Isomorphous Replacement (MIR), and (3) 
Multiple Wavelength Anomalous Dispersion (MAD) 
The simplest of the three methods for phase determination, molecular 
replacement (MR) depends on the existence of a solved model that is homologous to the 
present unknown protein. Further detailed explanation of this method will be provided in 
chapter III. 
Multiple Isomorphous Replacement (MIR) (95) involves either soaking the 
protein crystal or co-crystallizing with multiple heavy metals. When heavy metals are 
introduced in the protein, the crystal packing might be affected, resulting in weak 
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diffraction or loss of isomorphism. The major aim of this method is to get isomorphous 
data since datasets are collected from different derivative crystals. Isomorphism means 
almost same unit cell dimensions for both the derivative as well as the native datasets to 
minimize the error in phase determination. The stable addition of one or more heavy 
atoms will change the diffraction pattern in comparison to the native crystal as 
represented by the equation 
FPH = FP + FH, 
where FP is the structure factor of the protein, and FH and FPH are the structure factors for 
the heavy atom and the derivative protein, respectively. Structure factors can be 
represented as vectors, with lengths corresponding to their magnitudes and directions 
corresponding to their phases. There are two different ways to construct vector triangles 
with two sides whose lengths are |FP| and |FPH| on the line FH, resulting in two values for 
the phase angle α. More than one derivative is required to eliminate this phase 
ambiguity. The second derivative will also have two possible phase angles for FP 
provided the heavy atoms are not at the same positions as in the first derivative. One of 
these angles will be common between both the derivatives, thus, determining the correct 
phase. 
In situations where the molecular replacement method fails or the structure is 
totally novel (without any available homologous structure), the method of choice in 
recent years is single/multiple wavelength anomalous dispersion (SAD/MAD) (96). 
MAD (97) involves the integration of heavy metals inside the protein or 
naturally-occurring atoms in the protein (Fe, Cu or S) and collection of datasets of the 
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same crystal at different wavelengths to solve the phase problem. Use of single crystal 
for data collection eliminates any error in phase determination because of non-
isomorphism. Since the datasets need to be collected at different wavelengths, a tunable 
X-ray source such as in synchrotron is required. For Mtb PGDH, we have incorporated 
selenium as the heavy metal, replacing sulfur in methionine, to get the anomalous signal. 
When X-ray beam hits the PGDH crystal, it sets the electrons to vibrate, generating 
energy at same frequency (X-ray). This kind of diffraction is “coherent scattering”. If the 
photon has energy close to transition energy, the electron can go to an excited state and 
instead of emitting in phase with the incident beam; energy is radiated in a different 
phase. In this case, the energy of coherent scattering is also reduced as some energy is 
absorbed to bring the transition. The atomic scattering factor can be written as an 
equation 
ƒ(λ) = ƒ0 - δƒ′(λ) + iƒ" (λ), 
where ƒ0 is the conventional atomic scattering factor, 
δƒ′(λ) is the reduction of normal scattering at wavelength (λ), and 
iƒ"(λ) is the amount of anomalous scattering (out of phase component of the 
scattering) at this wavelength (λ) 
Defining the atomic scattering factor, ƒ′ = ƒ0 - δƒ′, the equation becomes 
ƒ = ƒ′ + iƒ" 
The anomalous scattering of selenium (ƒ") will be large at its absorption edge 
wavelength (0.9794), also called peak wavelength. At inflection (edge) wavelength 
(0.9796), the normal atomic scattering (ƒ′) is reduced to its lowest possible value.  
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Anomalous scattering disobeys Friedel’s law for normal scattering, which states 
that structure factor for reflections h, k, l and -h,-k,-l have the same amplitude but have 
opposite signs for phases. 
|Fhkl| = |F-hkl|         αhkl = -αhkl 
In this case, the amplitude of the Bijvoet pairs |Fhkl| and |F-hkl| is different because of the 
presence of the additional anomalous scattering factor ƒ". This difference in diffraction 
is enough to locate the position of the heavy metal in the unit cell and thereby determine 
the phase angle (Figure 2.7). 
 
 
 
 
 
 
 
 
FIGURE 2.7. Principles of MAD phasing. FT is the vector for normal scattering from 
all atoms, FA is the vector for anomalous scattering and λF is the vector for total 
scattering at a particular wavelength (λ) and Δϕ is the phase angle difference. During the 
MAD experiment, the amplitude of total scattering |λF| is measured. 
 
Two selenium sites with occupancies of 1.0 and 0.96 in PGDH were found using 
direct method SHELXD (98). These sites were further refined and initial phases were 
obtained using AUTOSHARP (99) with an overall anomalous phasing power of 0.26 
and figures of merit of 0.22 and 0.07 for acentric and centric reflections, respectively, for 
Δϕ
FT
FA
λF
39 
 
overall 3.15 Å resolution range. The phases obtained by solvent flattening with DM 
(100) has an improved figure of merit of ~ 0.72, having two molecules in the asymmetric 
unit.  
Using this unbiased density modified map, chain tracing was done using CAPRA 
in TEXTAL (101). Several rounds of manual model building was carried out with the 
Xfit module of the graphics program Xtalview (102) using the Shake&wARP (36) bias 
minimized electron density maps. The model was further refined against the high 
resolution (2.3 Å) data using REFMAC (103). The geometry of the model was greatly 
improved using CNS (104) in the initial stages of model building (rigid body refinement 
and then simulated annealed refinement at 4000 °K). In rigid body refinement, segments 
of protein such as domains move as rigid body. Simulated annealed refinement involves 
heating up of the model to high temperature (4000 ºK) and slowly cooling it with the 
intention to find its preferred geometry at the temperature of data collection i.e. 100 ºK. 
After the model reached a reasonable R factor and Rfree (below 30%), water molecules 
were added to the model using automated water picking option in Xtalview and also 
manually picked using the unbiased map. Reliability factor or R-factor is an indicator of 
the agreement between the model and the observed structure factor.  
It can be computed as: 
R = Σ ||Fobs|-|Fcalc||/ Σ |Fobs| 
where Fobs and Fcal are the structure factors of the observed and calculated data.  
Rfree value, which was introduced by Brunger in 1992 (105), assesses the effect of model 
biasness during refinement. To compute a free R-factor, Rfree, a set of test reflections 
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(5%) are randomly chosen and not used during refinement. This value also tells us how 
well the observed and experimental structure factor of the test set of reflection agrees. 
The model was subjected to TLS restrained refinement using REFMAC in the final 
round of refinement. The final structure had an R-factor of 20.4% and an Rfree of 25% 
with good stereochemistry as analyzed by PROCHECK (106).  
As the datasets for the HPAP-bound and the serine-bound Mtb PGDH were 
isomorphous with the apoenzyme, this structure (PDB code-1YGY) was refined against 
the ligand-bound datasets using simulated annealing at 4000 °K in CNS to eliminate any 
biasness as well as improve the geometry of the model. All the steps to yield the final 
model were similar to the apoenzyme. The overall statistics for data collection, 
refinement and geometry statistics are provided in Table 1. The coordinates (PDB code-
1YGY, 3DDN, 3DC2) and structure factors of the apoenzyme, HPAP-bound, and serine-
bound Mtb PGDH have been deposited with the Protein Data Bank, Research 
Collaboratory for Structural Bioinformatics, Rutgers University, NJ. The domain 
movements were analyzed using the program Dyndom (107) which determines the hinge 
axes and the residues involved in hinge bending. For this analysis, default settings of 
Dyndom were used. All the structure figures have been prepared using Chimera (108). 
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TABLE 1 
Data Collection, refinement and geometry statistics of Mtb PGDH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Values in parenthesis for the highest resolution bin 
b Rsym = Σ|I - <I>| /Σ<I>, where I is the observed intensity, and <I> is the average intensity of multiple observations of symmetry-related reflections 
c R = Σ ||Fobs|-|Fcalc||/ Σ |Fobs| where Fobs and Fcalc are the observed and calculated structure factors 
 
 
Selenium 
Peak 
Selenium 
Inflection 
Native PGDH PGDH+HPAP PGDH+serine 
Space group P6522 P6522 P6522 P6522 P6522 
Unit cell dimensions a=b=165.3 Å 
c=217.9 Å 
α=β=90° 
γ=120º 
a=b=165.4 Å 
c=218.1 Å 
α=β=90° 
γ=120º 
a=b=165.5 Å 
c=218.1 Å 
α=β=90° 
γ=120º 
a=b=165.6 Å 
c=218.3 Å 
α=β=90° 
γ=120º 
a=b=165.2 Å 
c=218.9 Å 
α=β=90° 
γ=120º 
Molecules per asymmetric unit 2 2 2 2 2 
Wavelength (Å) 0.9794 0.9796 0.9 0.9 0.9 
Resolution range (Å) 141.42 - 3.15 141.42 – 3.15 48.8-2.3 48-2.4 46.5-2.7 
Highest resolution bin (Å) 3.26 - 3.15 3.26 - 3.15 2.38-2.3 2.49-2.4 2.8-2.7 
Observed reflections 777664 802306 1117427 1495125 1011203 
Unique reflections 57572 57665 78223 69375 48518 
Completeness (%) a 100 (100) 100 (100) 99.7 (99.9) 100 (100) 99.2 (99.9) 
Average redundancy a 13.5 (10.2) 13.9 (11.9) 14.3 (9.8) 22.3 (21.6) 20.8 (19.5) 
I/σ(I) a 19 (3.6) 18.7(4.3) 24.7 (4.8) 26 (3.1) 19.2 (2.8) 
Rsyma, b 0.15 (0.68) 0.15 (0.70) 0.095(0.4) 0.038 (0.30) 0.037 (0.42) 
Refinement statistics (REFMAC)      
Free R value (5%)   25 24 26 
R value (%) c   20.4 20 22 
No. of protein residues   1054 1052 1049 
No. of water molecules   315 165 77 
r.m.s.d. bond length, (Å)   0.012 0.011 0.016 
r.m.s.d. bond angles, (°)   1.47 1.42 1.75 
Ramachandran plot (PROCHECK)      
Most favored region (%)   805 (88.0) 819 (90) 777 (85.4) 
Additional allowed regions (%)   107 (11.8) 89 (9.8) 130 (14.3) 
Generously allowed regions (%)   2 (0.2) 2 (0.2) 2 (0.2) 
Disallowed regions (%)   0 0 0 
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Results and discussion 
Purification and characterization of Mtb PGDH 
Initially, the His-tagged Mtb PGDH for structural studies was purified using one-
step Ni affinity chromatography. However, this protein did not result in good diffraction 
quality crystals. As a next logical step, untagged Mtb PGDH was constructed. This wild 
type protein was purified using two-step purification protocol of anion exchange and gel 
filtration chromatography. The protein was found to be 98% pure from the 4-12% SDS-
PAGE gel. Crystallization trials with this wild type protein yielded good quality crystals 
that diffracted to 2.3 Å.  
Fluorescence experiments were carried out to characterize Mtb PGDH. When 
excited at 280 nm, Mtb PGDH shows a single emission peak at 335 nm which is due to 
the presence of aromatic residues in the protein. In contrast to E. coli PGDH (73, 109), it 
does not show a second peak at 440 nm which is characteristics of intrinsically bound 
NADH. This suggests that NADH is not intrinsically present in Mtb PGDH. When 200 
μM NADH was mixed with the Mtb PGDH enzyme, there was the appearance of the 
second peak at 440 nm with subsequent decrease in the emission peak at 335 nm. This 
phenomenon is due to the FRET effect of NADH which absorbs the light at 335 nm and 
emits at 440 nm. On further addition of 0.5 mM substrate HPAP to this enzyme mixture, 
there is total disappearance of emission peak at 440 nm with subsequent increase in 
emission peak at 335 nm which indicates the conversion of NADH in the protein to 
NAD+ (Figure 2.8). As the rate of this reaction is very fast, further kinetic studies of this 
enzyme have been carried out using the stopped flow fluorescence spectrophotometer. 
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FIGURE 2.8. Fluorescence spectra of Mtb PGDH. This figure shows the emission 
spectra of Mtb PGDH enzyme alone (violet), after mixing PGDH with 200 μM NADH 
(green), and in presence of both 200 μM NADH and 0.5 mM HPAP (red) in the range of 
300-500 nm, when excited at 280 nm. 
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Structure determination and overall quality of Mtb PGDH apostructure  
The 2.3 Å apostructure of Mtb PGDH was determined using the selenium MAD 
phasing (97). To employ this method, the isoleucine residue at position 514 was mutated 
to methionine since this 529 residue protein lacked any methionine other than the 
starting Met. This mutation was carried out based on its sequence alignment with E. coli 
PGDH. It is generally recommended that there should be one selenomethionine for 
approximately 100 amino acids in order to yield sufficient MAD phasing (97). A 
complete and a highly redundant data set at 3.15 Å resolution provided an interpretable 
electron density map of high quality from a single selenomethionine in this 529 amino 
acid protein (2 per asymmetric unit, no NCS averaging). The structure was refined to an 
Rfactor of 20.4% and Rfree of 25% with good stereochemistry as analyzed by 
PROCHECK (Figure 2.9). No outliers were seen in the Ramachandran plot. The refined 
structure contains all the amino acid residues except the first two N-terminal residues of 
the protein.  
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FIGURE 2.9. Ramachandran plot generated by PROCHECK for Mtb PGDH 
apoenzyme (PDB code – 1YGY) 
 Glycine 
 Non-glycine and non-proline amino acids 
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Overall structure of Mtb PGDH 
The X-ray crystallographic structure shows that there are two molecules present 
in the asymmetric unit (chain A and chain B) which form a tetramer with the 
crystallographic symmetry related molecules (two fold axis of symmetry) (Figure 2.10 
B). Superimposition of Mtb PGDH chain A on chain B with the nucleotide-binding and 
substrate-binding domains as reference shows a rotation of the other two domains by 
approximately 160° as well as flipping of both the same domains. A similar effect is also 
seen when the other two domains-intervening and regulatory domains are used as a 
reference. Thus, this demonstrates the presence of two different conformations among 
the molecules of the asymmetric unit (Figure 2.11). 
Each subunit of 55,000 Daltons can be divided into four distinct domains (Figure 
2.10 A). These are referred to as the substrate-binding domain (residues 3-98 and 283-
319), the nucleotide-binding domain (residues 99-282), the regulatory domain (residues 
454-529) and an intervening domain (residues 320-453). The intervening domain 
between the substrate-binding and regulatory domain is not present in the other two 
forms of the PGDH, e.g. E. coli, pyrococcus.  
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FIGURE 2.10. Domain arrangements of Mtb PGDH. Ribbon diagram representation of (A) monomeric form (B) tetrameric 
form of Mtb PGDH. The tetramer has three domains in common to E. coli PGDH: the nucleotide-binding domain (green), the 
substrate-binding domain (pink) and the regulatory domain (violet). The fourth additional domain is the intervening domain 
(yellow).
A B
Subunit A 
Subunit B 
Subunit D 
Subunit C 
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FIGURE 2.11. Ribbon diagram of superimposition of chain A of Mtb PGDH on 
chain B. Figure shows superimposition of nucleotide-binding domain (NBD) and 
substrate-binding domain (SBD) of chain A (yellow) on chain B (blue) resulting in an 
flipping and rotation of intervening domain (INTD) and regulatory domain (RD) by 
160°, indicating the presence of two different conformations in the asymmetric unit. 
160º
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Subunit structure in Mtb PGDH 
The largest domain, the nucleotide-binding domain, in Mtb PGDH consists of 
residues Asn99 to Gly282 and contains seven parallel β strands (β8-β7-β6-β9-β12-β11-
β10) interconnected with helices (α6-α7-α8-α9-α10-α11-α12-α13). This is a variation 
of the Rossmann fold which is a characteristic of dehydrogenases (110). Sequence 
alignment of the nucleotide-binding domain in Mtb and E. coli PGDH shows 33.9% 
sequence identity and superimposition of these domains in chain A shows a r.m.s.d. of 
5.28 Å for 183 Cα atoms. This deviation is largely due to the presence of a helix (α9) 
between residues Ser176 and Gln182 in Mtb PGDH whereas a loop is present in E. coli 
PGDH, as well as, variable loop regions in this domain for both enzymes (Pro173 to 
Tyr174 in Mtb and Ala271 to Asp275 in E. coli). However, this helix α9 in the 
nucleotide-binding domain is also present in human PGDH (Pro179 - Phe185). 
Superimposition of the Mtb PGDH nucleotide-binding domain of chain B on chain A 
(r.m.s.d. =1.5 Å for 183 Cα atoms) shows that they have different conformations in the 
loop region (Leu203 - Ile213) where nucleotide binds.  
  The substrate-binding domain is geometrically adjacent to both the nucleotide-
binding and intervening domains and is composed of residues from two segments of 
protein sequence (Ser3 - Ser98 and Ala283 - Val319). This amino terminal domain 
contains five parallel β-strands (β2-β1-β3-β4-β5) flanked by five helices (α1-α2-α3-α4-
α5) like E. coli PGDH (r.m.s.d = 3.87 Å for 131 Cα atoms). It has only 29.7% sequence 
identity with E.coli PGDH in comparison to 39% sequence identity with human PGDH 
in both regions 3-98 and 283-319. There is no significant difference in the structure of 
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the substrate-binding domain in chains A and B of Mtb PGDH (r.m.s.d. for 131 Cα atoms 
is 0.96 Å). 
 The intervening domain (Val320 - Glu453) is named as such because it 
intervenes between the substrate-binding and regulatory domains where L-serine binds. 
This is a new domain not present in the other two forms of PGDH. This two layered 
sandwich domain consists of six β strands (β14-β13-β15-β16-β17-β18) out of which the 
first two strands (β14-β13) are flanked by 2 helices (α14-α15). The rest of the four 
strands form an anti-parallel β sheet. Superimposition of the intervening domains of 
chain B on chain A in Mtb PGDH (r.m.s.d. = 1.8 Å for 133 Cα atoms) does not show any 
significant secondary structure differences. However, as noted previously, the 
orientation of the intervening domain in chain B is approximately 160° opposite and 
flipped in comparison to that of chain A as shown in Figure 2.11. This flipping results in 
the regulatory domain of chain A occupying a position much closer (9 Å) to its 
nucleotide-binding domain than in chain B (71 Å). In addition, the reorientation of the 
domains results in the formation of two different interfaces between the nucleotide-
binding and intervening domains in the two unique subunits. Because of this flipping, a 
flexible loop region (Ala376-Asn386) in the intervening domain of chain B is totally 
exposed to the solvent, leading to its disordered electron density.  
The C-terminal regulatory domain of Mtb PGDH consists of residues Gly454 to 
Ser529 and contains four anti-parallel β strands (β19-β20-β21-β22) interconnected with 
two helices (α16-α17). This kind of arrangement (βαββαβ) belongs to the ACT 
(Aspartokinase, Chorismate mutase, and TyrA) domain family (111) which is very 
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common among enzymes that participate in amino acid metabolism. The interface of 
these domains also act as a locus for amino acid binding, which is involved in its 
metabolic regulation (negative feedback regulation) (e.g. ATP phosphoribosyl 
transferase of Mtb (112) involved in histidine biosynthesis, threonine deaminase (113) 
involved in isoleucine biosynthesis, α-isopropylmalate synthase (114) involved in 
leucine biosynthesis, and prephenate dehydratase (115) involved in phenylalanine 
biosynthesis). Thus, it has also been called the "regulatory domain in amino acid 
metabolism". This domain has also been the site for small molecules in proteins such as 
thiamine binding proteins involved in thiamine transport (116) and NikR protein 
involved in regulating the Ni level in the cells (117). Interestingly, this type of secondary 
structure arrangement is also seen in other proteins such as nucleoside diphosphate 
kinase and aspartate carbamoyltransferase involved in pyrimidine biosynthesis (118). 
These enzymes are not directly involved in amino acid metabolism and lack an allosteric 
site at the ACT domain interface. Superimposition of the regulatory domain of Mtb and 
E. coli PGDH (r.m.s.d. = 3.21 Å for 75 Cα atoms) shows a shift (4.8 Å) in one of the 
helices in Mtb PGDH (Pro507 - Val518) due to longer loop regions in Mtb PGDH 
(Glu489 - Ala496 and Leu502 - Val506). Kinetic analysis on serine inhibition of Mtb 
PGDH has shown that serine exhibits a mixed type of noncompetitive inhibition (19), so 
it is anticipated that it will bind at a site other than the active site. In E. coli PGDH, 
serine-binding site exists at the interface of the two regulatory domains. In Mtb PGDH 
apoenzyme, changes in the orientation of the side chains of residues Asp463 and Arg464 
at this site in chains A and B have been noticed when both the adjacent regulatory 
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domains are superimposed (r.m.s.d. = 0.8 Å for 75 Cα atoms). These changes in 
orientation of Asp463 and Arg464 side chains at the regulatory domain interface might 
indicate a path for serine entry. In E. coli PGDH tetramer, only two molecules of serine, 
one at each interface, are required for optimal inhibition (65). If the same is true for Mtb 
PGDH, this orientation change at the interface may delineate two sites that will bind 
serine easily from the other two that will not. However, an answer to the question of 
what is triggering this change in orientation in one subunit of an apoenzyme, but not in 
the other, is not clear.  
Quaternary structure-Mtb PGDH as a tetramer 
The overall arrangement of subunits in this tetramer is very unusual. The 
presence of the extra 130 amino acids polypeptide (the intervening domain) causes the 
movement of the entire regulatory domain towards the nucleotide-binding domain 
forming a curved structure in each subunit as seen in figure 2.8 B in comparison to the 
elongated form seen in E. coli PGDH (figure 2.4). The asymmetry in the tetramer, due to 
the shifting of this regulatory domain interface from the extreme ends, as in an elongated 
E. coli PGDH tetramer, to the sides of a more globular Mtb PGDH tetramer, is unique.   
There are two major points of interaction between the adjacent subunits in the 
Mtb tetramer. One, which is very extensive, is present between the nucleotide-binding 
domains of adjacent subunits, with a buried surface area of 2402 Å2. This interface is 
also preserved in the homologous enzymes like D-glycerate dehydrogenase (3), formate 
dehydrogenase (67) as well as E. coli (8) and human PGDH (PDB code-2G76). The 
other interface is between the regulatory domains from adjacent subunits, with buried 
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surface area of 1294 Å2. This interaction, responsible for tetramer formation, is also 
found in E. coli PGDH (74). In this interface, two adjacent regulatory domains create a 
sheet of eight antiparallel β strands. L-serine binds at this interface, forming a hydrogen 
bond network between the two domains. PGDH from E. histolytica (22) as well as P. 
horikoshii (PDB code-1WWK) exist as a dimer since they both lack this regulatory 
domain.  
Apart from the above mentioned interactions which are also seen in other forms 
of PGDH, there are certain unique interactions observed only in Mtb PGDH. They 
consist of: (1) Interaction between the nucleotide-binding domain of subunit B with the 
intervening domain of subunit C and by symmetry, the nucleotide-binding domain of D 
and the intervening domain of A. (2) Interaction between the nucleotide-binding domain 
of subunit A with the intervening domain of subunit C, and, by symmetry the nucleotide-
binding domain of C and the intervening domain of A. (3) Interaction between the 
intervening domains of subunits A and D (and B and C). It is worth mentioning here that 
the helix α9 (Ser176-Gln182) of the nucleotide-binding domain, which is the unique 
feature of this form of PGDH is involved in both the above kind of interactions (Table2). 
Intersubunit interactions were also observed in E. coli PGDH tetramer, but between the 
same domains i.e. between Asn190 residue of opposite nucleotide-binding domains 
(A&C and B&D).  
The flipping of the two unique subunits at the junction between the substrate-
binding and intervening domains results in two different and unique sets of intra subunit 
interactions between the nucleotide-binding and intervening domains. These are listed in 
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Table 3 and consist of the unique interactions between the nucleotide-binding and 
intervening domains of subunit B (and D) and the nucleotide-binding and intervening 
domains of subunit A (and C).  
A diagram comparing the subunit and domain arrangement of E. coli and Mtb 
PGDH is shown in Figure 2.12. 
 
 
FIGURE 2.12. Comparison of the subunit and domain interaction in E. coli and  
Mtb PGDH. Subunits are depicted as geometric representation. Parallelograms are used 
for the similar conformations in E. coli PGDH, and rectangles and trapezoids for the two 
different conformations in Mtb PGDH. The subunits are labeled A-D. N is nucleotide-
binding domain, S is substrate-binding domain, I is intervening domain and R is 
regulatory domain. The solid lines depicts the inter subunit interactions and dotted lines 
depict the intra subunit interactions that are not continuous in the polypeptide chain. 
E.coli PGDH M.tb PGDH 
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TABLE 2 
Inter subunit domain contacts 
 
Nucleotide-binding domain of B (D) Intervening domain of C (A) Distance (Å) 
Gln 159 NE2 Glu 405 OE1 2.66 
Gln 182 NE2 Arg 410 O 2.55  
Gln 182 O Glu 405 N 3.12 
Gln 182 OE1 Ser 406 N 2.99  
 
Nucleotide-binding domain of A (C) Intervening domain of C (A) Distance (Å) 
Gln 182 NE2 Ser 348 OG 3.05  
 
Intervening domain of A (B) Intervening domain of D (C) Distance (Å) 
Asn 408 OD1 His 409 ND1 3.22 
His 409 ND1 Asn 408 OD1 2.72  
Arg 410 N Asn 408 O 3.33 
Arg 410 NH2 Ser 406 O 2.8 
 
 
TABLE 3 
Intra subunit domain contacts 
 
Nucleotide-binding domain of B (D) Intervening domain of B (D) Distance (Å) 
Arg 179 NH1 Glu 323 OE1 2.95 
Arg 179 NH2 Glu 323 OE2 3.25  
Arg 179 NE Glu 356 OE2 2.83 
Gln 182 OE1 Arg 410 NE 3.3  
Lys 206 NZ Glu 360 OE2 2.97  
 
  
Nucleotide-binding domain of A (C) Intervening domain of A (C) Distance (Å) 
Arg 152 N Glu 393 OE1 2.87  
Gln 155 NE2 Glu 393 O 2.82  
Asp 172 OD1 Arg 394 NH1 3.28  
Asp 172 OD2 Arg 394 NH1 3.1  
Ser 176 N Arg 394 O  3.1  
Arg 179 NH2 Ala 392 O  3.36  
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Analysis of hinge regions in Mtb PGDH 
In Mtb PGDH, the nucleotide-binding and substrate-binding domains are linked 
to the intervening and regulatory domains by a long loop (316-322) which is 
responsible for the 160° rotation between the domains, resulting in tetramer formation. 
Interestingly, the point of transition for this rotation is occupied by three consecutive 
glycine residues (316-318). In E. coli PGDH, glycine residues are also found between 
domains which act as hinge regions and play a role in the cooperativity of serine 
inhibition. These are Gly294-Gly295, found between the nucleotide-binding and 
substrate-binding domains and Gly336-Gly337, present between the substrate-binding 
and regulatory domains. Thus, these hinge regions are present at both ends of a long 
helix connecting the catalytic site to the regulatory site. Mutation studies on E. coli 
Gly294-Gly295 resulted in reduced enzyme activity and mutation of Gly294 alone was 
found to be important in the cooperativity of serine inhibition (119). Also, mutations in 
Gly336-Gly337 (G336, 337V) have resulted in weak serine binding and less sensitivity 
of the enzyme for serine (120). In comparison, in Mtb PGDH, Gly282-Ala283 is 
present in the loop region between the nucleotide-binding and substrate-binding 
domains. There is only a short loop of three residues present between the regulatory and 
intervening domains. This loop is devoid of any Gly or Ala residues. This indicates that 
there is less flexibility in this region. This arrangement might indicate that the 
intervening and regulatory domains act together as an ensemble for allosteric inhibition. 
A long helix (α14) in Mtb PGDH, with Gly282-Ala283 on one end and a long loop 
containing Gly316-Gly318 on the other end, connecting the catalytic site to this 
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ensemble, is present. Similar mutant studies have been carried out to investigate the 
role of these three consecutive glycine residues in Mtb PGDH. Single and double 
mutants of the glycine residues 316-318 had no appreciable effect on serine inhibition. 
No protein expression was found in triple mutant (G316, 317, 318V) of this region (78). 
Thus, these findings may indicate that these glycine residues are not involved in the 
process of serine inhibition but, rather, maintain the overall tetrameric structure of this 
protein. 
Analysis of the active site of Mtb PGDH 
 The Mtb PGDH catalytic site is present in a cleft between the nucleotide and 
substrate binding domains. Each PGDH subunit has its own distinct active site and these 
sites are ~ 32 Å apart at the nucleotide-binding domain interface. The site is mostly lined 
by the loop regions Arg51-Val56, Ala73-Val80, Lys131-Ser136, Val229-Leu236, 
Pro279-Gly293 and Ile374-Phe384. The side chains of the basic residues in these loop 
regions are predominantly oriented in the active site for binding the negatively charged 
substrates (PGA and HPAP) of this enzyme. A loop region from the adjacent subunit 
(Lys131'-Ser136') also contributes to its formation. This region is dominated by polar 
residues like Lys and Ser and contains the Arg132′ required for anchoring the substrate in 
the active site. The loop also contains the conserved Trp residue (Trp130) that maintains 
the architecture of the active site as well as the nucleotide-binding domain interface of the 
tetramer. This residue supports the hydrophobic pocket containing the catalytic dyad 
Glu262-OE1 and His280-ND1, characteristics of the dehydrogenases. In E. coli PGDH, 
the residues in this loop region (Asn140-Gly145) are dominated by Ala and Gly and 
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presumably provide flexibility to this region. Mutagenesis studies on these residues in E. 
coli suggest that this region is important for the cooperativity of serine inhibition of 
catalytic activity (121). Interestingly, in human PGDH, which is not inhibited by L-
serine, this region is occupied by bulky side chain residues such as Lys, Phe and Met, 
suggesting less flexibility in this region.  
Cofactor-binding site 
 Since Mtb PGDH requires NAD+/NADH as a cofactor for its catalysis, it 
contains the Rossmann fold motif consisting of a Gly149-X150-Gly151-X152-X153-Gly154-
Xaa17-Asp172 sequence (110), which delineates the cofactor binding site. Interestingly, the 
PGDH crystals, which were formed in the presence of NADH/NAD+ or its analog, 3-
acetyl pyridine dinucleotide, do not show the electron density for the cofactor in any of 
these structures. However, NAD+/NADH can be modeled into the Mtb PGDH active site 
by superimposing the nucleotide-binding domain of either E. coli or human PGDH onto 
the Mtb PGDH structure as the residues interacting with the cofactor are conserved. 
Based on this model, OD1 and OD2 atoms of Asp172 residue in the Rossmann fold 
should form hydrogen bonds with the O2 and O3 atoms of the ribose sugar of adenosine 
moiety. The adenine ring of the cofactor is located in a hydrophobic pocket comprised of 
Pro173 and 205, Val148, Tyr171, and Leu204 and 213 residues. The two phosphate 
atoms connecting the nicotinamide part with the adenine part of NADH partly interact 
with the main chain amides of Arg152 and Ile153. The multiple Gly residues in the 
Rossmann fold prevent any spatial interference when the cofactor binds. The N7 atom of 
the nicotinamide ring forms hydrogen bonds with Asp257-OD1 as well as the main 
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chain oxygen of Ala231 (Figure 2.13). 
 
FIGURE 2.13. NADH interaction in Mtb PGDH chain B. The figure shows the 
possible interactions of protein residues with NADH modeled at the Rossmann fold of 
chain B. This figure is generated by Ligplot (122).
60 
 
  
In Mtb PGDH, the cofactor binding site exists in two different environments in 
contrast to all the known PGDH structures (E. coli, human, and Pyrococcus). This is 
possibly due to the presence of two different domain orientations in this enzyme. In chain 
A, the site is covered by the intervening domain due to its close vicinity to the nucleotide- 
binding domain, thus forming a channel (Figure 2.14 A). It appears that either the 
cofactor has to enter through this channel or the intervening domain has to change its 
conformation to further expose the binding site. In this regard, the channel opening 
appears to be large enough to allow the cofactor to enter (8 Å x 25 Å). In chain B, due to 
the change in the orientation of the intervening and regulatory domains, the cofactor-
binding site is present in an open cleft. However, in chain B of all Mtb PGDH structures, 
the cofactor-binding site appears to be blocked by the long flexible loop (Leu203 - 
Ile213) present between strand β8 and helix α11 due to the proximity of the neighboring 
symmetry related molecule. However, movement of this loop to an orientation similar to 
chain A would allow the cofactor to bind at this site as shown in the figure 2.14 B. 
Indeed, the presence of these two different environments for NADH binding has also 
been confirmed by stopped flow fluorescence experiments (78) which shows that there 
are two sets of NADH binding sites.  
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FIGURE 2.14. Differences in cofactor binding site. Molecular surface representation of Mtb PGDH structure showing two different 
cofactor-binding sites. In both the chains, the four domains are represented in different colors: the nucleotide-binding domain (green), the 
substrate-binding domain (pink), the intervening domain (yellow) and the regulatory domain (violet). NADH is represented in orange CPK 
form. (A) In chain A, the cofactor-binding site resides in a channel which is formed by the intervening (yellow) and nucleotide binding 
domains (green). (B) In chain B, the loop, which blocks the cofactor-binding site in these structures, has been placed in an orientation 
similar to chain A. As seen in the figure, this site is now totally exposed to the solvent, as the intervening domain is oriented in the other 
direction (~ 160 º rotation) in this chain. NADH has been modeled in both the figures based on E. coli PGDH structure.  
A B
62 
 
Previously, tartrate present in the crystallization condition was thought to force 
the structure into a stable form which is not capable of binding cofactor. However, 
crystals obtained from different crystallization conditions that lacked tartrate had the 
same space group and cell dimensions as ones that contained tartrate but diffracted 
weakly. Though these datasets generated poor maps, they were also devoid of the distinct 
electron density for the cofactor in their structures. Thus, these two different binding 
environments for NADH do not appear to be a crystallographic artifact due to the 
presence of tartrate. However, it appears that the high salt concentrations (1 M NaK 
tartrate) present in the crystallization condition or 100 mM potassium phosphate buffer 
used as the protein storage buffer might be one of the reasons for the absence of cofactor 
in these structures. This fact is supported by the analysis of stopped flow fluorescence 
experiments which showed weak NADH binding in the presence of high ionic strength 
buffer (78). 
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Mode of substrate recognition and enzyme catalysis 
 In Mtb PGDH, the reverse reaction of reduction of HPAP to PGA is the favored 
reaction. The Km value for the substrate HPAP is ~ 85 µM and a kcat/Km of ~ 5.6 x 106  
M-1sec-1  (78). In order to understand the mode of enzyme catalysis in Mtb, structure 
determination of ternary complex of PGDH with HPAP and NAD analog was carried out. 
The 2.5 Å HPAP bound Mtb PGDH structure revealed the residues interacting with the 
substrate at the active site, although the electron density for HPAP is observed only at the 
chain B active site. This structure lacks the presence of the cofactor. The active site cleft 
remains open on substrate binding, thus indicating a nonproductive form of PGDH 
structure. In this crystal structure, the phosphate group of HPAP forms hydrogen bonds 
with Arg51-NE (3.5 Å) and Gln289-OE1 (2.6 Å) from one subunit, and Arg132'-NH1 
from an adjacent subunit (2.8 Å). The carboxyl group of the substrate is hydrogen bonded 
to Asn99-ND2 (3.16 Å) and the keto group of HPAP interacts with the main chain amide 
of Gly76 (3.08 Å) (Figure 2.15A). On comparing this binding of HPAP to the binding of 
substrate analog malate in the truncated human PGDH structure, HPAP does not seem to 
be properly oriented, with the keto group pointing away from the catalytic His280 (4 Å). 
Also, we did not see the expected interaction of the substrate C1-carboxyl group with an 
arginine residue which is seen in the structure of human PGDH (Arg235) and many other 
dehydrogenases (67). Arg233 is a conserved residue in Mtb PGDH that corresponds to 
Arg235 in human PGDH, and Arg240 in E. coli PGDH. In Mtb PGDH, the side chain of 
Arg233 is facing away from the active site. In fact, in chain A, Arg233 side chain forms a 
salt bridge with Glu379 whereas in chain B it appears to be flexible, resulting in reduced 
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density for the side chain. Thus, in the absence of a cofactor, HPAP is not properly 
oriented for the enzyme to carry out catalysis in this structure. Based on the model of 
cofactor-bound PGDH, side chain of Asn99 has to move out of the way for the 
nicotinamide part of the cofactor to bind. It may be possible that the presence of the 
cofactor plays a key role in the proper positioning of the substrate for hydride transfer 
from His280 by stabilizing the formation of a salt bridge between Arg233 and the 
carboxyl group of the HPAP. Indeed, stopped flow fluorescence experiments (78) with 
Mtb PGDH shows that the substrate HPAP binds first and then the cofactor NADH, 
during the enzyme reaction at the active site. This is in contrast to E. coli PGDH, in 
which NADH is intrinsically bound as evident from the fluorescence spectra of purified 
E.coli PGDH (73).  
In the ternary complex of substrate analog malate and NAD+- bound truncated 
human PGDH structure, the active site cleft exists in a closed conformation. 
Superimposing the Mtb PGDH nucleotide-binding and substrate-binding domains on the 
same domains of malate bound human PGDH reveals a 15º rotation of the substrate-
binding domain towards the nucleotide-binding domain upon ligand binding at the active 
site. This domain motion is analyzed by Dyndom algorithm (107). Even with an open 
cleft, the HPAP in Mtb PGDH structure seems to occupy a site similar to that of malate in 
the human PGDH structure, suggesting that the binding of both cofactor and substrate is 
needed for the active site to close and for productive contacts to be made with HPAP. 
Based on this superimposition, a model for the closed conformation of the active site cleft 
in Mtb PGDH has been prepared to elucidate the mechanism of enzyme action (Figure 
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2.15B). Interestingly, all three of the catalytically important residues (His280, Glu262 
and Arg233) are present on different loop regions of the nucleotide-binding domain. 
His280 is present on the Thr278-Ser284 loop connecting the nucleotide-binding domain 
to the substrate-binding domain, Glu262 is present on the loop between β10 and α13, and 
Arg233 is present on the loop between β9 and α12, near the nicotinamide ring, at the 
entrance of the active site cleft. The rest of the cofactor lies at the base of the active site 
cleft. In the initial step of PGDH catalysis, HPAP will bind at the active site first and then 
on NADH binding, the side chain of Arg233 will orient toward the HPAP-binding site. 
As a result, the C1-carboxyl group of HPAP will form a salt bridge with the guanidinium 
group of Arg233 and the C2-keto group will point towards the His280 on closure of the 
active site cleft. The interaction of His280-ND1 with Asp262-OE1 properly positions the 
imidazole ring for proton transfer. The generation of a partial positive charge on C2 of 
HPAP will allow for the transfer of hydride ion from NADH to the substrate resulting in 
the formation of NAD+ and phosphoglycerate. 
  
66
 
FIGURE 2.15. Catalytic event at the Mtb PGDH active site: (A) HPAP binding at the PGDH active site. HPAP is shown in 
stick form (yellow) and shows all the residues interacting with HPAP at the active site. (B) Ribbon diagram representation of 
the superimposition of the Mtb apoenzyme (blue) on ligand bound Mtb PGDH model (gold) based on malate and NAD bound 
human PGDH. NADH (green) and HPAP (gray) are shown in ball and stick form. As seen in the figure, there is rotation of 
approximately 15º of the substrate-binding domain (arrow) in response to substrate and cofactor binding. The intervening 
domain and the regulatory domain have not been shown for the sake of clarity.
A B
Nucleotide 
Binding 
Domain 
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Binding 
Domain 
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Role of intervening domain as an anion-binding site 
To further explore the role of the intervening domain in Mtb PGDH, VAST (123) 
and DALI (124, 125) structural alignment searches, using the coordinates of this domain, 
were carried out. Interestingly, these search algorithms found structural similarity within 
a region of domain II of 2-methylcitrate dehydratase from E. coli (VAST score = 8.1, 
PDB code-1SZQ; r.m.s.d of 2.8 Å for 83 Cα atoms) (Figure 2.16). This enzyme is 
involved in propionate catabolism and catalyzes the conversion of 2- methylcitrate to 2 
methyl cis-aconitate. Unfortunately, similar to the intervening domain, the role of 
domain II is also unknown. Apart from numerous other candidates with Z score of 2 - 
4.5, the DALI search also found a structural similarity with chorismate mutase in B. 
subtilis (Z score = 5, PDB code-2CHS; r.m.s.d. of 3.8 Å for 83 Cα atoms). Chorismate 
mutase is a homotrimer with the monomer having a single domain that catalyzes the 
conversion of chorismate to prephenate in aromatic amino acid biosynthesis (126). There 
was also some structural similarity with urocanate hydratase from Pseudomonas putida 
(VAST score = 7.8, PDB code-1UWK; r.m.s.d. of 2.3 Å for 52 Cα atoms) (127) which is 
involved in the histidine degradation pathway. Interestingly, the structural similarity is 
seen in a region that is part of the NAD+ binding domain in this enzyme, but no such 
NAD+ binding fingerprint region is present in the intervening domain of the Mtb PGDH. 
This homology search, unfortunately, did not provide us with any clues about the role of 
the intervening domain. 
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FIGURE 2.16. Overlay of the intervening domain of Mtb PGDH on domain II of 2-
methylcitrate dehydratase from E. coli (PDB code-1SZQ). The figure shows a ribbon 
diagram representation of the superimposition of the intervening domain of Mtb PGDH 
(blue) and the domain II of methylcitrate dehydratase (gold). As seen in the figure, the 
four antiparallel β strands in the front and the two helices at the back align well in both 
the structures with an r.m.s.d. of 2.8 Å. 
 
Intriguingly, in the Mtb PGDH structures, there is some extra electron density 
visible in the region where adjacent intervening domains converge. This electron density 
is surrounded by the positively charged residues His447, Lys439', Arg451', and Arg501' 
(Figure 2.17). This density can be easily fitted with a tartrate, which is part of the 
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crystallization solution. The tartrate is within hydrogen bonding distance of His447-ND1 
from one subunit (2.5 Å) and Lys439'-NZ (3.5 Å), Arg451'-NH1 & -NH2 (2.98 Å), and 
Arg501'(3.5 Å) from the adjacent subunit. Arg501' is contributed by the adjacent 
regulatory domain and forms an ion-pair with the C4 carboxyl group of tartrate. Two 
molecules of tartrate bind to this interface due to the symmetry of the structure and 
appear to form an inter-subunit bonding network. In Mtb, tartrate does not seem to be 
involved in any metabolic process so it is not the natural ligand, binding to PGDH. 
Based on its structural similarity with tartrate, we can infer that this could be another 
binding site for the substrate HPAP, responsible for uncompetitive inhibition of this 
PGDH. Indeed, mutagenesis studies on the residues in this region (Arg446Ala, 
His447Ala, Lys439'Ala, Arg451'Ala, and Arg501'Ala) have resulted in reduced substrate 
inhibition in Mtb PGDH (128). Triple mutation (Lys439', Arg451', and Arg501') of 
residues from one subunit shows complete elimination of the substrate inhibition. This 
theory is further supported by the fact that the PGDH in rat liver, which has an 
intervening domain, also shows substrate inhibition (29), but HPAP does not inhibit E. 
coli PGDH, which lacks this domain. Thus, the intervening domain in Mtb PGDH may 
be required for additional regulation of serine biosynthetic pathway during the chronic 
infection of the host. This site can also act as a template for the development of 
inhibitors in this enzyme. 
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FIGURE 2.17. Anion binding site at the intervening domain interface of Mtb PGDH. 
The figure shows the interface of the regulatory domain (purple) and the intervening 
domain (yellow). In this figure, tartrate is shown in ball and stick form (green) 
interacting with the positively charged residues from both the domains. There are two 
tartrate bound at the interface due to two fold axis. In this figure, only one tartrate 
interaction is shown for the clarity of the figure. 
 
 
71 
 
Mode of serine binding 
L-serine inhibits Mtb PGDH with an IC50 of ~30 μM (64). This allosteric 
regulation of Mtb PGDH shows cooperativity with a Hill coefficient near 2.0 (78). 
Analysis of the 2.7 Å serine bound Mtb PGDH structure shows that L-serine binds at 
the interface of the regulatory domains, forming hydrogen bonds to both domains in a 
manner analogous to that seen in E. coli PGDH (9). Due to non-crystallographic two- 
fold axis, there are two serine molecules binding 17 Å apart at the regulatory domain 
interface. This allosteric site is 35 Å away from the active site. When the serine-bound 
PGDH structure is compared to the HPAP-bound structure or the apostructure, no 
major conformational changes or large domain movements are observed.  
Even though this domain shares the βαββαβ secondary structure with its E. coli 
counterpart, the sequence identity is only 30% and the residues that interact with serine 
are not well conserved. In the inhibited structure of E. coli PGDH, residues His344, 
Asn346, and Asn364' interact with L-serine at the regulatory domain interface (9). In 
the serine-bound Mtb PGDH structure, the L-serine carboxyl group forms a hydrogen 
bond with the hydroxy group of Tyr461 (2.7 Å) and Asp463-OD1 (2.5 Å). The amino 
group of serine hydrogen bonds with Asn481'-OD1 (2.9 Å) from the adjacent subunit. 
No water molecules are present in the regulatory site for bond formation with the serine 
side chain hydroxyl group as seen in E. coli PGDH, indicating that the site is more 
compact. Instead, the serine hydroxyl group makes direct hydrogen bond contact with 
the main-chain amide of Leu468. Mutation of all the residues that interact with L-serine 
(Y461A, D463A, and N481A) has resulted in reduced serine inhibition with an increase 
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in IC50 values for serine.  
There are significant local changes in the orientations of the side chains of the 
residues at this allosteric site. The side chains of Asp463 and Arg464, present on the 
loop region at the allosteric site, flip their positions when serine binds in the regulatory 
domain (Figure 2.18). This flipping is necessary for hydrogen bond formation between 
the effector molecule and Asp463 side chain. Even though all the residues in this loop 
region (Val462-Gly466) are quite similar to E. coli PGDH, this flip is not seen in the E. 
coli allosteric site. In E. coli PGDH, there is a movement (4 Å) of this loop region near 
the proline residue (Pro348) to cover the allosteric site in response to serine binding. In 
Mtb PGDH, this change occurs at the flipped region to cover the serine-binding site. 
Because of this flipping, considerable movement in the neighboring residues (His460-
Val462 and Pro465 - Gly466) is also observed. A surface representation of the 
regulatory domain shows that the path to the binding site, at the regulatory domain 
interface, is closed upon serine binding (Figure 2.19).  
The orientation of the side chain of Asn481' from the adjacent subunit also 
changes, in addition to all the aforementioned changes. When serine binds, the side 
chain orients to face Asp463, forming a hydrogen bond with the serine amino group 
(2.9 Å). These interactions further strengthen the regulatory domain interface. The 
mutation of Asn481′ residue (N481A) from the adjacent subunit has resulted in loss of 
cooperativity of serine binding with a decrease in the Hill coefficient to 1.1 (78). 
In serine unbound PGDH, Asn481'-ND2 hydrogen bonds with Asp503-OD2 on the 
neighboring loop of the same chain (~3.4 Å). There is also a change in the orientation 
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of the side chain of His460-NE2 which forms hydrogen bonds with Asp490-OD1 (3.1 
Å) and OD2 (3.4 Å) when serine binds. In response to this change, the orientation of 
the phenol side chain of Tyr521 also shifts 90°. There is also variation in the orientation 
of Glu489 which, in the absence of serine, is hydrogen bonded to Arg464 but faces 
toward the anion-binding site when serine binds. Interestingly, all these residues, which 
undergo changes on serine binding, are present on the loop regions adjacent to the 
allosteric site.  
Different members of the ACT domain family show different mechanism for 
allosteric regulation, e.g. E. coli aspartokinaseIII changes its oligomeric state from a 
dimer to a tetramer in response to the lysine binding at the allosteric site (129). Also, in 
E. coli PGDH, serine binding prevents the movement of the nucleotide-binding domain 
with respect to the other two domains (74). In comparison, the changes seen in Mtb 
PGDH in response to serine binding seem to be quite different. 
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FIGURE 2.18. Changes occurring at the loop region of allosteric site on serine binding. (A) In Mtb PGDH, 
superimposition of the regulatory domain of chain A of the apoenzyme (purple) and the serine bound form (green) shows a 
flip in the side chains of Asp463 and Arg464, present on the loop region lining the allosteric site. Also visible, is the change 
in orientation of Asn481′ side chain from the adjacent subunit on serine binding, which covers the allosteric site. (B) In E. 
coli PGDH, superimposition of the regulatory domain of chain A of the apoform (purple) with the serine inhibited form 
(green) shows transition of the loop region at Pro348, with no flipping of side chain on serine binding. In this case, transition 
of the Pro348 covers the allosteric site on serine binding. In both the figures, serine is shown at this site in the stick form 
(yellow). Not all the interactions with serine have been shown in this figure to maintain the clarity of the figure. 
A B
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(A) (B) 
  
 
 
 
 
 
 
 
 
FIGURE 2.19. Molecular surface representation of the serine binding site. This figure shows the molecular surface 
representation of the regulatory domain interface with the changes occurring at the allosteric site on serine binding. Adjacent 
regulatory domains are colored gray and yellow with the labeled residues lining the allosteric site. (A) The presence of an 
opening (channel) for entry of serine(shown with an arrow) (B) The closure of this entrance on serine binding, as shown in 
the figure. 
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The Mtb PGDH structures reported in this chapter and the insights gained from 
them will aid considerably in understanding the mechanism of action of the ACT 
domains in regulation not only for this form of PGDH but also for other less closely 
related members of the ACT domain family. In addition, since the human enzyme is 
insensitive to serine, this structure may also provide a stepping-stone for the 
development of new drugs against Mtb. As a future work, this allosteric site can be used 
as a template for virtual screening against the fragment-based library. In addition, as the 
mechanism of feedback inhibition is not quite clear from this serine-bound Mtb 
structure, a situation, similar to leucine-bound Mtb LeuA structure (114); further 
crystallization trials can be conducted in search for other crystal forms which may lead 
to a different Mtb PGDH structure that can answer this question. 
Cloning, purification and crystallization of human PGDH 
Sequence alignment of human PGDH with Mtb PGDH has shown that humans 
also possess a similar form of PGDH with insertion near the C-terminus but have a 
sequence identity of only 33%. Further analysis of the sequences of both human and Mtb 
PGDH showed that all the residues interacting with the cofactor and the substrate at the 
active site are conserved in these proteins. However, human PGDH lacked sequence 
identity in the other two domains: the intervening and regulatory domains (20%). The 
residues that are thought to be responsible for the substrate inhibition in Mtb PGDH are 
not conserved in human PGDH even though it is thought to be also inhibited by HPAP 
due to its high sequence identity (94%) with rat liver PGDH. The stretch of three glycine 
residues (G316-G318) which are the locus for the 160º rotation of the nucleotide-binding 
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and substrate-binding domains in relation to the other two domains during tetramer 
formation in Mtb PGDH, are also not present in human PGDH. This fact raises the 
question of how the domains as well as subunits are arranged in this form of PGDH in 
humans. Since, human PGDH has a high sequence identity with rat liver PGDH, which 
does not show any serine inhibition, we also wanted to know about the inhibitory effect 
of L-serine on human PGDH.  
Although a truncated version of human PGDH structure with nucleotide-binding 
and substrate-binding domain was recently deposited in the protein data bank (PDB code 
– 2G76), it does not provide us with any information regarding the domain organization 
as well as oligomeric formation of the whole mammalian protein. Hence, it would be 
necessary to determine the three-dimensional structure of the full-length protein to 
understand the differences in domain organization and regulatory domain interface 
between human and Mtb PGDH.  
Toward this end, we have successfully cloned and purified the human PGDH 
(both His-tagged and untagged) to homogeneity using various purification protocols 
described in the methods section. His-tagged PGDH protein was purified using a single-
step Ni affinity column where as the wild type PGDH was purified using anion exchange 
and size exclusion chromatography (Figure 2.20). Further kinetic studies have shown 
that the human protein is insensitive to serine inhibition (78). This fact is quite 
fascinating since PGDHs having an insertion near the C-terminus show different 
inhibitory effects of serine, the end product of this biosynthetic pathway and hence 
prompted us to determine the three-dimensional structure of human PGDH. The 
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resulting human PGDH structure will explain the role of the C-terminal domain that is 
present even though the enzyme is not inhibited by L-serine, and also determine the 
residues involved in substrate inhibition.   
We have further tried to crystallize human PGDH complexed with the cofactor 
NADH. The crystallization procedure always requires a high protein concentration (10 
mg/ml or greater), but human PGDH could not be concentrated beyond 4 mg/ml as the 
protein precipitates at higher concentrations. Several tricks were devised to overcome 
this problem: the addition of 200 mM LiSO4 or reducing agents like 10 mM DTT/TCEP 
to the protein storage buffer or incubation of the dilute protein with the cofactor NADH 
to stabilize the protein before concentration. The addition of LiSO4 as well as TCEP did 
not help in stabilizing the protein; however, the addition of 10 mM DTT as well as 
incubation of the protein with NADH resulted in protein concentrations of up to 16 
mg/ml. It was also observed that human PGDH was mostly stable in potassium 
phosphate (pH 7.5) or HEPES buffer (pH 7.5) than in Tris buffer (pH 7.5). To further 
facilitate the process of crystallization in this protein, we have also constructed a 
truncated version of human PGDH (Ser323-Phe533) containing only the intervening and 
regulatory domains. Crystallization trials for all the different constructs of human PGDH 
with different matrix screens from Hampton Research as well as Emerald BioSystems 
have been carried out and we are awaiting the results from these trials.  
 
 
 
  
79 
            B 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
0 20 40 60 80 100 120 140 160 180
volume in ml
A
b
s
o
r
b
a
n
c
e
 
a
t
 
2
8
0
n
m
 
(
A
U
)
 
 
FIGURE 2.20. Purification of human PGDH. This figure shows (A) the chromatogram of a gel filtration column for human 
PGDH purification (B) the 4-12% SDS-PAGE gel stained with Coomassie Blue dye, containing the fractions of wild type 
human PGDH purified using gel filtration column. Lane M specifies Perfect proteinTM marker (10-225 kDa) (Novagen). The 
molecular weight of human PGDH is approximately 57 kDa. 
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In conclusion to the human PGDH part of the chapter, we have successfully 
cloned and purified different constructs of human PGDH in preparation for the three- 
dimensional characterization of this enzyme. 
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CHAPTER III 
 
CRYSTALLOGRAPHIC STUDIES ON 7, 8-DIAMINOPELARGONIC ACID 
SYNTHASE IN THE BIOTIN BIOSYNTHETIC PATHWAY 
 
Background  
7, 8-Diaminopelargonic acid synthase (DAPAS), a pyridoxal-5′-phosphate (PLP) 
dependent enzyme, catalyzes the antepenultimate step of biotin biosynthesis. It catalyzes 
the transamination reaction of 7-keto, 8-aminopelargonic acid (KAPA) into 7, 8-
diaminopelargonic acid (DAPA) (Figure 3.1). This is the only aminotransferase known 
to utilize S-adenosyl methionine (SAM) as the amino donor for its reaction.  
Preliminary biochemical characterization of the DAPAS enzyme has been carried 
out in B. sphaericus (47), Brevibacterium divaricum (130), and B. subtilis (48). Studies 
were conducted in B. subtilis mainly to increase the production of biotin and dethiobiotin 
by fermentation process for commercial purposes (48). Although DAPAS has been 
extensively studied, biochemically (131-133) as well as structurally (134, 135) in E. coli, 
the mechanism of dual substrate recognition in this transaminase has not been resolved 
to date.  
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FIGURE 3.1. Reaction catalyzed by 7, 8-diaminopelargonic acid synthase. DAPAS 
follows a bi-bi ping-pong reaction mechanism in which SAM donates its amino group to 
cofactor PLP in the first half-reaction, forming pyridoxamine-5'-phosphate (PMP). With 
the release of the product S-adenosyl-2-oxo-4-methylthiobutyric acid, KAPA binds at 
the active site in the second half-reaction and accepts the amino group from PMP, in 
turn, converting it back into PLP. 
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Genetic approaches in the form of transposon mutagenesis site hybridization 
(TraSH) (9) in Mtb H37Rv strain as well as bioA mutant studies in M. smegmatis (57) 
have indicated the role of a bioA gene, which codes for DAPAS, in persistence and 
survival during mycobacterial infection. Furthermore, recent kinetic analysis on the Mtb 
DAPAS (136) shows that its kinetic efficiency is quite low compared to the E. coli 
enzyme (133) (Kcat for Mtb DAPAS (1±0.2 min-1) versus E. coli DAPAS  
(0.013±0.001s-1)) even though it has 48% overall sequence identity with the E. coli 
counterpart. 
Hence, in order to understand the active site architecture, we have characterized 
the crystal structure of Mtb DAPAS in complex with the cofactor PLP. In addition, 
characterization of the substrate-bound DAPAS structures elucidates the basis of 
recognition of the enzyme’s two diverse substrates, SAM and KAPA. Utilizing the 
active site of KAPA-bound Mtb DAPAS as a template, we further carried out virtual 
screening of large compound libraries to search for potent inhibitors.  
Furthermore, in this study, in order to understand the variations in the 
architecture of the DAPAS active site in certain Bacillus species and thermophiles, we 
have also determined the three-dimensional structure of the B. subtilis DAPAS enzyme 
in the apoform, PLP-bound form as well as in a ternary complex with PLP and substrate 
KAPA using X-ray crystallography (Figure 3.2). 
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FIGURE 3.2. Alignment of sequences of DAPAS in Mtb, E. coli and B. subtilis. The 
residues colored in green are conserved among DAPAS in all three organisms. Residues, 
which are identical and similar in all the three sequences, are colored yellow and cyan. 
The residues, which are involved in catalysis, are marked with red asterisks. This 
alignment is prepared using ClustalW (79) 
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Methods 
Reagents 
Restriction enzymes for bioA cloning were purchased from New England 
Biolabs. All the chemicals for purification and assays including SAM, SAH and 
sinefungin were purchased from Sigma except KAPA which was purchased from 
Toronto Research Chemicals Inc., Canada. DAPA was chemically synthesized by Dr. 
Joel Freundlich of Princeton University using the protocol of Gibson et al. (137). 
Cloning, protein overexpression and purification 
The bioA gene (Rv1568) from Mtb H37Rv genomic DNA was PCR amplified 
and cloned into pET28b with TEV site using NdeI and HindIII restriction sites. The NdeI 
site contained the ATG start codon and the stop codon preceded the HindIII site. The 
Y25A mutant form of DAPAS was constructed using QuikChange mutagenesis kit 
(Stratagene) with pET28b-Rv1568 as the template. The primers used in this study were: 
For the native DAPAS: 
Forward primer: 5' AGAGAAGCATATGGCTGCGGCGACTGGCGGGTT 3' 
Reverse primer: 5' CCCAAGCTTTCATGGCAGTGAGCCTACGA 3' 
 
For the Y25A DAPAS mutant:  
Forward primer: 5' CATCTGTGGCACCCTGCCAGCTCCATCGGCAG 3' 
Reverse primer: 5' CTGCCGATGGAGCTGGCAGGGTGCCACAGATG 3' 
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Both the clones (pET28b-Rv1568 and Y25A mutant) were then transformed into 
the E. coli expression host BL21 (DE3). The cell culture was grown in LB media with 
kanamycin (50 μg/ml) at 37 ºC till the A600 reached 0.8 and then induced with 0.5 mM 
IPTG at 25 ºC and grown overnight. There was no protein expression seen at 
temperatures lower than 25 °C and protein was mostly insoluble at temperatures above 
25 °C. The cells were harvested by centrifuging at 3000 rpm for 30 min and resuspended 
in 50 mM Tris buffer (pH 7.5), 500 mM NaCl, 1 mM PMSF, 20 μg/ml DNase, and 100 
μM PLP. The cells were lysed using French press at 11,000 psi and the cell debris was 
removed by centrifuging the cell lysate at 15,000 rpm for 1 hour. The supernatant was 
then loaded on a HisTrapTM FF Ni column, which was pre-equilibrated with 50 mM Tris 
buffer (pH 7.5), 500 mM NaCl, and the protein, was eluted with a gradient of imidazole 
(50 mM - 400 mM). The protein is 98% pure as judged from the SDS-PAGE. The 
fractions containing the pure protein were pooled and dialyzed overnight against a buffer 
containing 25 mM Tris (pH 7.5), 50 mM NaCl, 1 mM EDTA, and 1 mM DTT.  
The B. subtilis bioA gene was PCR amplified from the B. subtilis 168 genomic 
DNA (Bacillus Genetic Stock Centre, Ohio State University), further cloned, and the 
His-tagged protein was purified in the same way as the Mtb DAPAS. 
Spectroscopic studies of Mtb DAPAS 
Absorbance spectra for the Mtb DAPAS enzyme (12 μM) alone and in reaction 
with substrate SAM (1 mM) and its analogs (1 mM)-sinefungin and SAH in the range of 
300-600 nm were measured on the Cary 100 spectrophotometer (Varian). Similar spectra 
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for the Y25A mutant form of DAPAS with 1 mM SAM and DAPA were also scanned. 
On excitation at 280 nm, fluorescence emission scans for the Mtb DAPAS (5 μM) with 1 
mM sinefungin, and S-adenosyl homocysteine (SAH) were followed in the range of 300-
450 nm on the LS 55 luminescence spectrometer (Perkin Elmer Instruments) with 
constant stirring. All the experiments were performed at room temperature. The buffer 
used was 50 mM AMPSO (pH 8.5), 150 mM NaCl, 10% glycerol, 4 mM  
β-mercaptoethanol and 100 μM PLP. Concentrations of DAPAS and its Y25A mutant 
were calculated from their absorbance at 280 nm using extinction coefficient 64490 
/mM/cm and 63210 /mM/cm, respectively (138). Further kinetic parameters for Mtb 
DAPAS with SAM and sinefungin have been determined by performing the first half of 
the enzyme reaction at 335 nm to measure the formation of PMP (ε of PMP = 8300 
/M/cm) (139). The Michaelis-Menten equation was used to calculate the Kmapp and Kmax 
values with the curvefit option in the Kaleidagraph software. 
For the inhibition assays of the top ranked compounds from virtual screening, we 
have tried two different concentrations of the compounds, 10 μM and 50 μM. All the 
compounds were dissolved in 100% DMSO to prepare stock solutions (10-100 mM). In 
a typical 100 μl enzyme reaction, 5 μM of Mtb DAPAS was incubated with the 
compound for 1 min. The buffer used was 50 mM AMPSO (pH 8.5), 150 mM NaCl, 
10% glycerol, 4 mM β-mercaptoethanol and 100 μM PLP. The reaction was started by 
the addition of 800 μM of SAM and change in absorbance of the enzyme reaction was 
monitored at 335 nm. We also confirmed that DMSO did not affect the enzyme reaction 
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by replacing the DMSO dissolved compounds with an equal volume of DMSO in the 
reaction mixture and monitoring the absorbance at 335 nm. 
Crystallization and data collection 
The crystal trials for Mtb and B. subtilis DAPAS were carried out at 18 °C using 
the crystal screen I and II, and Index screen of Hampton Research and wizard I, II and 
III of Emerald Biosystems. Crystals were initially obtained using robotic screening with 
a 1:1 ratio on 96 well intelliplates (Hampton Research). Yellow crystals for Mtb DAPAS 
would appear after heavy precipitation in conditions having PEG 8000 as the common 
precipitant (Figure 3.3A). These crystals have a single random mutation of H315R in the 
protein. The quality of the crystals could not be improved by any optimization method 
(different types and concentrations of PEG, additive screens, detergent screens etc.). A 
2.2 Å intensity dataset for Mtb DAPAS crystal in PEG 8000, 0.1 M Tris buffer (pH 7.0), 
0.1 M MgCl2 (WIZARD II # 43) was collected after a lot of screening.  
To determine the crystal structure of SAM-bound DAPAS, we soaked the 
crystals with different concentrations (10-40 mM) of SAM, but the crystals resulted in 
no diffraction to X-rays. For cocrystallization, mixing high concentrations of SAM with 
the protein, led to precipitation of the protein. The dataset for the sinefungin-bound 
DAPAS was obtained by soaking the crystal in 10 mM sinefungin for 45 min. This 
condition was obtained after the DAPAS crystals were soaked with different 
concentrations of sinefungin at different time points. This dataset was also collected in-
house at the resolution of 2.2 Å. This DAPAS crystal was obtained in 20% PEGMME 
5000, bis-tris buffer (pH 7.5) (# 46 of Hampton Research’s Index Screen). However, 
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soaking the DAPAS crystals for a longer time in sinefungin or using higher 
concentration of sinefungin also resulted in deteriorated or no diffraction of the crystal.          
Crystals for B. subtilis DAPAS were obtained in 4 μl drop of protein (10 mg/ml) 
and precipitant (20% PEG 3350, 0.2 M sodium thiocyanate, #13 PEG/Ion screen of 
Hampton Research) in a 1:1 ratio (Figure 3.3B). The quality of the crystal greatly 
improved with the addition of 5% xylitol from the additive screen (#56 of Hampton 
Research) to the crystallization drops. The PLP-bound and PLP + KAPA-bound DAPAS 
datasets were obtained by cocrystallization of the DAPAS protein with 1 mM PLP and 1 
mM PLP + 5 mM KAPA respectively, in hanging drop plates. Simply soaking the 
DAPAS crystals with PLP (5 mM) or PLP (5 mM) + KAPA (5 mM) would result in no 
diffraction of the crystals.  
 
 
  FIGURE 3.3. Crystals of DAPAS enzyme. (A) Mtb and (B) B. subtilis using hanging 
drop-vapor diffusion method in PEG conditions from Hampton research. DAPAS 
crystals are in the dimension of 50 μM x 50 μM x 50 μM. 
A B 
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 All the DAPAS crystals were cryoprotected with paratone oil and the data were 
collected at the home-source on Rigaku Raxis IV ++ image plate detector at 120 ºK. All 
the datasets for Mtb and B. subtilis DAPAS were processed and scaled using the 
HKL2000 suite (90).  
Structure determination 
The structure of PLP-bound Mtb DAPAS was determined using molecular 
replacement (MR) with Phaser (94). The E. coli PLP-bound DAPAS structure (PDB 
code - 1QJ5) was used as the search model (LLG = 1437.6) for this MR. Even though, 
both the Mtb DAPAS structures possessed the same orthorhombic space group (P212121) 
they had quite a different unit-cell dimensions as provided in the Table 4. So the 
structure of sinefungin-bound DAPAS was solved by MR using the PLP-bound Mtb 
DAPAS as the model (LLG = 4189.75). Phasing of the B. subtilis DAPAS dataset was 
also achieved by MR with Phaser using the coordinates of chain A of Mtb DAPAS (PDB 
code - 3BV0; LLG = 279). Using chain A of E. coli DAPAS (PDB code - 1QJ5) as a 
model, the LLG was 243.  
Molecular replacement technique 
Molecular replacement method that was used to solve the crystal structures of 
DAPAS in this chapter requires the presence of an already solved homologous model 
with at least 25% sequence identity between the two protein sequences. In this case, we 
used the E. coli DAPAS structure (PDB code-1QJ5) as the search model (sequence 
identity of 48%). The aim is to properly place the known E. coli DAPAS structure in the 
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unit cell which was determined from the diffraction data of the Mtb DAPAS. This idea 
of molecular replacement was first initiated by Rossmann and Blow in 1962 (140). The 
structure factors obtained from the search model and the diffraction data were used to 
calculate the corresponding Patterson maps. This map is a Fourier map calculated with 
the square of the structure factor amplitude and phase angle of zero. The idea is to best 
overlap the Patterson map generated from the E. coli DAPAS onto the Patterson map of 
the Mtb DAPAS. 
Molecular replacement involves two steps: calculation of the rotation and 
translation functions. In the rotation function search, the search molecule is 
systematically rotated through all the possible orientations (α, β, γ).  The characteristic 
pattern for each orientation is compared with the Patterson map from the experimental 
data, and close correspondences suggest that the orientation of the experimental 
molecule and the search molecule are the same.  After the orientation of the 
experimental molecule has been determined by this rotation function search procedure, a 
related procedure can be carried out using the properly oriented search molecule, this 
time systematically translating the search molecule through the asymmetric unit (x, y, z) 
and calculating the corresponding Harker vectors, again looking for a match to the 
experimental Patterson map (Figure 3.4). 
Over the years, many mathematical transformations have been developed to 
make the MR search computationally more efficient. In recent years, program such as 
Phaser (94) uses maximum-likelihood-based algorithms for the calculation of fast 
rotation and translation functions for MR solutions. 
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TABLE 4 
Data collection, refinement and geometry statistics of Mtb DAPAS 
 
 Mtb-DAPAS Mtb-DAPAS + sinefungin
Data collection   
Space group P212121 P212121 
Unit cell dimensions a= 63.1 Å 
b=66.5 Å 
c=203.4 Å 
α=β=γ=90° 
a=62.6 Å 
b=83.4 Å 
c=157.9 Å 
α=β=γ=90° 
Molecules per asymmetric unit 2 2 
Wavelength (Å) 1.54 1.54 
Resolution range (Å) 35-2.2 30-2.2 
Highest resolution bin (Å) 2.3-2.2 2.3-2.2 
Observed reflections 1149410 618111 
Unique reflections 121230 30270 
Completeness (%)a 99.5 (96.1) 99.9 (99.8) 
Average redundancya  18.7 (10.8) 20.4 (16.4) 
I/σ(I)a 19.3 (1.6) 39.8 (5.2) 
Rsyma,b 0.16 (0.85) 0.081 (0.59) 
   
Refinement statistics (REFMAC)   
Free R value (5%) 24 23 
R value (%)c 19 18.7 
No. of protein residues 860 841 
No. of water molecules 200 280 
r.m.s.d. bond length, (Å) 0.009 0.016 
r.m.s.d. bond angles, (°) 1.2 1.81 
   
Ramachandran plot (PROCHECK)   
Most favored region (%) 629 (90.4) 631 (89.1) 
Additional allowed regions (%) 60 (8.6) 65 (9.2) 
Generously allowed regions (%) 3 (0.4) 5 (0.7) 
Disallowed regions (%) 4 (0.6) 4 (0.6) 
a Values in parenthesis for the highest resolution bin 
b Rsym = Σ|I - <I>| /Σ<I>, where I is the observed intensity, and <I> is the average intensity of multiple 
observations of symmetry-related reflections. 
c R = Σ ||Fobs|-|Fcalc||/ Σ |Fobs| where Fobs and Fcalc are the observed and calculated structure factors 
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FIGURE 3.4. Principle of Molecular replacement method.  This figure represents the 
principle of molecular replacement strategy to obtain phases for structure determination. 
The correct position, X′ in the unit cell of search model with coordinates X is obtained 
by applying the rotation function R and translation function T to X. 
 
SEARCH
MODEL (X)
TARGET
MOLECULE (X’)
R
X’=X[R]+T
T
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Model building and refinement 
Iterative rounds of model building were performed using the Xfit module of 
Xtalview (102) and Coot (141) with the Shake&wARP (142) bias-minimized electron 
density maps. These models were refined (rigid body and restrained refinement) using 
REFMAC of the CCP4 suite (103). When the models have reached decent Rfactor and 
Rfree values below 30%, water molecules were added to the model, and inspected 
manually during refinement. Criteria for adding water molecules to the model are as 
follows: 1) a minimum of 3σ peak present in the Fobs- Fcalc difference map 2) water 
molecule should make sensible hydrogen bonds with protein atoms, and 3) the B factor 
values of the water molecules should not be unusually high compared to the protein 
residues during refinement. The quality of the models was validated by generating the 
Ramachandran plots using PROCHECK (106). Data collection, refinement and 
geometry statistics of Mtb DAPAS and B. subtilis DAPAS are provided in the Table 4 
and 5, respectively. All the structure figures in this chapter have been prepared using 
Chimera (108). 
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TABLE 5 
Data collection, refinement and geometry statistics of B. subtilis DAPAS 
 Bs-DAPAS Bs-DAPAS + 
PLP 
Bs-DAPAS 
+PLP+ KAPA
Data collection    
Space group P21 P21 P21 
Unit cell dimensions a=58.1 Å 
b=102.8 Å 
c=74.53 Å 
α=γ=90° 
β=105.1º  
a=58.1 Å 
b=102.8 Å 
c=74.53 Å 
α=γ=90° 
β=105.1º  
a=57.72 Å 
b=104.9 Å 
c=74.96 Å 
α=γ=90° 
β=105.3º  
Molecules per asymmetric unit 2 2 2 
Wavelength (Å) 1.54 1.54 1.54 
Resolution range (Å) 35-2.2 35-1.9 30-2.26 
Highest resolution bin (Å) 2.3-2.2 2.0-1.9 2.34-2.26 
Observed reflections 1149410 372563 157974 
Unique reflections 121230 65085 39726 
Completeness (%)a 99.5 (96.1) 98.5 (96.8) 98 (82.2) 
Average redundancya 18.7 (10.8) 5.7 (5.6) 4.0 (2.9) 
I/σ(I)a 19.3 (1.6) 22.1 (2.0) 10.5 (1.2) 
Rsyma,b 0.16 (0.85) 0.06 (0.72) 0.12 (0.73) 
    
Refinement statistics (REFMAC)    
Free R value (5%) 26 24 27 
R value (%)c 23 20 21 
No. of protein residues 830 833 894 
No. of water molecules 250 385 261 
r.m.s.d. bond length, (Å) 0.012 0.009 0.014 
r.m.s.d. bond angles, (°) 1.7 1.32 1.74 
    
Ramachandran plot (PROCHECK)    
Most favored region (%) 657 (89.5) 658 (90.0) 681 (87.3) 
Additional allowed regions (%) 67 (9.1) 68 (9.3) 94 (12.1) 
Generously allowed regions (%) 6 (0.8) 1 (0.1) 1 (0.1) 
Disallowed regions (%) 4 (0.5) 4 (0.5) 4 (0.5) 
PDB code 3DRD 3DOD 3DU4 
a Values in parenthesis for the highest resolution bin 
b Rsym = Σ|I - <I>| /Σ<I>, where I is the observed intensity, and <I> is the average intensity of multiple 
observations of symmetry-related reflections. 
c R = Σ ||Fobs|-|Fcalc||/ Σ |Fobs| where Fobs and Fcalc are the observed and calculated structure factors 
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Results and discussion 
Description of the overall fold in Mtb DAPAS 
Mtb DAPAS has two distinct domains in its monomer, a small domain (residues 
1- 60 and 339 – 437) and a large domain (residues 61 – 338), similar to E. coli DAPAS 
(134) (Figure 3.5A). The N-terminal part of the small domain consists of one helix (α1) 
and three antiparallel β strands (β1-β3) connected by a long loop, and the C-terminal 
part starts with a helix-loop-helix having three antiparallel β sheets (β11-β13) and three 
helices (α10-α12) laid against these strands. The large domain consists of seven β 
strands (β4-β10-β9-β8-β7-β5−β6), six of which are parallel with the exception of β10 
which is placed antiparallel in the sheet. These β strands are interconnected by helices 
(α2-α9), which also bear the cofactor-binding site. Superposition of the chain A on 
chain B of Mtb DAPAS using 435 Cα atoms results in an r.m.s.d. of 0.38 Å, indicating 
similar structure between the two chains as well as less flexibility between the large and 
small domains in contrast to aminotransferases of subclass I (143).  
Dimer interface 
The asymmetric unit of the crystal structure consists of a homodimer which is 
mostly formed by the extensive contact between the large domains of both subunits 
(Figure 3.5B). The buried surface area between the two monomers forming the dimer is 
approximately 4021 Å2, 13.6% of the total surface area of the protein. In this dimer 
formation, the helix α2 (Pro74-Arg85) of the large domain of subunit A is placed 
antiparallel to the helix α2' of the large domain of subunit B at the non-crystallographic 
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2-fold axis, having only one hydrogen bond contact between the main-chain oxygen of 
Leu84 with Asp77-OD1 through a water molecule, at both ends of the helix. There are 
several other hydrophobic interactions throughout the interface. Monomer contacts are 
also present in the form of hydrogen bond interactions between His71-ND1 and Asp88′-
OD1 (2.74 Å) at the loop regions, connected with this helix α2. There are also hydrogen 
bond interactions between the N-terminal part of the small domain and the large domain 
of the two subunits at His20-ND1:Asp116′ main-chain oxygen (2.5 Å) and His23-
ND1:Phe93′ main-chain oxygen (2.82 Å). The helix α1 of the small domain from one 
subunit crosses over the helix α3′ of the large domain of the other subunit. This mostly 
involves hydrophobic interactions with Pro, Val and Ile residues from both the subunits. 
Comparison with E. coli DAPAS 
The 437 amino acid Mtb DAPAS, which is eight residues longer than E. coli 
DAPAS, has a very similar overall structure with the exception of the loop regions 
(r.m.s.d. for 420 Cα atoms = 1.07 Å). This is also the case with other members of this 
class of aminotransferases, as discussed later. The orientation and length of the loop 
regions (Asp51 - Gly52, Thr111- Asp116, Pro189 - Asp196 and Ala307 - Asn322) of the 
Mtb enzyme differ from their E. coli counterpart. The position of helix α6 (Pro197 - 
Glu213) differs with a movement of 2 Å. Certain interactions unique to Mtb DAPAS, 
not visible in E. coli enzyme, are a salt bridge between Arg246:Glu204 (3.0 Å) and 
several hydrogen bond networks (Tyr195-OH: Asp239- OD2: Ser200- γO, Lys105-NZ: 
Asp109 (2.9 Å and 2.7 Å), Trp45-NE1: Glu418-OE2 (3 Å)).   
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FIGURE 3.5. Ribbon diagram of Mtb DAPAS structure. (A) Monomer (B) Dimer of Mtb DAPAS. The monomer is divided 
into small and large domains. The small domain consists of residues from N- (pink) and C- (green) termini. The large domain 
of chain A and chain B are colored dark and light blue, respectively. As shown in the figure, the active sites are present at the 
interface of the dimer, 18 Å apart. The cofactor, PLP is shown as a sphere (yellow) to indicate the position of the active site. 
A B
Chain A 
Chain B 
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Comparison with other PLP-dependent enzymes 
A VAST (123) search for other structural homologs, using the coordinates of Mtb 
DAPAS, found an interesting similarity to lysine aminotransferase (Rv3290c) in Mtb 
(PDB code-2CJG, VAST score-34.6 with r.m.s.d. for 403 Cα atoms of 2.9 Å). Other 
homologs with high VAST scores were E. coli 2, 2 dialkylglycine decarboxylase (PDB 
code-2DKB: VAST score - 41.9 with r.m.s.d. for 402 Cα atoms of 2.3 Å) and GABA 
aminotransferase (PDB code-1OHW: VAST score - 33.9 with r.m.s.d. for 398 Cα atoms 
of 2.7 Å). E. coli KAPA synthase (PDB code -1BS0) (144), also related to the biotin 
biosynthetic pathway, which catalyzes the first reaction of KAPA formation, has a 
VAST score of 31.1 with r.m.s.d. for 350 Cα atoms of 3.5 Å. It has a similar secondary 
structure with Mtb DAPAS, mostly at the N-terminus with change in the orientation of 
the helix α1. In Mtb lysine aminotransferase (LAT), which is also highly upregulated in 
a nutrient starved TB model and a member of the subclass II of aminotransferases, L-
lysine is the amino donor (145). Both of these enzymes have similar structural folds with 
the exception of variable loops and a few helices (α2, α4, α6, α7, α14) having different 
length and orientations (Figure 3.6). Mtb LAT uses a glutamate switch to distinguish 
between the substrates at the active site. The residues Glu243 and Arg422, required for 
substrate recognition in LAT, are not conserved in Mtb DAPAS. Dialkylglycine 
decarboxylase (146) belongs to the aminotransferase subclass II and PLP fold type I 
family, which catalyzes both decarboxylation and transamination reactions and does not 
undergo conformational changes on ligand binding at the active site. GABA 
aminotransferase (147) which also belongs to subclass II of aminotransferases catalyzes 
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the degradation of GABA into succinic semialdehyde. When all of these above 
mentioned enzyme structures were compared with Mtb DAPAS, despite having less 
sequence identity (21-27%), the overall fold is quite similar to Mtb DAPAS with the 
exception of the loop regions. These structural similarities strongly suggest that the Mtb 
DAPAS also belongs to subclass II of the aminotransferases (148).  
 
 
FIGURE 3.6. Superimposition of Mtb DAPAS on Mtb LAT. This figure is a ribbon 
diagram representation of an overlay of chain A of Mtb DAPAS (gold) on Mtb LAT 
monomer (blue; PDB code-2CJG) with r.m.s.d. of 2.9 Å for 403 Cα atoms. 
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Analysis of Mtb DAPAS active site 
The active site of DAPAS is approximately 24 Å deep with a wide entrance of 
dimension 22 Å x 23 Å which narrows to a dimension of 14 Å x 10 Å at the bottom. 
This cavity is mainly formed by the loop regions Pro24 - Ser34, Arg156 - Asp160, 
Gln224 - Gly228, and Arg400-Arg403 from one subunit and Ala307'-Asn322' and 
Met87'-His97' from the other subunit. Thus, the active site cavity consists of residues 
from both the domains of one subunit but only the large domain of the adjacent subunit. 
Even though residues from both chains form the catalytic site, each subunit has its own 
distinct site, approximately 18 Å apart. The entrances of the cavities are present on 
opposite sides of the non-crystallographic two-fold dimer axis. In this structure, the loop 
at the entrance of the active site (Tyr25-Val33), as well as, the long loop that lines the 
active site (Ala307'-Pro317') are disordered. The latter loop has four alanine and three 
glycine residues in the sequence (307'-AGAAGALMHGP-317') at the entrance of the 
cavity which makes it quite flexible on solvent exposure. This stretch of residues in the 
active site is not conserved in E. coli as well as B. subtilis enzyme. In addition, 13 other 
residues, which are lining the Mtb active site, are also not conserved in E. coli DAPAS. 
Cofactor-binding site 
The inherent feature of any aminotransferase enzyme is the presence of cofactor 
PLP (vitamin B6) at the active site. The electron density for PLP is clearly visible at the 
bottom of the active site cavity in both subunits of the DAPAS structure. This cofactor 
forms a covalent link with the Nε group of conserved Lys283 as evident from the 
continuous electron density between PLP and Lys283 (Figure 3.7). In Mtb DAPAS, the 
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phosphate groups of the PLP are hydrogen bonded to the main-chain amides of Gly124 
(3.5 Å), Ser125 (3.2 Å), and Thr318' from a loop in the adjacent subunit (3.2 Å). The 
pyridine nitrogen forms a hydrogen bond with the carboxylate-OD2 atom of the 
conserved Asp254 (2.8 Å), which is further stabilized by a hydrogen bond interaction 
with His158-ND1 (2.7 Å). The pyridine ring is also sandwiched between the 
perpendicularly stacked phenol ring of Tyr157 from the front (re side) and Ile256 from 
the back (si side). The hydroxyl group of PLP does not directly form any hydrogen 
bonds with the protein atoms, but interactions are seen with the carboxyl group of 
Glu220 and the main-chain amide of Ala226 via a water molecule (2.8 Å). There are 
several other ordered water molecules present around PLP in the active site. Thus, all 
these protein residues interacting with the  cofactor PLP are contributed by both the 
subunits, characteristics of PLP fold type I family (149). These interactions with PLP are 
also conserved in E. coli DAPAS. 
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FIGURE 3.7. PLP binding at the active site of Mtb DAPAS.  This figure shows the 
internal-aldimine form of the enzyme with the 2Fo – Fc electron density map at 1σ level 
for PLP-Lys283 covalent linkage. All the hydrogen bond interactions with PLP are 
shown as green dotted lines and at a distance below 3.5 Å. The surrounding protein 
residues as well as cofactor PLP are shown in yellow stick form. Atoms are colored 
based on their type (N as blue, O as red, P as green) 
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Biochemical characterization of Mtb DAPAS  
DAPAS is an aminotransferase that is responsible for the transfer of the amino 
group from SAM to KAPA to form DAPA, using PLP as a cofactor. The unique aspect 
of this enzyme is its usage of SAM as the amino donor for the transamination reaction. 
In E. coli DAPAS, other analogs of SAM such as SAH (4 mM), S-methyl-L-methionine 
(4 mM), adenosine (4 mM), and amino acids such as L-methionine (4 mM), L-leucine (8 
mM) were not found to be the amino donor, thus, E. coli DAPAS was thought to be very 
specific for SAM (131). Recent studies of Mtb DAPAS have also shown that amino 
acids such as L-Asp, L-Glu, L-Met, L-Lys do not act as the amino donor (136), even at a 
concentration of 5 mM. This is in contrast to other aminotransferases such as glutamine 
transaminase K (150) and glutamine:phenylpyruvate aminotransferase (151) which can 
use a variety of amino acids like Asp, Glu, Met, and aromatic amino acids like Phe, Tyr, 
Trp as substrates. In this chapter, we have studied the Mtb DAPAS reaction with SAM 
and its analogs, and product DAPA, discussed later in this section. 
All aminotransferases contain the cofactor PLP as an internal-aldimine, having 
an imine linkage with the ε-amino group of lysine at the active site. After the 
noncovalent binding of the first substrate at the active site, the amino group of the 
invariant lysine residue is replaced by the amino group from the substrate, thus forming 
an external-aldimine complex with the enzyme. PLP abstracts electrons from this 
substrate in the external-aldimine complex, acting as an electron sink. The release of any 
one of the Cα substituents leads to the formation of a resonance stabilized quinonoid 
intermediate in the PLP-dependent reactions (152) (Figure 3.8).  
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This cofactor PLP acts as a chromophore having absorption maxima around 340-
550 nm due to the presence of delocalized electrons on the pyridine ring. For this reason, 
the PLP form of the protein is yellow in color. Around 320-340 nm range, the 
predominant species is the PMP form of the enzyme which is the result of sp3 
hybridization of the pyridine C4 atom and reduced π-electron delocalization. Sometimes 
a quinonoid intermediate, which absorbs at 490 nm, is formed during the PLP-dependent 
reaction. This shift in absorbance to a longer wavelength is also due to π-electron 
delocalization.  
In this study, we utilized these chromophore properties of the cofactor (PLP or 
PMP) in studying the single-turnover half-reactions of Mtb DAPAS with substrate SAM 
and its analogs sinefungin and S-adenosyl homocysteine (SAH), as well as, with the 
product DAPA using spectroscopic methods. SAM and SAH differ from sinefungin by 
the presence of a sulfonium ion at the δ position. The sulfonium ion in SAM is 
methylated; sinefungin has an amine on its δ carbon (Figure 3.9). 
  
106 
FIGURE 3.8. PLP reaction intermediates in the first half of the aminotransferase reaction.
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FIGURE 3.9. Structure of SAM and its analogs sinefungin and S-adenosyl 
homocysteine (SAH). 
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An absorbance scan of Mtb DAPAS showed absorption maxima at 420 nm due to 
the presence of PLP. This peak at 420 nm decreases with a corresponding increase in 
absorbance peak at 335 nm, when Mtb DAPAS reacts with 1 mM SAM or sinefungin. 
This peak at 335 nm is due to the formation of PMP. In contrast to the E. coli DAPAS 
reaction with SAM, the presence of the quinonoid intermediate at 487 nm was not 
detected in these reactions. This may indicate that this intermediate does not accumulate 
during the transaminase reaction and it is rapidly converted into the product. Similar 
absorption spectra were also observed when PLP-DAPAS was mixed with product 
DAPA (reverse of the second half-reaction) and scanned in the range from 300 to 500 
nm. The reaction also shows a decrease in the absorption peak at 420 nm, with a 
subsequent increase in absorbance at 335 nm. This change in the absorption peaks 
results from the formation of PMP in the single-turnover transamination reaction with 
DAPA. From the absorbance spectra of Mtb DAPAS with SAM and with DAPA, it 
appears that the PMP formation occurs faster with DAPA compared to SAM (Figure 
3.10). This is similar to the E. coli DAPAS half-reactions with SAM and with DAPA 
where the Kmax value for the DAPA reaction is 49 times greater than that of SAM (133).  
Interestingly, similar kinetic studies with the other SAM analog SAH (concentrations up 
to 3 mM) showed no absorption peak at 335 nm. This indicates that SAH may not be 
capable of donating its amino group to PLP. This finding is analogous to that reported 
for the E. coli (153) and B. sphaericus DAPAS (47) where SAH is not the amino donor.  
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FIGURE 3.10. UV-VIS absorbance scans of Mtb DAPAS with the substrate SAM and the product DAPA.  (A) The absorption 
spectra of Mtb DAPAS alone (blue) and after mixing DAPAS with 1 mM SAM (purple), after 30 sec. These spectra are very similar to the 
one reported by Bhor et al. (154) (B) The absorption spectra of Mtb DAPAS alone (red), immediately after the addition of 0.5 mM DAPA 
(blue), and 30 seconds (green) after addition of DAPA. The buffer used in these scans is 50 mM AMPSO (pH 8.5), 150 mM NaCl, 10% 
glycerol, 5 mM β mercaptoethanol at room temperature. 
A B 
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Further kinetic parameters for the single-turnover half-reactions of Mtb DAPAS 
with SAM and sinefungin have been calculated by monitoring the increase in absorbance 
at 335 nm with varying concentrations of substrate. The Kmapp values for sinefungin and 
SAM in Mtb DAPAS is nearly similar to the Kmapp value for SAM in E. coli DAPAS 
(132). However, the enzyme efficiency for the first-half reaction in E. coli DAPAS is 
much higher compared to its Mtb counterpart (Table 6). 
 
TABLE 6 
Kinetic parameters for the single-turnover-half reactions of Mtb and E.coli DAPAS 
 
 Kmapp (SAM) Kmax(SAM) Kmapp(sinefungin) Kmax(sinefungin)
Mtb DAPAS 0.45±0.2 mM 3.6 x 10-6 /sec 0.7±0.2 mM 5.2 x 10-7 /sec 
E.coli DAPAS 0.3 mM 0.016 /sec Not determined Not determined 
 
Furthermore, fluorescence emission spectra of Mtb DAPAS on excitation at 280 
nm results in a peak at 335 nm. The Mtb DAPAS reaction with 1 mM sinefungin, when 
excited at 280 nm, demonstrated a decrease in the emission peak at 335 nm with a 
subsequent increase in the peak at 385 nm (characteristic of PMP form of the enzyme). 
The initial emission peak of the enzyme alone at 335 nm, upon excitation at 280 nm, 
resulted from the presence of aromatic residues in the protein. This phenomenon of an 
increase in emission at 385 nm is due to the FRET (Förster resonance energy transfer) 
effect on chromophore PMP, which absorbs the light at 335 nm and emits at 385 nm, 
thus, confirming the formation of PMP on DAPAS reaction with sinefungin. Hence, this 
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study indicates that sinefungin can also bind at the active site and donate its amino group 
to PLP.  Thus, it acts as a substrate for Mtb DAPAS (Figure 3.11).  
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.11. Fluorescence spectra of Mtb DAPAS with SAM analog, sinefungin. 
Upon excitation at 280 nm, fluorescence emission spectra were scanned in the range 
between 300–450 nm for Mtb DAPAS (12 μM) alone (green), and after mixing DAPAS 
with 1 mM sinefungin (blue) after 30 sec at room temperature. 
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Possible substrate recognition in Mtb DAPAS 
In order to understand the mode of the SAM binding at the active site, attempts 
were made to determine the crystal structure of Mtb DAPAS complexed with the 
physiological substrate SAM, which were unsuccessful. Therefore, the crystal structure 
determination of DAPAS complexed with the SAM analog, sinefungin was tried and 
phases were obtained at a resolution of 2.18 Å. In this structure, sinefungin can be fitted 
to the extra electron density, which is present adjacent to the C4′ atom of PLP at a 
distance of 3.56 Å, in the active site of the DAPAS chain A. On further refinement of 
this enzyme structure, the occupancy of sinefungin is found to be lower than one (0.8) 
due to high B-factor. The electron density for sinefungin is mostly disordered in chain B 
also due to its low occupancy. Surprisingly, in this structure, PLP is still covalently 
attached to the conserved Lys283 in both the chains; no PMP form is visible. This may 
be due to a short period (45 minutes) of 10 mM sinefungin soaking to avoid damage to 
the crystal and the smeary diffraction pattern. We believe that this structure depicts the 
precatalytic state of sinefungin binding. In this structure, the amino group of sinefungin 
points towards the internal-aldimine complex (3.56 Å) thus, oriented properly to form an 
external-aldimine complex with the enzyme. The carboxy oxygen atoms of sinefungin 
form hydrogen bonds with the main-chain amide of Gly316' (3.4 Å) and the hydroxyl 
group of Tyr157 via a water molecule in the active site. The aliphatic chain of sinefungin 
spans the entire length of the active site cavity making van der Waals interactions with 
residues Trp64, Trp65, and Phe402. At the entrance of the active site cavity, the electron 
density for the adenine ring of sinefungin is mostly disordered due to its complete 
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exposure to the solvent. The loop near the entrance of the cavity is also disordered 
(Ser26-Ala32), similar to the native structure. However, the loop region (Ala307'-
Pro317') lining the active site at the interface of the dimer in chain A is ordered due to 
the presence of the ligand. Superimposition of the sinefungin-bound structure on the 
PLP- bound Mtb DAPAS structure shows that the enzyme does not undergo any major 
conformational changes (r.m.s.d. for 429 Cα atoms is 0.3 Å) except for the movement of 
the side chains of Trp64, Trp65, Met409, and Phe402 to accommodate sinefungin in the 
active site. The changes in the active site are in the form of 90° rotation of the indole 
side chain of both Trp64 and Trp65, causing the side chain of Met409 to move by 2 Å. 
There is also a 180º rotation of Tyr25 side chain (based on E. coli DAPAS apostructure). 
Thus, the change in the unit-cell dimension of sinefungin-bound DAPAS structure (a= 
62.6 Å, b=83.4 Å, c=157.9 Å, α=β=γ=90º) in comparison to PLP-bound structure (a= 63 
Å, b=66.5 Å, c=203.4 Å, α=β=γ=90º) might be due to the crystal packing.  
Based on the precatalytic form of the sinefungin-bound DAPAS structure, SAM 
was modeled in the DAPAS active site. Comparing this model with the sinefingin-bound 
structure, the amino group of SAM is positioned 2 Å further inside the active site cavity. 
This positioning of the amino group of SAM inside the active site would allow the 
formation of the Schiff’s base with the C4' group of PLP. The carboxy oxygen atoms of 
SAM would interact with the hydrogen bond network of Tyr157-OH: Asp160-OD2. The 
aliphatic chain in SAM would span the hydrophobic active site pocket, and the adenine 
ring of SAM would have stacking interactions with the phenol ring of Tyr25. This 
stacking interaction of Tyr25 with the adenine ring is analogous to Tyr85 in the structure 
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of 1-aminocyclopropane-1-carboxylate (ACC) synthase-AMA enzyme-adduct complex 
(PDB code-1M4N). ACC synthase also uses SAM as the substrate; AMA is an amino-
oxy analog of SAM (155). These interactions are in contrast to other members of 
subclass II aminotransferase in which the carboxy groups of the amino donor are mostly 
hydrogen bonded to the Arg residues in the active site. The sulfonium ion of SAM might 
form a hydrogen bond with the hydroxyl group of Tyr407, which is also conserved in all 
DAPAS, and the oxygen atom of the ribose sugar might form hydrogen bonds with 
Arg400 and the N-atom of Trp65 imidazole ring (Figure 3.12A).  
 To locate the binding site of the amino group acceptor KAPA in the active site, 
we have superimposed the KAPA-bound E. coli DAPAS structure on the Mtb enzyme 
structure. In the E. coli DAPAS structure, KAPA is bound to the PLP form of the 
enzyme, thus, it provides an unproductive form of the enzyme complex. Based on this 
superimposition, in Mtb DAPAS, the 7-keto group of KAPA would point towards the 
internal-aldimine at a distance of approximately 2.6 Å in the model. The 8-amino group 
of KAPA would form a hydrogen bond with the hydroxyl group of Tyr25 (2.5 Å) as well 
as with the main-chain oxygen of Gly316' (2.5 Å). Tyr25 is involved in stabilizing 
KAPA binding in the active site as well as the proper positioning of KAPA for amino 
group acceptance by forming a hydrogen bond with the N8-amino group. The carboxyl 
group of KAPA has a specificity for conserved Arg400, whose side chain would move 3 
Å towards KAPA to form the salt bridge (3.15 Å), resulting in a hydrogen bond 
breakage between Arg400 and Thr389 observed in the PLP-bound structure. It is worth 
mentioning here that this movement of the guanidinium group of Arg400 in response to 
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the KAPA binding in the active site is not observed with sinefungin binding. The rest of 
the aliphatic chain in KAPA is within van der Waals distance to Tyr25, Trp64, Tyr157, 
and Phe402 of the active site (Figure 3.12B). Analogous to sinefungin binding, KAPA 
binding would also result in the movement of the side chains of a few residues in the 
active site (Trp64, Trp65, and Met409). Thus, no major conformational changes in terms 
of large domain movement are observed (r.m.s.d.= 0.3 Å for 429 Cα atoms). This is in 
contrast to some aminotransferases, like aspartate aminotransferase, in which the active 
site closes on ligand binding with a 13° rotation of the small domain as a rigid body 
toward the large domain (156). Thus, from the sinefungin-bound DAPAS structure and 
the KAPA-bound DAPAS model, we can derive that both SAM and KAPA will bind at 
the same place in the active site with differences in the movement of side-chains of the 
active site residues. Kinetic studies have shown that at high concentrations (14±2 μM), 
KAPA has also been found to be an inhibitor of this enzyme, forming a dead end 
complex in the active site (136). This also indicates that both KAPA and SAM occupy a 
similar position in the active site, even though they have very different size and 
characteristics. 
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FIGURE 3.12. Model for substrate recognition at the active site of Mtb DAPAS. 
(A) Interaction of amino group donor SAM with DAPAS: SAM is shown in green ball 
and stick form in the figure. The active site residues of DAPAS are shown in yellow 
color. The amino group of SAM is pointing towards PLP and the carboxy group would 
hydrogen bond with the network of Tyr157-OH and Asp160-OD2, and the Tyr25 has 
stacking interaction with the adenine ring of SAM. The side chains of Trp64 and Trp65 
have changed their orientation to accommodate SAM in the active site. (B) Interaction of 
amino group acceptor KAPA with DAPAS: KAPA is shown in green ball and stick form 
in the figure. KAPA is binding at a similar position as SAM in the active site. In this 
case, PLP is covalently linked to Lys283. Tyr25 side chain has changed its orientation to 
form hydrogen bond with the amino group of KAPA. The carboxy group of KAPA 
forms salt bridge with Arg400.  
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Transaminases utilize various modes to identify the dual substrates in the same 
active site since they follow the Bi Bi ping-pong mechanism. These enzymes employ 
two different mechanisms or their combination to recognize the substrates at the active 
site. The induced fit model proposed by Koshland (157, 158) involves the 
conformational change of the active site on substrate binding and the Lock and Key 
model proposed by Fischer (159) suggests the complementarity of the active site and the 
substrate to each other (active site is a lock that all the substrates can fit in as a key). In 
the case of subclass I enzymes like aspartate aminotransferases (156, 160) and 
glutamine: phenylpyruvate aminotransferase (151), they follow the induced fit model, 
since there is a large movement of the small domain (13º rotation) involved in substrate 
recognition. Other transaminases such as lysine aminotransferase utilizes the glutamate 
switch (145) or tyrosine aminotransferase (161) and GABA aminotransferase (162) 
utilize the arginine switch. Acetylornithine aminotransferase, which uses acetylornithine 
and alpha-ketoglutarate as substrates, employs a combination of a lock and key and the 
induced fit mechanism for substrate recognition (161). In this regard, DAPAS appears to 
follow the lock and key mechanism in which certain residues in the active site change 
their side chain orientations to accommodate SAM and KAPA. There is no large 
conformational change in the form of domain movement as mentioned above. When 
SAM binds in the DAPAS active site, its amino group forms a Schiff’s base with the 
PLP and the carboxy group of SAM hydrogen bonds to the Tyr157-OH: Asp160-OD2 
hydrogen bond network. The conserved Tyr25 changes its orientation of the phenol 
group (approximately 180°) to provide a platform for stacking interactions with the 
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adenine ring. Following the release of SAM when KAPA binds in the same active site 
region to the PMP form of the enzyme, the side chain of Tyr25 will change its 
orientation (90°) to interact with the amino group of KAPA. This bond formation with 
Tyr25 helps in positioning KAPA in the active site for amino group acceptance from 
PMP. In response to this interaction, the guanidinium group of Arg400 also moves 
towards KAPA to form a salt bridge with the carboxy group of KAPA.  
Kinetic properties of Y25A mutant form of Mtb DAPAS 
Based on the analysis of aforementioned structural studies, we recognized a key 
role played by Tyr25 in substrate recognition in the Mtb DAPAS active site. In order to 
confirm the role of Tyr25 in substrate recognition, we mutated this residue at position 25 
to Ala. Single-turnover half-reactions of the mutant Mtb DAPAS with the substrate SAM 
and the product DAPA were monitored spectrophotometrically. The Y25A mutant form 
of the DAPAS did not show any detectable enzyme activity with SAM at 335 nm, in the 
form of increase in absorbance, even at concentrations of up to 3 mM. There was also no 
change in the absorbance peak at 420 nm on SAM addition (Figure 3.13A). The mutant 
showed approximately 70% enzyme activity with product DAPA (0.5 mM) in 
comparison to the native protein (Figure 3.13B). Thus, this mutation study confirms the 
role of Tyr25 in substrate recognition.
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FIGURE 3.13. Comparison of absorbance scans of native Mtb DAPAS and Y25A mutant. The figure shows absorption 
spectra of DAPAS reaction with (A) SAM and (B) DAPA. In both the plots, the absorption spectra for native DAPAS is shown 
in solid line and for mutant DAPAS is shown as dotted line. As shown in figure A, there is no change in the absorption spectra 
of mutant form on reaction with SAM (blue) where as for native DAPAS, there is a decrease in absorption spectra at 420 nm 
with an increase in peak at 335 nm (orange). In figure B, in comparison to the native DAPAS reaction with DAPA (green), 
Y25A mutant shows approximately 70% enzyme activity with product DAPA (orange). The absorbance scans of native 
DAPAS and mutant enzymes are shown in solid blue and dotted magenta lines.
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Variation in the DAPAS active site 
 The Mtb DAPAS structures indicated the crucial role played by Tyr25 in 
substrate binding at the active site, both in SAM binding with recognition of the adenine 
ring as well as in proper positioning of the KAPA for amino group acceptance. Sequence 
alignment of DAPAS from different organisms show that Tyr25 is a conserved residue 
in most organisms except in certain species of Bacillus such as B. subtilis and B. cereus 
as well as Brucella melitensis, Leptospira interrogans, and Aquifex aquenox where Phe 
replaces this Tyr residue in the protein sequence (Figure 3.14). Mutation studies on the 
replacement of this Tyr residue with Phe in E. coli DAPAS (132) have resulted in 60-
fold less enzyme activity for the reverse second half-reaction with DAPA, but with no 
effect on the first half-reaction with SAM, since Phe can still stack against the adenine 
ring of SAM. We also noticed that on mutating Tyr25 to Ala, the Mtb enzyme totally 
loses its activity against SAM and retains only 70% activity with DAPA in the reversed 
second half-reaction. Thus, this raises the question of how substrate binding especially 
KAPA binding, takes place in these organisms to maintain the enzyme activity for their 
survival.  
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FIGURE 3.14. Parts of the amino acid sequence alignment of Mtb and E. coli 
DAPAS along with other organisms showing changes at position 25. (Numbers are 
based on Mtb DAPAS). All the DAPAS sequences are from Swiss-Prot and TrEMBL 
databases: B. subtilis (P53555), B. cereus (Q818W8), A. aeolicus (O66557), B. 
melitensis (Q8YBV8), E.coli (P12995), and Mtb (O06622). 
 
Variation in KAPA binding in Bacillus subtilis DAPAS 
To understand the mode of KAPA binding in the DAPAS active site of the 
aforementioned organisms, we have determined the crystal structures of DAPAS in B. 
subtilis as an apoprotein, PLP-bound complex, and PLP and KAPA bound ternary 
complex at resolutions of 2.2 Å, 1.9 Å and 2.3 Å respectively. Molecular replacement 
technique was used to determine the phase information for these structures. Sequence 
alignment of DAPAS from different organisms shows that B. subtilis DAPAS possess 
32% sequence identity with Mtb DAPAS and 33% with E. coli DAPAS. The overall 
structure of B. subtilis DAPAS is quite similar to both Mtb as well as E. coli DAPAS 
with pair wise r.m.s.d. of ~1 Å for 325 Cα atoms. Similarly, all three DAPAS structures 
of B. subtilis superimpose very well with a pair wise r.m.s.d. of 0.41 Å for 414 Cα atoms, 
indicating similar structures. However, in the apo form as well as in the PLP bound form 
of this homodimeric enzyme, large parts of the active site (Lys143-Glu172) are found to 
be totally disordered in both the chains. Even binding of cofactor PLP did not help in 
B. subtilis DAPAS 
B. cereus DAPAS 
A. aeolicus DAPAS 
B. melitensis DAPAS 
E. coli DAPAS 
Mtb DAPAS 
25 157 160
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ordering this region of the active site. On the other hand, on KAPA binding, the electron 
density for the above-mentioned 29 residues is ordered in both the chains of this 
structure. This suggests that the active site in B. subtilis stabilizes only on substrate 
binding.  
In contrast to the KAPA-bound E. coli DAPAS structure, there are very few local 
conformational changes visible in this nonproductive KAPA-bound Bacillus structure. 
This change is in the form of side chain movement of Arg403 to form a salt bridge with 
the carboxy group of KAPA (2.8 Å). However, in this case, the side chain of Arg residue 
moves backward by 2.2 Å in contrast to that observed in E. coli DAPAS. In E. coli, the 
side chain of Arg residue moves forward towards KAPA by 3 Å. Interestingly, the 
amino group of KAPA is hydrogen bonded to the OH group of Tyr146 (2.8 Å) and the 
main-chain oxygen of Gly315' (2.65 Å). The keto group of KAPA points towards the 
internal-aldimine. Thus, this kind of interaction still maintains the hydrogen bond 
network of Tyr146-OH: Asp149-OD2 in absence of a Tyr residue at position 17 (B. 
subtilis numbering). It is worth mentioning here that Tyr146 and Asp149 are part of the 
loop region which is disordered in the apoform and PLP-bound form of the enzyme. In 
comparison to the KAPA-bound E. coli structure, there is a shift of 1 Å in the position of 
KAPA binding in the active site towards Tyr146 for hydrogen bond formation (Figure 
3.15). In this way, the substrate KAPA stabilizes the loop region of the active site.  
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In the E. coli Y17F mutant, an additional water molecule at the active site fulfils the role 
of the hydroxyl group of Tyr17. These findings may also indicate the importance of this 
hydrogen bond network of Tyr25:Tyr157:Asp160 (Mtb numbering) in the maintenance 
of the active site structure. It may also be noted here that there are two consecutive Trp 
residues in the Mtb (W64 and W65) and the E. coli (W52 and W53) DAPAS active site, 
which change their conformation on substrate binding, in place of Val53, Trp54 in B. 
subtilis. The empty space created by this substitution of Trp to Val53 in Bacillus active 
site is filled by Leu82' (Gly in Mtb and E. coli) from the neighboring subunit. Thus, this 
KAPA-bound structure answers the question of how the enzyme maintains its activity in 
the absence of Tyr25 but leaves us with another question of why DAPAS from Bacillus 
and other above-mentioned organisms possess Phe rather than Tyr at the active site. This 
question can be answered by interpreting the phylogenetic tree analysis of DAPAS from 
different organisms which reveals that DAPAS from B. subtilis evolved long before 
DAPAS from E. coli and Mtb DAPAS.  
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FIGURE 3.15. Binding mode of KAPA at B. subtilis DAPAS active site. 
Superimposition of KAPA-bound E. coli DAPAS (blue) upon the respective B. subtilis 
DAPAS (orange) shows the binding pattern of KAPA in absence of Tyr at position 17 of 
Bacillus DAPAS. As shown in this figure, PLP is covalently linked to Lys, thus, 
providing an unproductive form of the enzyme. KAPA in this figure is shown in stick 
form, which is colored light green in E. coli and dark green in B. subtilis DAPAS. 
Arg403 forms salt bridge with the carboxy group of KAPA. Val53 and Trp54 have 
hydrophobic interactions with KAPA. 
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Search for Mtb DAPAS inhibitors 
To search for potent inhibitors, there are mainly three different ways: using 
substrate mimics/suicide substrates/transition state mimics, high throughput screening or 
virtual screening. 
 DAPAS is a PLP-dependent enzyme and PLP acts as a cofactor for many other 
enzymes, which catalyze diverse reactions. Even though the reactions are different, they 
share certain similarities in the enzyme mechanism i.e. aldimine formation with PLP. 
Hence, most of the inhibitors of these enzymes utilize a mechanism-based inhibition 
such as substrate mimics, activated nucleophiles or electrophiles as well as reversible 
competitive inhibitors. 
The known natural antibiotic, amiclenomycin (ACM) irreversibly inhibits Mtb 
DAPAS with Ki = 12±2 μM (136). It has been found to be most effective against Mtb in 
cell culture (60) in comparison to other bacteria and yeast. Amiclenomycin inhibition of 
any other PLP-dependent enzyme has not been reported so far. A model of ACM 
binding at the Mtb DAPAS active site, which was generated based on the cis-
amiclenomycin-bound structure of E. coli DAPAS (PDB code-1MLY) (135), suggests a 
mechanism of suicide substrate inhibition. In this structure, ACM occupies the same 
place in the active site as the substrates (KAPA or SAM). In this process of ACM 
binding, PLP would be tilted at an angle of 17° in comparison to the PLP complexed 
DAPAS structure to form a covalent bond with the 4-amino group of ACM and results in 
an irreversible aromatic adduct.  
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This aromatic adduct would be further stabilized by hydrophobic interactions with 
Trp64, Trp65, and Phe402 at the active site. All the other local changes in the form of 
side chain movements observed on KAPA binding at the active site are also seen with 
ACM binding. The 1-amino group of the ACM does not seem to interact with any part of 
the protein and thus, may not be essential for its inhibitory effect. Similar to KAPA 
binding, the side chain of Arg400 would move closer (3 Å) to hydrogen bond with the 
carboxy group of the antibiotic (2.8 Å), thus, providing specificity (Figure 3.16).  
Although the natural antibiotic, ACM was found to be ineffective in vivo (60), 
we can still use this compound as a template to design new inhibitors by modifying its 
chemical characteristics to improve its biological properties. Infact, attempts have been 
made recently to synthesize variations of ACM like 4-(4c-aminocyclohexa-2,5-dien-1r-
yl) propanol which also irreversibly inhibited Mtb DAPAS (Ki = 20±2 μM) and had a 
good whole cell activity in M. smegmatis (MIC = 10 μg/ml) (136). 
 
127 
 
 
 
FIGURE 3.16. Changes observed on amiclenomycin binding at the Mtb DAPAS 
active site. This figure shows a superimposition of Mtb DAPAS structure upon ACM-
bound Mtb DAPAS model. Irreversible inhibitor amiclenomycin is modeled in the active 
site of Mtb DAPAS based on the ACM-bound E. coli DAPAS structure (PDB code-
1MLY). ACM is shown in ball and stick form (green) having covalent linkage with C4' 
atom of PLP shown in stick form. The Mtb DAPAS and the ACM-bound structure are 
colored gold and blue, respectively. This structure shows the conformational changes at 
the active site on ACM binding. Also seen is Lys283, which is present next to the ACM 
aromatic adduct; its side chain is oriented away from the PLP. PLP is also tilted at 
certain angle to covalently link with ACM. 
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Cycloserine and gabaculine effectively inhibit other PLP enzymes alanine 
racemase (163), and GABA aminotransferase (164) and ornithine aminotransferase 
(165), respectively. Even though these inhibitors follow a same inhibition mechanism as 
of ACM, they were reported not to inhibit Mtb DAPAS (136). In this study, we also 
found that vigabatrin, which is another potent inhibitor of GABA aminotransferase (147) 
and forms irreversible aromatic adduct analogous to ACM, does not inhibit the Mtb 
DAPAS even at concentrations of 1 mM. This insensitivity of Mtb DAPAS may be due 
to these compounds not being long enough to form both, covalent bond with PLP and 
ionic bond with Arg400, at the active site. Also, there are no other Arg residues present 
in the active site lining that can provide hydrogen bond partners for the carboxy group of 
these inhibitors or provide any specificity to these compounds in the Mtb DAPAS active 
site. Interestingly, several other compounds, which possess a chemical structure 
analogous to substrate KAPA, also did not show any inhibition (Table 7). This may 
suggest that Mtb DAPAS enzyme is very specific for its own substrates and possesses 
scaffolds at the active site which can distinguish between different substrates. For the 
inhibitor studies of Mtb DAPAS, the single-turnover half-reaction of PLP form of 
DAPAS (5 μM) with SAM was monitored at 335 nm. 
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TABLE 7 
Compounds having chemical structure similar to the substrate KAPA 
 
 
COMPOUND STRUCTURE 
 
Mol. 
Wt. 
(g/mol)
 
 
Vigabatrin 
 
 
 
129.16 
 
 
Canavanine 
 
 
 
176.2 
 
 
Aminoethylcysteine 
 
 
 
200.7 
 
 
DL-alpha-
aminosuberic acid 
 
 
 
189.21 
 
 
Chembridge ID 
5190771  
 
 
187 
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Virtual screening of Mtb DAPAS 
In this study, after mapping the active site of Mtb DAPAS, we proceeded to 
conduct a structure-based virtual screening of this enzyme to search for potent inhibitors. 
Virtual screening (VS) or in silico screening is the selection of the compounds based on 
their predicted binding, using different computer algorithms in contrast to High 
throughput screening. The aim here is to identify the compounds that have high 
likelihood of binding at the active site, thus, minimizing the need for screening large 
number of compounds experimentally by performing assays. VS has been successfully 
carried out against other Mtb enzymes such as dihydrofolate reductase (DHFR), enoyl-
acyl carrier protein reductase (InhA), isocitrate lyase (ICL) etc in search of potential 
inhibitors. VS mostly involves four steps: 1) Preparation of the compound library and 
protein template 2) docking of the compounds 3) selection of compounds from the list of 
top hits, and 4) Validation of these compounds. 
 In this study, a docking algorithm, DOCK 6.0 (UCSF) was used for virtual 
screening in collaboration with Dr. T. Ioerger (Dept. of Computer Science, Texas A&M 
University). “Hits” are defined as the compounds having high docking scores from the 
VS runs. DOCK scoring function calculates two components of interaction energy: 
electrostatic and van der Waals energy. This computationally intensive task was 
performed utilizing the computer resources on the TAMU campus. These docking jobs 
were run on a Grid cluster (connected to over 1000 computers) using MP Agent software 
from United Devices, Austin TX.  
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We utilized the active site of the KAPA-bound DAPAS model as a template for 
docking. All the non-protein molecules, e.g. water or substrate were removed. Ideal 
situation is to have both the template and the ligands flexible. However, due to the 
limitations in computing power, the templates generally act as a rigid body and the 
ligands (compounds) are flexible entities. In this case, the cofactor PLP was retained in 
the model to prevent any compound from occupying its position as well as to improve 
the number of hits due to affinity with PLP. Virtual screening was carried out against 2 
million drug-like compounds contained in the commercially available ZINC database 
(166). These compounds in the database are mostly present in multiple conformations 
and are based on Lipinski’s rule of 5 (167) which states that poor absorption or 
permeation of compounds is more likely to happen when 
1) There are more than 5 hydrogen bond donors, 
2) There are more than 10 hydrogen bond acceptors, 
3) The molecular weight is greater than 500, 
4) The Log P (octanol-water partition coefficient) is over 5 and 
5) Classes of compounds that are substrates for biological transporters 
Compounds from the list of top hits of virtual screening were selected for 
inhibitor studies based on (1) Visual inspection (using ViewDock option in Chimera) to 
evaluate the mode of binding of the compounds and prevent redundancy (2) The DOCK 
scores (3) Easy availability, and (4) Economical pricing (Figure 3.17).  
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FIGURE 3.17. Overlay of docked compounds at the Mtb DAPAS active site. This 
figure shows the active site cavity of Mtb DAPAS with the overlay of docked 
compounds from the virtual screening. 
 
The compounds chosen for inhibitor studies were purchased from Chembridge as 
presented in Table 8. In this table, molecular weight, calculated logP values and energy 
scores obtained from the virtual screening using DOCK algorithm is provided. 
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TABLE 8 
Chembridge compounds used for virtual screening 
 
Compound 
ID 
Structure Mol. 
Wt. 
clogP Energy 
Score 
 
5881639 
 
469 
 
2.90 
 
-74.39 
 
5904890 
  
451 
 
3.07 
 
-73.16 
 
6094188 
  
426 
 
 
5.69 
 
-76.59 
 
6384549 
  
493 
 
3.02 
 
-73.63 
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TABLE 8 (Continued) 
Compound 
ID 
Structure Mol. 
Wt. 
clogP Energy 
Score 
 
6410766 
  
499 
 
4.95 
 
-74.96 
 
6531042 
  
488 
 
4.29 
 
-74.74 
 
7586634 
  
448 
 
3.00 
 
-73.79 
 
7713211 
  
483 
 
4.80 
 
-73.58 
 
7714429 
  
463 
 
3.16 
 
-74.0 
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TABLE 8 (Continued) 
Compound 
ID 
Structure Mol. 
Wt. 
clogP Energy 
Score 
 
7876301 
  
474 
 
4.32 
 
-72.92 
 
7908679 
  
486 
 
2.77 
 
-73.16 
 
6939388 
  
483 
 
4.99 
 
-72.81 
 
6656927 
  
466 
 
3.92 
 
-73.19 
 
7102000 
  
487 
 
5.16 
 
-75.52 
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TABLE 8 (Continued) 
Compound 
ID 
Structure Mol. 
Wt. 
clogP Energy 
Score 
 
7103108 
  
477 
 
5.20 
 
-74.68 
 
6498331 
  
498 
 
 
4.56 
 
-73.16 
 
6238769 
  
492 
 
2.87 
 
-76.45 
 
7746089 
  
493 
 
4.71 
 
-74.43 
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Validation of the top candidates is generally carried out using enzyme or binding 
assays. Due to the presence of unique cell wall structure in Mtb, cell permeability tests in 
the form of whole cell assays in either M. smegmatis (mc2155 strain) or other 
mycobacterium strains are also performed. This combination of virtual screening and 
enzyme assays is recognized to be an effective way to find inhibitors in the low micro-
molar range (168). In this study, quick screening of the top hits for an IC50 near 10 μM 
was carried out by inhibition studies of the single-turnover half-reaction of the Mtb 
DAPAS enzyme with SAM at 335 nm using spectrophotometric methods. 
Unfortunately, we did not yet find any useful inhibitor in this study. In this regard, more 
screening of the compounds from the VS results needs to be done. 
Future work will involve docking the commercially available compound library 
against the sinefungin-bound DAPAS active site as a VS template and varying different 
parameters of the docking algorithm to get better hits. Once we get some compounds 
with good IC50 values from enzyme assays, their whole cell activity will be tested against 
different mycobacterium strains. Further, crystallization of the Mtb DAPAS with these 
potent inhibitors, which are active in both assays, will be carried out. Either soaking or 
cocrystallization will be attempted to understand the mode of inhibitor binding and its 
mechanism of inhibition. Any successful candidate can be further improved upon by 
synthetic chemistry and QSAR to develop a more potent analog. 
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CHAPTER IV 
 
STRUCTURAL INSIGHTS OF DETHIOBIOTIN SYNTHETASE IN 
Mycobacterium tuberculosis 
 
Background 
Dethiobiotin synthetase (DTBS; EC 6.3.3.3) catalyzes the penultimate step in the 
biotin biosynthesis: carboxylation of 7, 8-diaminopelargonic acid (DAPA), leading to 
the formation of the ureido ring of dethiobiotin (DTB). This amidoligase reaction 
requires Mg2+-ATP (Figure 4.1).  
 
 
FIGURE 4.1. Reaction catalyzed by Mtb DTBS 
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This enzyme has been extensively studied in E. coli (169-173). The Mtb DTBS 
has a poor sequence identity with the E. coli DTBS (28%) (Figure 4.2). In 1970, Krell 
and Eisenberg reported that CO2 and not HCO3- is the substrate for this enzyme in E. 
coli, based on their experiments with carbonic anhydrase (169). Structurally and 
mechanistically, DTBS also differs from other carboxylases like biotin dependent 
carboxylase (174) and ribulose-1, 5 bisphosphate carboxylase (175). The information 
gained from the E. coli DTBS structures were used to develop herbicides in plants such 
as A. thaliana (176). In 2007, another DTBS structure from H. pylori (PDB code-
2QMO, sequence identity with Mtb DTBS – 18%) has been solved by Minor et al. 
However, no further biochemical characterization of the H. pylori enzyme is available. 
 
FIGURE 4.2. Alignment of E. coli, Mtb and H. pylori DTBS sequences. The 
conserved, identical, and similar residues between the different DTBS sequences are 
colored green, yellow, and cyan, respectively. The important residues at the active site 
are marked by black lines and red asterisks. This alignment is prepared using ClustalW 
(79).  
 
  
140
As mentioned in previous chapters, biotin acts as a cofactor in several 
carboxylases, including acetyl-CoA carboxylase, which is involved in the initial stages 
of fatty acid synthesis. This is important for Mtb survival during the chronic phase of 
infection (37). Genetic studies such as microarray analysis conducted on Mtb H37Rv 
strain under nutrient starved conditions report that the bioD gene, which codes for 
DTBS, gets upregulated in 96 hours of starvation (58). This study was performed to 
simulate the host environment during infection. Also, due to the absence of a homolog of 
this enzyme in humans, Mtb DTBS would be an excellent choice for inhibitor studies.  
In order to better understand the DTBS enzyme in Mtb, we have carried out the 
preliminary biochemical characterization of this enzyme using a coupled assay. We 
further determined the three-dimensional structures of DTBS apoenzyme as well as 
enzyme complexes with substrate and products using X-ray crystallography. With the 
help of these structures, we have compared the overall structure of Mtb DTBS with the 
known E. coli and H. pylori DTBS structures. We have further determined the residues 
involved in substrate/product binding at the active site. In addition, we have been able to 
derive a possible mechanism for the enzyme action, which will be further helpful in 
inhibitor studies. 
Methods 
 
Reagents 
 
The restriction enzymes for Rv1570 cloning were purchased from New England 
Biolabs. All the reagents for purification procedures were from Sigma. KAPA and DTB 
used in the structural studies were purchased from Toronto Research Chemicals Inc., 
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Canada and Sigma, USA, respectively. DAPA was chemically synthesized by Dr. Joel 
Freundlich of Princeton University using the protocol of Gibson et al. (137). 
Cloning, protein expression and purification of Mtb DTBS 
The bioD gene (Rv1570) from the Mtb H37Rv genome was PCR amplified and 
ligated into the pET28b vector with the TEV cleavage site using NdeI and HindIII 
restriction sites. The NdeI site contained the ATG start codon and the stop codon (TCA) 
preceded the HindIII site. The DTBS (D47A) mutant clone was constructed by using the 
QuikChange site-directed mutagenesis kit (Stratagene) with pET28b-Rv1570 as the 
template. The primers used in this study were: 
For the native DTBS protein: 
Forward primer: 5' AGAGAAGCATATGACGATCCTGGTCGTCA 3' 
 
Reverse primer: 5' CCCAAGCTTTCAGCCGACCAGCCCGGCAACCCA 3' 
 
For the D47A mutant: 
Forward Primer: 5′ CGCCCGCGGTGCCGACGACCTCG 3' 
Reverse Primer: 5′ CGAGGTCGTCGGCACCGCGGGCG 3'  
The plasmids so obtained were checked for the presence of the insert using restriction 
digestion as well as sequencing (Gene technologies Lab, TAMU). The pET28b-Rv1570 
and the D47A mutant clones were then transformed into the E. coli overexpression host 
BL21 (DE3). The transformed cell culture was grown in LB media with kanamycin (50 
μg/ml) at 37 ºC till the A600 reached 0.8. It was then induced by adding IPTG at a final 
concentration of 0.5 mM and grown overnight at 25 ºC. There was no protein 
overexpression seen in the cultures grown at temperatures lower than 25 °C. The cells 
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were harvested by centrifuging at 3000 rpm for 30 min and the cell pellet was 
resuspended in a buffer containing 50 mM Tris buffer (pH 7.5), 500 mM NaCl, 1 mM 
PMSF and 20 μg/ml DNase. The cells were lysed using a French press at 11,000 psi and 
the cell debris was removed by centrifuging the cell lysate at 15,000 rpm for 1 hour. The 
supernatant was then loaded on a HisTrapTM Ni column (GE Healthcare) which was pre-
equilibrated with 50 mM Tris buffer (pH 7.5), 500 mM NaCl and washed with a buffer 
containing 25 mM imidazole till the absorbance was zero. The protein was then eluted 
using an imidazole gradient (50–400 mM). The protein is 98% pure as judged by a 4-
12% gradient SDS-PAGE gel. However, the yield of the protein was very low (0.5 
mg/L). Hence, the presence of DTBS protein in the fractions as well as in the crystals 
was confirmed by western blot technique. The expression of the protein could not be 
improved by trying different cell strains, fusion tags or growth media. The fractions 
containing the pure protein were pooled and dialyzed overnight against a buffer 
containing 25 mM Tris (pH 7.5), 50 mM NaCl, 1 mM EDTA and 1 mM DTT. 
Spectroscopic studies of Mtb DTBS 
Coupled assays for native Mtb DTBS and its D47A mutant form with pyruvate 
kinase/lactate dehydrogenase (40 units) (177) were carried out to determine the kinetic 
parameters of both the substrates ATP and DAPA while keeping the other substrate at a 
saturating concentration. The reaction buffer contained 50 mM Tris (pH 7.5), 150 mM 
NaCl, 15 mM NaHCO3, 5 mM MgCl2, 250 μM phosphoenol pyruvate, 80 μM NADH. 
In this 500 μl coupled reaction, ADP formation was measured by monitoring the 
decrease in NADH absorbance at 340 nm (ε = 6.22 /mM/cm). These assays were carried 
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out on a Cary 100 spectrophotometer (Varian) at room temperature. The DTBS and the 
D47A mutant concentrations were calculated from their absorbance at 280 nm using 
extinction coefficients 12840 /M/cm and 14120 /M/cm, respectively (138). 
Crystallization of Mtb DTBS  
Initially, microcrystals of Mtb DTBS were found in sitting drop vapor-diffusion 
plates (96 well intelliplates from Hampton Research) at a protein concentration of 2 
mg/ml. Crystallization screens with 1:1 ratio of protein to precipitant were setup using a 
Hydra Plus One dispenser (Art Robbins Instruments). In this process, different 
precipitant conditions from Hampton Research (Crystal Screen, Crystal Screen II, 
PEG/Ion and SaltRx screen) and Emerald Biosystems (WIZARD I, II) were used. There 
were several different conditions in which Mtb DTBS crystals were obtained. These 
conditions were further optimized with protein concentrated to 10 mg/ml, at a ratio of 
2:2 in a hanging drop plate at 18 ºC. To obtain the protein at concentration of 10 mg/ml, 
iterative rounds of protein purification was carried out. The dataset for the apoenzyme 
was collected using the crystal from 1 M sodium citrate, 0.1 M imidazole (pH 7.5) 
(WIZARD I # 36) (Figure 4.3). 
Data collection and processing 
A 1.85 Å high resolution dataset of the DTBS crystal was collected in-house 
using a Rigaku Raxis IV++ image plate detector coupled to a Rigaku (MM007HF) X-ray 
generator with a copper rotating anode. Using the E. coli DTBS structure (PDB code-
1BYI, sequence identity-28%) as the search model, structure determination by molecular 
replacement was not successful. Expression of selenomethionine-substituted protein was 
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tried in an attempt to solve the structure using MAD phasing. However, we did not get 
any DTBS protein expression with selenomethionine. As a next logical step, in order to 
obtain phase information using the anomalous or the isomorphous signal, native DTBS 
crystals were soaked with different heavy metals (mercury, platinum, iridium and iodine) 
and datasets were collected at the home source and the synchrotron (mercury dataset). 
However, all these attempts were also unsuccessful. Ultimately, we were able to obtain 
the phase information from samarium-derivatized crystals. In this regard, native DTBS 
crystals were soaked in 50 mM samarium chloride for 1 hour and a dataset at 2.6 Å 
resolution with 1º oscillation per image was collected using the home source at Cu Kα 
wavelength (1.54 Å).  
DTBS complexed with DAPA, DAPA analog-KAPA and dethiobiotin + ADP 
datasets were obtained by soaking DTBS apocrystals in 10 mM DAPA, 10 mM KAPA 
and 10 mM dethiobiotin + 10 mM ADP + 10 mM MgCl2 overnight, respectively.  
All the crystals were cryoprotected with paratone oil and datasets were collected 
at 120 ºK. All the datasets were indexed, integrated and scaled using the HKL2000 suite 
(90). 
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FIGURE 4.3. Crystal of Mtb DTBS. These rhombohedral shaped crystals of Mtb DTBS 
(50 μM x 75 μM x 100 μM) were obtained in 1 M sodium citrate and 0.1 M imidazole 
(pH 7.5) using hanging drop vapor-diffusion technique. 
Structure determination 
For the Mtb DTBS structure determination, four sites for samarium were found 
using direct method- SHELXD (98). After refinement of these samarium sites and initial 
phasing with AutoSHARP (99), an overall anomalous phasing power of 1.4 and figures 
of merit of 0.4 and 0.14 for acentric and centric reflections, respectively, were obtained 
over the full 2.6 Å resolution range. Phases were further improved with a figure of merit 
of ~0.85 by solvent flattening with DM (100). This phase was extended to a higher 
resolution using the 1.85 Å dataset of the DTBS apostructure. DAPA, KAPA and 
dethiobiotin-ADP complexed Mtb DTBS structures were further obtained by molecular 
replacement of the DTBS apostructure as a search model against these datasets. 
Iterative rounds of model building were performed with the Shake&wARP (178) 
unbiased electron density maps using graphics software such as the Xfit module of 
Xtalview (102) and Coot (141). One round of simulated annealed refinement at 4000 ºK 
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using CNS (104) was performed to improve the geometry and remove bias from the 
model. Further refinements were carried out using REFMAC from the CCP4 suite (103). 
Water molecules were added to the models after Rfactor and Rfree values below 30% 
were achieved and inspected manually during refinement. All the structure figures have 
been prepared using Chimera (108). 
Results and discussion 
Use of samarium for structure determination of Mtb DTBS  
Simple molecular replacement using E. coli DTBS structure (PDB code-1BYI) as 
a search model was not successful. MIR/SIR/SAD using heavy metals such as Hg, Pt, Ir, 
I at concentrations of 5-10 mM was also unsuccessful. Protein structures have been 
successfully solved using the anomalous behavior of Se or S at their respective 
absorption wavelength. Se-SAD was not possible as there was no expression of Mtb 
DTBS with selenomethionine. Finally, the crystal structure of Mtb DTBS was solved 
using the single anomalous dispersion (SAD) method with the Lanthanide metal-
samarium (Sm) at home source. Since Sm can easily diffuse in the protein and occupy 
the sites of the Mg ion in DTBS, it can be used at a higher concentration (100 mM) than 
the abovementioned heavy metals without causing any damage to the crystal. In this 
study, we obtained the best data at the concentration of 50 mM. At Cu Kα wavelength, 
samarium has large anomalous signal (f"=12.1 e-). Taking advantage of this large 
anomalous signal, we were able to obtain an excellent electron density map.  
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The initial phase at 2.6 Å, obtained using the SAD method, was extended to a 
higher resolution of 1.85 Å and the final DTBS structure was refined to an Rfactor of 
22% and an Rfree of 26%. The stereochemistry of the final model was excellent as no 
outliers were seen in the disallowed region in the Ramachandran plot as per 
PROCHECK evaluation (106) (Figure 4.4). The data collection, refinement and 
geometry statistics are provided in Table 9. 
 
FIGURE 4.4. Ramachandran plot for the Mtb DTBS apoenzyme. Torsion angles (φ 
and ψ) of the amino acid residues of DTBS are plotted against each other. This plot is 
mostly used to evaluate the quality of the model. 
 Glycine Non-glycine and non-proline amino acids 
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TABLE 9 
Data collection, refinement and geometry statistics of Mtb DTBS 
 
 DTBS-Sm Native DTBS DTBS + DAPA DTBS + KAPA DTBS+DTB+ADP
Data collection      
Space group P212121 P212121 P212121 P212121 P212121 
Unit cell dimensions a=55.13Å 
b=104.45Å 
c=151.13Å 
α=β=γ=90° 
a=55.13Å 
b=104.45Å 
c=151.13Å 
α=β=γ=90° 
a=55.13Å 
b=104.45Å 
c=151.13Å 
α=β=γ=90° 
a=55.13Å 
b=104.45Å 
c=151.13Å 
α=β=γ=90° 
a=55.13Å, 
b=104.45Å 
c=151.13Å 
α=β=γ=90° 
Molecules per asymmetric unit 4 4 4 4 4 
Wavelength (Å) 1.54 1.54 1.54 1.54 1.54 
Resolution range (Å) 35-2.6 35-1.85 31.5-2.11 30-2.14 35- 2.3 
Highest resolution bin (Å) 2.7-2.6 1.95-1.85 2.22-2.11 2.24-2.14 2.3-2.2 
Observed reflections 392314 1149410 249621 618111 84334 
Unique reflections 52020 121230 47727 30270 25289 
Completeness (%)a 100 (99.9) 99.5 (96.1) 93.9 (86.6) 99.9 (99.8) 99.5 (100) 
Average redundancya 7.5 (6.9) 18.7 (10.8) 5.2 (4.6) 20.4 (16.4) 3.3 (3.3) 
I/σ(I)a 18.7 (2.5) 19.3 (1.6) 31.7 (11.8) 39.8 (5.2) 20.1 (4.8) 
Rsyma,b 0.15 (0.90) 0.16 (0.85) 0.04 (0.12) 0.08 (0.60) 0.05 (0.21) 
Refinement statistics (REFMAC)      
Free R value (5%)  25 24 27 26 
R value (%)c  21 20 22 21 
No. of protein residues  904 904 904 904 
No. of water molecules  321 208 195 180 
r.m.s.d. bond length, (Å)  0.011 0.010 0.016 0.012 
r.m.s.d. bond angles, (°)  1.3 1.3 1.8 1.6 
Ramachandran plot (PROCHECK)      
Most favored region (%)   725(94.9) 708(94.3) 710(94.5) 696 (92.4) 
Additional allowed regions (%)  37(4.8) 38(5.1) 38(5.1) 50 (6.6) 
Generously allowed regions (%)  1 (0.1) 2 (0.3) 2 (0.3) 5 (0.7) 
Disallowed regions (%)  0 0 0 0 
a Values in parenthesis for the highest resolution bin 
b Rsym = Σ|I - <I>| /Σ<I>, where I is the observed intensity, and <I> is the average intensity of multiple observations of symmetry-related reflections. 
c R = Σ ||Fobs|-|Fcalc||/ Σ |Fobs| where Fobs and Fcalc are the observed and calculated structure factors 
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Overall structure of Mtb DTBS 
In the Mtb DTBS structure, there are four molecules in the asymmetric unit. Each 
pair of molecules (chains A&B and C&D) forms a dimer. The electron density for all 
four of the polypeptide chains is well defined in the apostructure.  
Each subunit of DTBS (226 amino acids) consists of one globular domain that 
has seven parallel β strands (β3-β2-β4-β1-β5-β6-β7) interconnected with α helices. 
Being an ATP binding protein, the structure contains the classical P loop motif (also 
called Walker A motif), Gly8-X-Gly10-X-Gly12-Val13-Gly14-Lys15-Thr16, which 
binds the phosphate group of the nucleotide (179, 180). This motif is in a loop region 
between the strand β1 and helix α1 at the N-terminus of the protein. There is also a 
Walker B motif at the strand β4 (Leu104-Thr105-Leu106-Val107-Glu108) of this 
structure. The N- and C-termini of this structure are in proximity to each other (9 Å 
between the Cα atoms of Met1 and Gly226) on the same side of the protein but do not 
participate in dimer formation. This dimer interface occupies a buried surface area of 
approximately 1321 Å2 (7.5% of total surface area of the dimer). The 37.2 Å elongated 
dimer interface mainly involves the helices α3 (Pro74-Ala81), α6 (Gly144′-Gln159′) 
and α7 (Leu177′-Ile189′), the loop (Gly109-Leu124) between the strand β5 and helix 
α5, and the P loop (Thr9-Gly14) between the strand β1 and helix α1 of both the subunits 
(′ indicates the residues in the adjacent subunit).  
 
  
150
There are six helices present at the dimer interface, the inner helices, α5 and α5′, of both 
subunits and the outer helices, α6 & α3′ and α3 & α6′, which are arranged 
perpendicular to each other (Figure 4.5). As the dimer forms at a non-crystallographic 
two-fold axis, all the contacts between the residues at the interface occur twice. The 
interface of the helices α5 and α5′ involves a stacking interaction of the imidazole rings 
of His148 and His148′. The interface of helices α3 and α6′ makes hydrogen bond 
contacts between Arg188-NH2 and Glu79′-OE2 (3.5 Å) and hydrophobic interactions 
with Met72, Leu177 and Val178. Other interactions at the dimer interface include 
hydrogen bonding with the Thr9 main chain oxygen of the P loop with His148-NE2 (2.7 
Å), and the Asn147-OD1 of one monomer with the main chain amide nitrogen of 
Leu114′ of the other (2.9 Å) as well as a salt bridge between Arg125 and Glu154′ (2.85 
Å and 3.0 Å). Superimposition of chain A on chain B of the dimer does not show much 
variation in the overall structure (r.m.s.d. = 0.62 Å). 
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 Figure 4.5. Ribbon diagram representation of Mtb DTBS dimer. This figure shows 
the dimer interface of Mtb DTBS. The β-strands and the loops are colored yellow and 
pink in both the subunits. The helices are colored green in one subunit and blue in the 
other. 
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Other structural neighbors of Mtb DTBS 
A search for other structural homologs of Mtb DTBS using VAST (123) and 
DALI (25, 26) algorithms resulted in numerous hits of nucleotide-binding proteins; 
prominent among them was E. coli CTP synthetase (PDB code-1S1M) with a score of 
17.8 as analyzed by VAST. CTP synthetase regulates the intracellular CTP levels in 
bacteria and produces CTP from UTP and glutamine (181). The N-terminus of this 
protein consists of an amidoligase domain which is similar in structure to DTBS (the 
r.m.s.d. is 1.13 Å for 74 Cα atoms) with differences in the residues of the P loop 
(GGVVSSLGKG). Another protein showing a high DALI score of 16.2 is the bacterial 
cell division regulator MinD from A. fulgidus (PDB code-1HYQ) with an r.m.s.d. of 1.1 
Å for 77 Cα atoms (182). MinD activity also requires ATP hydrolysis. Unlike DTBS, 
MinD is a monomer with a slight variation in the P-loop (GKGGTGKT). Furthermore, 
Mtb DTBS also shows structural homology with the nitrogenase iron protein (NIP) from 
C. pasteurianum (PDB code-1CP2) with a DALI score of 14.7 (r.m.s.d. for 75 Cα atoms 
is 1.14 Å). All seven parallel β strands of both the proteins superimpose quite well at the 
core of the structure. However, except for the helix α1, all other NIP helices differ in 
their orientation. NIP, which is involved in nitrogen fixation, couples ATP hydrolysis 
with electron transfer (183). It requires a FeS cluster for its activity which is coordinated 
by Cys residues (97 and 132), not present in DTBS. 
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Kinetic characterization of Mtb DTBS 
DTBS catalyzes an amidoligase reaction to form dethiobiotin by using DAPA 
and Mg2+-ATP. We carried out a coupled reaction of Mtb DTBS with pyruvate 
kinase/lactate dehydrogenase (177) (Figure 4.6) to study the formation of ADP by 
monitoring the decrease in the absorbance of NADH at 340 nm. The kinetic parameters, 
Km and Kcat values for ATP were found to be 29 μM and 2.9 x 10-4 /s and for DAPA were 
2 μM and 1.5 x 10-2 /s, keeping the other substrates at saturation. This study shows that 
the Km for ATP in Mtb DTBS (29 μM) is quite high compared to that of the E. coli 
DTBS (~ 7 μM) (173). This might explain the low occupancy of ATP analogs in the 
active site of Mtb DTBS structures as discussed later in this chapter. 
 
 
FIGURE 4.6.  Coupled assay of Mtb DTBS with pyruvate kinase/lactate 
dehydrogenase. 
 
Interaction of Mtb DTBS with substrate DAPA, and its analog KAPA 
In order to determine the binding mode of the substrate at the active site, we have 
soaked the Mtb DTBS crystals with substrate DAPA. The 2.2 Å crystal structure of Mtb 
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DTBS complexed with DAPA reveals a long distinct electron density at the dimer 
interface, which fits DAPA very well. Interestingly, there is some additional electron 
density attached to the N7 atom of DAPA which fits the carbon dioxide molecule very 
well (Figure 4.7). The carboxy group of the carbamate occupies the position of the water 
molecule (W11 in chain A) at the active site of the apostructure and its carboxy oxygen 
atoms are within hydrogen bond distance to the catalytic Lys37-NZ (3 Å and 3.4 Å) and 
the Thr41 main-chain amide nitrogen (2.8 Å). The N7 atom of DAPA also has hydrogen 
bond links with Thr41-OG1 (2.9 Å) and the N8 atom with Thr11-OG1 through an 
ordered water molecule (W221 in chain A). The long aliphatic chain of this nonstandard 
amino acid spans the active site pocket at the dimer interface. This pocket formation is 
contributed by a stretch of residues from the helix α6 (Leu143'-Asn147') from the 
adjacent subunit and loops Pro71-Pro74 and Ala110-Gly112. One of the C1-carboxy 
oxygen atoms of DAPA coordinates with the main-chain amide of Leu146' (2.8 Å) and 
an ordered water molecule (2.6 Å). The other C1-carboxy oxygen atom is within 
hydrogen bonding distance of the main-chain amide of Asn147' (2.6 Å) in the helix α6 
and of the α7 helix’s Asn182′-OD1 through a neighboring water molecule (3 Å). This 
water molecule is not present in the active site of the Mtb DTBS apostructure. Due to the 
presence of this water molecule at the active site, there is a peptide flip at Gly111 of the 
loop region 110-112. This phenomenon of peptide flipping is not observed in DAPA-
bound E. coli DTBS, even though both enzymes share the same sequence at this region 
106-112 (LVEGAGG). Furthermore, in E. coli DTBS, the Tyr187′ on the helix α6 
changes its side chain orientation (approximately 90º) upon DAPA binding to hydrogen 
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bond with the carboxy oxygen of DAPA. This Tyr187′ is replaced by the Asn182′ in 
Mtb DTBS (Figure 4.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4.7.  Electron density for DAPA-carbamate. This figure shows the electron 
density of Shake-warp omit map for DAPA-carbamate at 3σ level, visible in the Mtb 
DTBS active site. This also confirms that DTBS in Mtb is specific for carbamate at N7 
position of DAPA. 
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FIGURE 4.8.  Mode of DAPA-carbamate binding in the Mtb DTBS active site. 
Residues interacting with the substrate DAPA-carbamate in the DTBS active site are 
shown in this figure. This plot has been prepared using Ligplot (122). The protein 
residues are colored orange and the ligand DAPA-carbamate is colored purple. 
Hydrogen bonds are shown in green dotted lines. Hydrophobic interactions are shown in 
brick-red sunbursts. Water molecules are shown in cyan. Atoms are colored by type (C- 
black, O- red, N- blue). 
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Similar interactions are also observed for KAPA at the DTBS active site (Figure 
4.9). However, as evident from the weak electron density for KAPA and its high B 
factor, the occupancy of KAPA (0.5) is much lower than DAPA (1.0) at the active site of 
all four chains of the asymmetric unit. This low occupancy of KAPA might suggest its 
low affinity as a substrate for this enzyme. In this KAPA-bound DTBS structure, there is 
also a presence of sulfate ion from the crystallization solution, bound at the P loop 
(Gly8-Thr16). This sulfate ion mimics the β phosphate of the nucleotide. The 7-keto-
oxygen atom of KAPA is oriented towards this sulfate ion with an ordered water 
molecule (W24 in chain A) occupying a similar position to the γ-phosphate of the 
nucleotide at the active site (3.2 Å). The N8 atom of KAPA forms a hydrogen bond with 
Asp47-OD2 (2.9 Å) at the active site. Thus, KAPA also occupies a similar position to 
that of DAPA in the hydrophobic pocket of the enzyme, away from the P loop. 
The DAPA-bound DTBS structure illustrates that the first substrate DAPA can 
bind to the enzyme in the absence of the second substrate ATP. It also demonstrates the 
enzyme’s specificity for the N7-DAPA carbamates as carbamylation of DAPA might 
have occurred at either N7 or N8 position in crystallization drops from atmospheric CO2. 
Furthermore, the diamino group of the substrate is bound to one subunit and the carboxy 
group is in contact with the other adjacent subunit. Thus, the substrate is anchored to 
both the subunits at the active site. 
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FIGURE 4.9. Schematic diagram of KAPA interactions in the Mtb DTBS active site. 
The protein residues are colored in orange. KAPA and the sulfate ion are colored purple. 
Water molecules are shown in cyan. Hydrogen bonds are shown in green dotted lines. 
Hydrophobic interactions are shown in brick-red sunbursts. Atoms are colored by type 
(C- black, O- red, N- blue, S- yellow). This plot has been prepared using Ligplot (122). 
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ATP/ADP binding site 
To understand the interaction of nucleotides with the enzyme and the resulting 
conformational changes on its binding, the crystal structures of Mtb DTBS complexed 
with ATP analogs (AMP-PCP and ATP γ-S) as well as ADP were determined. However, 
only partial electron density for these entities was visible at the active site. Phosphate 
ions were clearly visible at the P loop but electron density for the rest of the molecules 
was less well defined. Hence, to pinpoint the residues involved in the interaction with 
the nucleotide at the active site, the E. coli DTBS structure complexed with ADP (PDB 
code-1DAM) has been overlaid on this Mtb structure. In a surface representation of the 
Mtb DTBS active site, it appears that this 17 Å long nucleotide binding region is 
completely exposed to solvent, resulting in disordered electron density for ATP/ADP. 
This might be due to a variation in the conformation of the loop regions Gln168-Val176 
and Leu196-Asp204 near the adenine ring-binding pocket in comparison to the E. coli 
enzyme. A unique feature of this loop region is the presence of multiple proline residues 
(Pro172, Pro174, and Pro175) which would make the loop less flexible. It also appears 
that the only interaction of the protein with the nucleotide’s ribose sugar would occur 
between its O2' atom and the carboxy group of Glu52 probably via a water molecule. 
This Glu residue is present on the helix α2 of Mtb DTBS which is positioned 5.3 Å 
closer to the active site than in its E. coli counterpart. The corresponding residue in E. 
coli DTBS, which makes direct hydrogen bond contact with the O2' atom of the 
nucleotide’s ribose sugar is Glu211 present in the loop region (Trp209-Glu212) between 
the strand β7 and the helix α9. This nucleotide interaction in E. coli DTBS orders the 
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loop region which is disordered in its apostructure (PDB code-1DTS). This loop 
stabilization upon nucleotide binding has also been reported in other enzymes such as 
GTPases (184) and adenylosuccinate synthetase (185). Intriguingly, clear electron 
density for this loop (Leu196-Asp204) in Mtb DTBS can be seen in the unliganded 
structure as well. This might be due to the presence of the long helix α7 just behind the 
loop region, not present in E. coli DTBS. Furthermore, the nitrogen atoms of the adenine 
ring have hydrogen bond contacts with this loop. The N1 atom would hydrogen bond 
with the main-chain amide of Gly199 from the loop region (2.7 Å) and the N7 atom 
would bond with the main-chain oxygen of Gly169 (2.7 Å). It is evident from this study 
that the solvent exposed nucleotide-binding site is located adjacent to the hydrophobic 
DAPA binding pocket.  
DAPA and ATP occupy distinct binding sites in the protein similar to the E. coli 
DTBS enzyme. It appears that if the γ phosphate of ATP is bound to one monomer it 
would be too far (23.8 Å) from the carboxy group of the DAPA-carbamate bound to the 
same monomer to perform the catalytic reaction. Therefore, it is anticipated that the 
enzyme reaction will involve the ATP bound to one monomer with the DAPA from the 
other, with both subunits forming the active site. The DTBS dimer still possesses two 
active sites, which are approximately 13 Å apart at the interface, with the entrances 
facing the same side of the dimer.  
In addition, based on the superimposition of the apostructure on the substrate- 
bound structures (r.m.s.d. of 0.3 Å for 226 Cα atoms), it appears that there are no 
significant changes in the conformation of the enzyme upon substrate binding. This is 
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also evident from the soaking experiments, since the crystals did not crack in the 
presence of substrate. There are local conformational changes in the form of movement 
of the loop regions Thr9-Gly14 (2.4 Å), Gly109-Leu113 (1 Å) and Thr140′- Gly144′ 
(0.8 Å) in response to substrate binding. Most of these changes result in increased 
compactness of the active site for better substrate interaction. 
Interaction of Mtb DTBS with the products DTB and ADP 
To obtain a clear picture of the mechanism of the enzyme reaction and 
understand the binding mode of the products at the active site, we have tried to capture 
the ternary complex by soaking the DTBS apoenzyme crystal with dethiobiotin, Mg2+-
ADP and phosphate. The 2.3 Å electron density map of this DTBS complex clearly 
reveals the position of the product DTB just opposite the P loop in the active site. The 
C1-carboxyl group of DTB buried inside the active site pocket forms hydrogen bond 
contacts with the main-chain amide nitrogen atoms of Leu146′ (2.8 Å) and Asn147′ (2.6 
Å), and with Asn182′ via a water molecule, in the same manner as with the substrate 
DAPA. There is a peptide flip at Gly111 due to the presence of this water molecule, not 
seen in the E. coli DTB complexed structure. As a result, the main-chain oxygen of 
Gly111 forms a hydrogen bond with Thr7-OG1 via a water molecule. The aliphatic 
chain of DTB spans the space between the dimer interface, making hydrophobic contacts 
with Pro74, Ala73, Gly111, and Val115. The N7 atom of the ureido ring of DTB is 
hydrogen bonded to the Asp47-OD1 (3.3 Å) and in this process, the salt bridge between 
Arg45 and Asp47 is broken at the active site. The N8 atom of DTB is hydrogen bonded 
to the Thr11-OG1 of the P loop (3.4 Å) (Figure 4.10).  
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FIGURE 4.10. Interactions of product DTB and phosphate ions in the Mtb DTBS 
active site. The protein residues are colored orange, and DTB and phosphate ions are 
colored purple. Water molecules are in cyan. Hydrogen bonds are shown in green dotted 
lines. Hydrophobic interactions are shown in brick-red sunbursts. Atoms are colored by 
type (C- black, O- red, N- blue, P- purple). This plot has been prepared using Ligplot 
(122). 
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Comparison of the DTB-bound Mtb structure to the DAPA-bound structure, it is 
clear that the substrate DAPA and the product dethiobiotin both occupy the same 
position in the active site. There is no major change in the conformation of residues 
lining the active site during the substrate or the product binding except in the orientation 
of the ligand to fit in this hydrophobic pocket. The C1-carboxy end of the ligand anchors 
to the other subunit of the dimer and the diamino end of the substrate participates in 
catalysis. In the DTB-bound E. coli DTBS structure, the aliphatic chain of the product 
was curved compared to DAPA in order to fit into the active site. It was thought to be 
due to the formation of the ureido ring in DTB (172). Contrary to this, a similar curving 
of the aliphatic chain of DTB is not observed in the Mtb structure, probably due to the 
hydrogen bond formation of the N7-ureido ring of DTB with Asp47 rather than Thr41. It 
is worth mentioning here that at this position in Mtb DTBS, the active site is lined by a 
short loop (Gly42-Asp47), whereas in E. coli DTBS there is an extension of two 
antiparallel β strands (Gly42-Ser53). Interestingly, there are three contiguous Asp 
residues (47-49) in this region of the Mtb active site, Asp47 hydrogen bonds with Arg45 
of the active site, as well as, with the substrate/product, Asp48 hydrogen bonds with 
Arg67 (3.3 Å) and Asp49-OD1 forms hydrogen bond with Lys37-NZ (2.9 Å) or a Mg2+ 
ion. 
In this ternary complex of DTBS, there is presence of two phosphate ions at the 
nucleotide-binding site in place of the product ADP. One phosphate ion is bound at the P 
loop (Gly8-Thr16) which is similar to the β phosphate of ADP and a second one is 
present between the P loop bound phosphate and dethiobiotin, occupying the γ 
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phosphate’s position. This mimics the position of the intermediate state DTB-Pi-ADP 
complex at the active site, just before the release of the products (Figure 4.11). In 
response to the phosphate bound at the P loop, all the main-chain amide N atoms in this 
region (Thr11-Lys15) are oriented inward, creating a positively charged environment 
that causes the phosphate group of the nucleotide to bind tightly. Also, the Thr11 side 
chain changes its rotamer 90° in response to hydrogen bond formation with the γ 
phosphate-O4, with a movement of 1 Å towards the active site. These phosphate ions (β 
and γ) are kept in position by conserved lysine residues (15 and 37) and the magnesium 
ion.  
Thus, these DTBS structures also indicate that the P loop is involved in binding 
both substrates at the active site, providing a reason for the longer than usual peptide 
sequence in this region, as compared to other enzymes with a P loop.   
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FIGURE 4.11. Surface representation of the active sites of Mtb DTBS. This figure 
represents the dimeric form of dethiobiotin synthase in Mtb, showing the products bound 
at both the active sites, 13 Å apart. Subunit A and B are colored grey and rose, 
respectively. At the active site, DTB is positioned inside the hydrophobic pocket, 
anchored to the other subunit and ADP is modeled in the open cleft, completely exposed 
to the solvent. The product inorganic phosphate is positioned between DTB and ADP.  
ADP 
DTB 
Pi
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Like other nucleotide-binding proteins, Mtb DTBS uses divalent metal ion such 
as Mg2+ for stabilizing the phosphate groups (mostly β and γ) of the nucleotides. This 
structure displays an octahedral arrangement of the Mg2+ ion with six ligands. These 
ligands are the two oxygen atoms- one from each of the phosphate groups β and γ, the 
side chains of residues Thr16, Asp49, and Glu108 and a water molecule (figure 4.12). 
These interacting amino acid residues are also conserved in E. coli and almost conserved 
in H. pylori DTBS with Asp49 being replaced with Asn46. However, Mtb DTBS lacks 
the second Mg2+ binding site as reported in E. coli DTBS structure (186). 
 
 
FIGURE 4.12. Mg2+ ion coordination in the Mtb DTBS active site.  The figure shows 
the octahedral arrangement of Mg2+ ion (green) with the active site residues Thr16, 
Asp49 and Glu108, and the phosphate groups (β and γ) of the nucleotide, and a water 
molecule. 
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Comparison with other DTBS structures 
Superimposition of the monomer of E. coli DTBS (PDB code–1BYI) on Mtb 
DTBS results in an r.m.s.d. of approximately 1.79 Å which might be due to the low 
sequence identity of Mtb DTBS (28%) with E. coli DTBS. Comparison of both 
structures reveals significant structural differences, which explains the failure of 
molecular replacement for the Mtb DTBS structure determination using the E. coli 
DTBS structure as the search model (Figure 4.13). Interestingly, when the Mtb DTBS 
structure was overlaid with a recently solved DTBS structure from H. pylori (PDB code-
2QMO, sequence identity-18%, r.m.s.d. = 1.05 Å for 111 Cα atoms), similar differences 
in the overall structure were found. Firstly, in E. coli DTBS active site, two extended 
antiparallel β−strands of unknown function are present between the residues Gly42-
Ser53 in place of a short loop (Gly42-Asp47) in Mtb. There is a long loop (Lys35-Ser49) 
present in this region in H. pylori DTBS. Secondly, a long loop followed by a short one-
turn helix is seen in both the E. coli enzyme (Arg62-Pro72) as well as in H. pylori 
(Leu61-Ile70) in place of a single β−strand (β3) in Mtb DTBS (Gln61-Leu65). Thirdly, 
there is a stretch of three short one-turn helices connected by loops in the region Pro209-
Asn224 in E. coli DTBS instead of a long helix (α7, Ala205-Ala215) followed by a 
short one-turn helix at the C-terminus in Mtb. Some parts of this C-terminal region have 
disordered electron density in the E. coli apoenzyme as well as in the substrate 
complexed structures (PDB codes – 1DTS, 1DAI and 1DAE). This might be due to the 
presence of these short stretches of helix at this terminus, responsible for its flexibility 
upon solvent exposure. In this case, the H. pylori DTBS differs in having a very different 
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structure at the C-terminus; the strand β7 and the helices α6 and α7, which is the 
binding site for the adenine ring of the nucleotide from Mtb, are missing in H. pylori. 
Therefore, the exact mode of nucleotide binding in the H. pylori DTBS remains 
unknown until a structure of DTBS complexed with nucleotide can be determined. Even 
the residues in the P loop motif differ in all three DTBS enzymes. The Mtb enzyme has 
glycine residues in place of the charged residues in the loop region of its E. coli (Glu and 
Asp) and H. pylori (Asn) counterparts. Furthermore, at the P loop of the E. coli enzyme, 
Glu12 forms a salt bridge with Lys148 of the active site. As the nucleotide binds the 
Walker A motif, this bond is broken and Glu12 orients toward the β-phosphate of ATP 
and DAPA-carbamate at the active site. Initially, Glu12 was thought to participate in E. 
coli enzyme catalysis as a general base/acid, however, mutation studies on Glu12 
(E12A) suggest that this residue has synergistic effects on substrate binding and is not 
involved in catalysis (187). Lys148 stabilizes the P loop by supporting the pocket 
formed at the back of the loop through an interaction with Glu12. In Mtb DTBS, Gly12 
and Asp142 are present in place of Glu12 and Lys148, respectively. Thus, this ionic 
interaction is missing in the Mtb DTBS active site. These comparisons also indicate that 
the Mtb DTBS possesses some structural features which are not present in the DTBS of 
the other two organisms. 
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FIGURE 4.13. Superimposition of Cα atoms of DTBS monomer from E. coli and 
Mtb. Ribbon diagram of an overlay of E. coli DTBS (PDB code-1BYI) structure (cyan) 
on Mtb DTBS (blue). All the core β strands (gold) from both the structures overlay very 
well. The arrows point toward the major differences in the two structures (red). The 
r.m.s.d. for 224 Cα atoms for both chains is 1.79 Å. 
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Possible Mtb DTBS reaction mechanism 
Based on the structures of Mtb DTBS complexed with substrates and products, 
we can outline a possible reaction mechanism for this amidoligase. Like E. coli DTBS 
(170), the Mtb DTBS reaction involves three steps, the carbamylation of the N7 position 
of DAPA, the hydrolysis of ATP and the formation of a carbamate–phosphoric 
anhydride intermediate, and ultimately, the closure of the ureido ring to form DTB with 
the release of inorganic phosphate.  
The first step of the enzyme reaction is the carbamylation of the substrate DAPA. 
A carbamylation reaction is possible either at the N7 or the N8 position of DAPA in 
solution (188). The DAPA-bound Mtb DTBS structure suggests that this enzyme has 
specificity for the N7-carbamate. However, it is not clear, whether this enzyme catalyzes 
the carbamylation at the N7 position of DAPA or if it happens freely in solution. In the 
next step of the reaction, one of the carbamate oxygen atoms attacks the γ phosphate of 
ATP, based on the positions of the carbamate-carboxyl oxygen atom and Pi in DAPA 
and DTB complexed DTBS structures, respectively. As a result, there is cleavage of the 
P-O bond between the β and γ phosphate of ATP. One of the protons from the amino 
group of the N8 atom is also abstracted by the water molecule (W221 in chain A) 
present next to it. Furthermore, the Lys37 residue, which is in the close vicinity of the 
phosphate-carbamate anhydride intermediate, stabilizes this complex. In the final step of 
the formation of the ureido ring of DTB, a second deprotonation of the N8 atom of the 
carbamate-phosphoric anhydride must occur so that it can attack the carbamyl carbon to 
close the ring. Initially, we thought that Asp47 could act as a base to abstract a proton 
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from the N8 atom due to its presence in the loop region of the active site, a unique 
feature of this enzyme. However, our kinetic analysis on the D47A mutant suggests that 
this Asp residue might not be involved in proton abstraction from N8 atom since the 
mutant enzyme still retains the normal activity. In this situation, it is quite difficult to 
further pinpoint which residue might act as a base due to the lack of a DTBS crystal 
structure complexed with carbamate phosphate anhydride. However, based on the 
analogy with the p21ras protein mechanism (189, 190), it can be speculated that the 
oxygen atom on the phosphate of the intermediate complex could act as a base. After the 
ureido ring closure, there is transfer of electrons, resulting in the breakage of the C-O 
bond and the release of the inorganic phosphate to form DTB (Figure 4.14). 
 Thus, using the knowledge gained from the different Mtb DTBS complexed 
structures as well as the preliminary biochemical analysis of this enzyme, our future goal 
will be to search for potential inhibitors against this enzyme. In this regard, the analogs 
of DAPA carbamate and variable length analogs of substrate DAPA and KAPA seem to 
be good candidates. The natural antibiotic acidomycin has a chemical structure similar to 
DTB/biotin. It also had a good whole cell activity against Mtb (MIC = 0.0625-0.125 
μg/ml) (59). However, our studies show that Mtb DTBS is not the target of acidomycin 
since it did not inhibit the DTBS reaction even at a concentration of 200 μM. Besides 
targeting the DAPA-binding site, the mimics of the carbamate-phosphoric anhydride 
complex can also act as good inhibitors for this enzyme as they will irreversibly bind at 
the active site, not resulting in product formation.  
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FIGURE 4.14. Schematic representation of the possible mechanism of Mtb DTBS.
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CHAPTER V 
PURIFICATION AND PRELIMINARY CHARACTERIZATION OF  
7-KETO, 8-AMINOPELARGONIC ACID SYNTHASE  
IN Mycobacterium tuberculosis 
 
Background 
7-keto, 8-aminopelargonic acid synthase (KAPAS; EC 2.3.1.47) catalyzes the 
first step in the biotin biosynthetic pathway. During this step, the condensation reaction 
of L-alanine with pimeloyl-CoA and the simultaneous decarboxylation of L-alanine 
occur. This process requires pyridoxal 5′-phosphate (PLP) as a cofactor and results in the 
formation of 7-keto, 8-aminopelargonic acid (KAPA) (Figure 5.1). In Mtb, the source of 
the starting material for biotin production, pimeloyl-CoA, is not clear. 
 
 
 
FIGURE 5.1. Reaction catalyzed by 7-keto, 8-aminopelargonic acid synthase. 
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KAPAS has been studied in both E. coli (191, 192) and B. sphaericus (42, 193). 
The only known crystal structure of KAPAS is determined in E. coli and, likewise, 
inhibition studies of this enzyme have also been carried out only in this organism. 
Biochemical and crystallization trials of KAPAS in B. sphaericus have been performed 
for increasing the biotin production in the food industry. Preliminary biochemical studies 
have also been performed in plants such as Arabidopsis thaliana (50) and pathogens like 
Mtb (194) with the intent to develop herbicides and antibiotics. 
Knockout studies on the Mtb H37Rv bioF1 gene, which codes for KAPAS, have 
suggested that this gene is required during the early stages of mycobacterial infection in 
mice (9). Further in vitro studies of the bioF1 mutant strain in culture results in cell 
death instead of growth arrest suggesting that it cannot survive without biotin (55). This 
indicates the requirement for a de novo biotin biosynthetic pathway for mycobacterial 
survival. Hence, KAPAS in Mtb is a good candidate for inhibitor design against this 
pathogen.  
To this end, we will discuss the cloning, protein purification and preliminary 
biochemical characterization of the KAPAS in Mtb in order to further facilitate the 
process of structure determination and inhibitor studies in this enzyme. 
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Methods 
Reagents 
The restriction enzymes for Rv1569 cloning were purchased from New England 
Biolabs. All the reagents have been purchased from Sigma except KAPA was purchased 
from Toronto research chemicals Inc., Canada and pimeloyl-CoA was provided to us by 
Dr. Richard Lee, University of Tennessee. 
Cloning and protein expression of Mtb KAPAS  
The 1161 base pair bioF1 gene (Rv1569) from Mtb H37Rv genome was PCR 
amplified and cloned into pET28b with the TEV site using NdeI and HindIII restriction 
enzymes. This clone generates the His-tagged KAPAS. The NdeI site contained the ATG 
start codon and the stop codon preceded the HindIII site. The different primers used in 
this study were:  
For N-terminal His-tagged or wild type KAPAS, 
Forward Primer: 5′ AGAGAAGCATATGAAAGCCGCCACGCAGGCACG 3′ 
Reverse Primer:  5′ CCCAAGCTTTCAACGGCGCGCCACGGCGAGAACATC 3′ 
For C-terminal His-tagged KAPAS, 
Forward Primer: 5′ AGAGAAGCATATGAAAGCCGCCACGCAGGCACG 3′ 
Reverse Primer: 5′ CCCAAGCTTACGGCGCGCCACGGCGAGAACATC 3′ 
For truncated N-terminus KAPAS (40-386), 
Forward Primer: 5′ AGAGAAGCATCTGGTCGCCACCGAGCTGGACTTGG 3′  
Reverse Primer: 5′ CCCAAGCTTTCAACGGCGCGCCACGGCGAGAACATC 3′ 
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 For untagged KAPAS, the Rv1569 gene was inserted in the pET30b vector with 
NdeI and HindIII sites. The truncated Rv1569 gene was also cloned into pET28b with 
TEV sites to generate the N-terminal His-tagged truncated protein. All the constructs 
were checked for the presence of the insert by DNA sequencing. 
The clones (pET28b-Rv1569, pET30b-Rv1569 and the truncated version of 
Rv1569) were transformed into the E. coli expression host BL21 (DE3). The cell culture 
was grown in LB media with kanamycin (50 μg/ml) at 37 ºC till the A600 reached 0.8. 
The culture was then induced with 0.5 mM IPTG at 25 ºC and grown overnight. There 
was no expression of KAPAS at temperatures lower than 25 °C.  
Purification of His-tagged KAPAS 
Cells were harvested by centrifuging at 3000 rpm for 30 min and resuspended in 
50 mM Tris buffer (pH 7.0), 500 mM NaCl, 10% glycerol, 20 μg/ml DNase, 100 μM 
PLP and one tablet of Complete EDTA-free protease inhibitor cocktail (Roche) per cell 
pellet (6 grams). The cells were lysed using a French press at 11,000 psi and the cell 
debris was removed by centrifuging the cell lysate at 15,000 rpm for 1 hour. The 
supernatant was then loaded on a HisTrapTM FF Ni column (GE healthcare) which was 
pre-equilibrated with buffer A (50 mM Tris buffer (pH 7.0), 500 mM NaCl, 10% 
glycerol, 4 mM β-mercaptoethanol). The column was then washed with buffer A 
containing 50 mM imidazole to remove all the contaminants. The protein was eluted 
using an imidazole gradient (100-500 mM) in the buffer. KAPAS was 99% pure as 
judged by the 4-12% gradient SDS-PAGE gel. The fractions containing the protein were 
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pooled and dialyzed overnight against a buffer containing 25 mM Tris (pH 7.0), 50 mM 
NaCl, 1 mM EDTA, 1 mM DTT, 10% glycerol and 100 μM PLP. The protein was 
further concentrated by ultrafiltration using 30 kDa molecular weight cutoff Centriprep 
(Millipore) filters before being used for crystallization experiments.  
Purification of wild type KAPAS 
Purification of wild type KAPAS (untagged) began by resuspending cell pellet in 
buffer containing 50 mM potassium phosphate (pH 7.0), 10% glycerol, 2 mM DTT, 20 
μg/ml DNase and one tablet of Complete EDTA-free protease inhibitor cocktail (Roche) 
per cell pellet. The cells were lysed using a French press at 11,000 psi and the cell debris 
was removed by centrifuging the cell lysate at 15,000 rpm for 1 hour. After 
centrifugation, the supernatant was saturated with 30% ammonium sulfate. The solution 
was again centrifuged at 10,000 rpm for 15 min.  
Phenyl sepharose HP column: The resultant pellet was further resuspended in buffer 
containing 50 mM potassium phosphate (pH 7.0), 30% (NH4)2SO4, 10% glycerol, 1 mM 
DTT and loaded on phenyl sepharose HP column (GE Healthcare) equilibrated with 
buffer A (50 mM potassium phosphate (pH 7.0), 1 M (NH4)2SO4, 1 mM DTT and 10% 
glycerol). After the column was washed thoroughly with 100 ml of buffer A to remove 
the contaminants, the protein was eluted with 400 ml of linear gradient of (NH4)2SO4 in 
buffer A (1-0 M).  
SP sepharose FF column: The fractions containing KAPAS were pooled and loaded on a 
SP sepharose column pre-equilibrated with buffer B (50 mM PIPES (pH 6.5), 1 M NaCl, 
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10% glycerol, 1 mM DTT). After the column was washed with 100 ml of buffer B 
containing 25 mM NaCl, the protein was eluted with 400 ml of linear gradient of NaCl 
in buffer B (50 mM - 800 mM). The fractions containing KAPAS were pooled and 
concentrated, using 30 kDa molecular weight cutoff Centriprep (Millipore) filters. 
Gel filtration: In the last step, the concentrated KAPAS is injected into a gel filtration 
column (Superdex 200 XK16/60, GE healthcare) which was pre-equilibrated with 25 
mM PIPES (pH 6.5), 100 mM NaCl, 10% glycerol, 2 mM DTT and 1 mM EDTA and 
eluted with the same buffer at a rate of 0.5 ml/min.  
 The fractions containing KAPAS were pooled and concentrated as before and 
used for crystallization experiments. All the purification experiments have been carried 
out at 4 ºC.  
Determination of oligomeric state of Mtb KAPAS 
 KAPAS with concentration of 10 mg/ml was injected into the gel filtration 
column (Superdex 200 XK16/60, GE Healthcare) which was pre-equilibrated with buffer 
containing 25 mM bis-tris propane (pH 7.0), 50 mM NaCl, 2 mM DTT and 1 mM EDTA 
at 4 ºC. The protein was eluted at the rate of 0.5 ml/min with 2 ml fractions being 
collected. BioRad standards (thyroglobulin (670kDa), BSA (158kDa), chicken 
ovalbumin (44kDa), equine myoglobin (17kDa) and vitamin B12 (13.5kDa)) were used 
for the calibration purpose.  
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Spectroscopic studies of Mtb KAPAS 
Absorbance spectra for the Mtb KAPAS (10 μM) reaction with 10 mM alanine 
and 100 μM pimeloyl-CoA was measured in the range of 300-600 nm using a Cary 100 
spectrophotometer (Varian). These experiments were conducted at room temperature, 
using a buffer containing 50 mM AMPSO (pH 9.0), 150 mM NaCl, 10% glycerol, 4 mM 
β-mercaptoethanol and 100 μM PLP. KAPAS concentration was calculated from its 
absorbance at 280 nm using its extinction coefficient (ε = 21270 /mM/cm) (138). 
For the measurement of the kinetic parameters of Mtb KAPAS, we performed the 
enzyme (2.5 μM) reaction with Ellman’s reagent (DTNB- 5, 5’-dithio-bis (2-nitobenzoic 
acid)) at 412 nm. 5mM stock solution of Ellman’s reagent was prepared in 50mM 
phosphate buffer (pH7.5) and stored at -80 ºC. The buffer used for the reaction was 20 
mM potassium phosphate buffer (pH 7.5), 150 mM NaCl, 10% glycerol and 2 mM 
EDTA. The reaction was monitored by measuring the absorbance of thiophenolate 
formation at 412 nm (ε = 13600 /M/cm) at room temperature using a Cary 100 
spectrophotometer. Michaelis-Menten equation was used to calculate the Km and Kcat 
values for L-alanine and pimeloyl-CoA, with the curvefit option in the Kaleidagraph 
software. 
Crystallization trials of Mtb KAPAS 
Crystallization trials for Mtb KAPAS in complexes with 100 μM PLP, substrates 
10 mM L-alanine and 100 μM pimeloyl-CoA as well as product KAPA (5 mM) were 
carried out at 18 °C using the crystal screen I and II, SaltRx, PEG/Ion, Membfac, Index 
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screen of Hampton Research and Wizard I, II and III of Emerald BioSystems. Initial 
crystal screening was performed using Hydra Plus One dispenser (Art Robbins 
instruments) with a 1:1 ratio of KAPAS protein (10 mg/ml) and crystallization condition, 
on 96 well intelliplates (Hampton Research). 
Results and discussion  
Purification and crystallization of Mtb KAPAS   
We have successfully cloned the Rv1569 gene from Mtb H37Rv genomic DNA 
and overexpressed KAPAS protein in E. coli BL21 (DE3) host strain. In figure 5.2, the 
DNA agarose gel shows the amplified 1.2 kbps Rv1569 gene from Mtb H37Rv genome. 
This gene was inserted in the modified pET28b vector. The pET28b-Rv1569 clone was 
transformed into an overexpression host E. coli BL21 (DE3). Both His-tagged and wild 
type Mtb KAPAS (untagged) proteins were purified to homogeneity using different 
purification protocols outlined in the methods section. Figure 5.3 A represents a typical 
Ni column purification profile which provided one-step purification of KAPAS. SDS-
PAGE analysis of Mtb KAPAS from this purification experiment revealed a single band 
at 40 kDa which is in agreement with the molecular mass determination of the Rv1569 
gene sequence (Figure 5.3 B). This His-tagged protein was further used to setup 
crystallization trials.  
There are instances in crystallization trials when an N-terminal His-tag may 
hinder crystal lattice formation due to its flexible nature. Cleavage of this His-tag from 
the protein or no tag can readily lead to crystal formation. Hence, to cleave the N-
  
181
terminal His-tag of KAPAS, we used TEV protease. The reaction was carried out at a 
ratio of 20 mg of KAPAS to 1 mg of TEV protease at 4 ºC under overnight dialysis. The 
buffer containing 20 mM potassium phosphate buffer (pH 7.0), 150 mM NaCl, 10% 
glycerol and 5 mM β-mercaptoethanol was used. However, the protein became cloudy 
under overnight dialysis and TEV cleavage was also not successful, resulting in only 
20% cleavage of KAPAS. This might indicate that the protein is not stable during TEV 
cleavage. To circumvent this problem, C-terminal His-tagged KAPAS was purified. 
However, this construct was not very pure and had low yield.  
As a next logical step towards crystallization of Mtb KAPAS, we constructed the 
wild type KAPAS protein. This protein was purified in four steps: ammonium sulfate 
precipitation (30% saturation), phenyl sepharose (hydrophobic) column, SP sepharose 
(anionic) column and gel filtration chromatography. The protein from this protocol was 
judged 99% pure from the 4-12% SDS –PAGE gel. This protein was further 
concentrated up to 10 mg/ml and crystallization screens were set up using over 1000 
different precipitant conditions.   
Different buffers (Tris, potassium phosphate, Hepes, PIPES, bis-tris propane) 
with pH conditions in the range 6.0-9.5 have been screened to determine the stability of 
the protein as well as to setup crystallization trials. This protein is stable in potassium 
phosphate and Hepes buffer (pH 7.0). Although Mtb KAPAS seemed to be stable in 
phosphate buffer, crystallization trials in this buffer mostly resulted in the formation of 
salt crystals.  
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Based on the crystal structure of E. coli KAPAS (PDB code-1BS0), the N-
terminal region contains a helix followed by a long loop (Figure 5.4). It was believed 
that this floppy region would prevent crystal formation. In order to facilitate the process 
of crystallization in KAPAS, 40 residues at the N-terminus have been truncated. Further 
crystallization trials of this truncated protein in complex with ligands such as 
substrate/product as well as inhibitor are in progress. 
 
 
 
 
 
 
 
 
 
FIGURE 5.2. PCR amplification of Rv1569 gene. 1% agarose gel shows the PCR 
amplified Rv1569 gene product from Mtb H37Rv genomic DNA. 1161 bps Rv1569 gene 
product is shown in lanes 1-4. The extreme right lane, M is the Perfect DNATM marker 
(0.5–12 kbp) (Novagen).
1000bp
1500bp
M4321
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FIGURE 5.3. Elution profile of a Ni affinity column chromatography and SDS-
PAGE gel of KAPAS purification. (A) The elution profile of the Ni affinity 
chromatography showing the absorbance peak at 280 nm (marked by an arrow) which 
contains the fractions with Mtb KAPAS. (B) 4-12% gradient SDS-PAGE gel stained 
with Coomassie Blue showing lanes with Mtb KAPAS in the fractions eluted from the 
Ni column and Perfect proteinTM marker (10-225 kDa) (M). As evident in the figure, 
KAPAS runs at 40 kDa on PAGE gel. 
M 26 27 28 2930 31 32  33 
50 
35 
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FIGURE 5.4. Ribbon diagram of E. coli KAPAS (PDB code-1BS0). The helices, β 
strands, and the loops are colored blue, yellow and green, respectively. In order to yield 
better crystals, the N-terminal helix with the loop (pink) was truncated in Mtb KAPAS. 
 
 
 
 
 
N
C
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Based on the elution profile of size exclusion chromatography, which contained a 
single peak, the molecular weight of KAPAS in solution was calculated to be 
approximately 80 kDa (data not shown). This indicates the oligomeric state of KAPAS 
as a dimer. This is analogous to E. coli KAPAS protein. Furthermore, on sequence 
alignment of KAPAS from both the organisms, we found that Mtb KAPAS has 36% 
sequence identity with E. coli KAPAS (Figure 5.5).  
 
FIGURE 5.5. Sequence alignment of E. coli and Mtb KAPAS. The residues colored in 
green and cyan depict conserved and similar residues in both organisms, respectively. 
 
To gain some insights into the residues, which might constitute the active site, 
structural alignment using the ligand bound complexes of E. coli KAPAS structure with 
Mtb KAPAS homology model (generated by Swiss model) was carried out. Key residues 
from the E.coli AONS-PLP structure (PDB code-1BS0) include Lys236 (Mtb Lys239) 
which binds PLP to form the internal-aldimine and His133 which forms a stacking 
interaction with the PLP ring, also conserved in Mtb (His134). Other residues in the 
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active site of the E. coli enzyme that contribute to PLP binding are Asp204, Ala206, 
His207, Arg361 which are also conserved in Mtb (Asp205, Ala207, His208, Arg358). 
Based on the ternary complex of KAPA-PLP bound AONS structure (PDB code-1DJ9), 
the O7-keto group of KAPA is hydrogen bonded with His133 (Mtb His134) and the 
carboxylate group of KAPA is hydrogen bonded with Arg21 and Arg349 which 
corresponds to Gln21 and Arg346 in Mtb. However, there is an Arg present next to 
Gln21 in Mtb, which might be involved in the hydrogen bond interaction with the 
carboxylate of KAPA, or the amino group of Gln21 can also serve as the hydrogen bond 
partner. The methylene long chain of KAPA is in van der Waals contact with Val79 
(Mtb Val80), Met180 (Mtb Ala181), Ile263′ (Mtb Ile266) and Tyr264′ (Mtb Phe267). 
Other residues involved in catalysis of KAPAS are Ser179 (Mtb Ser180) and Glu175 
(Mtb Asp176). Although there are some differences in KAPA interaction between the 
two enzymes, we expect the active site of the E. coli enzyme to be similar to the Mtb 
KAPA synthase. However, there is no three-dimensional structure of KAPAS 
complexed with substrates L-alanine or pimeloyl-coA available. Hence, there is lack of 
information regarding the residues involved in substrate interaction as well as 
conformational changes accompanying the substrate binding at the active site. Since 
these substrates have very different structural characteristics compared to the product 
KAPA, three-dimensional structure of substrate-bound Mtb KAPAS still needs to be 
determined to pinpoint the residues involved in its binding. 
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Spectroscopic properties of Mtb KAPAS 
Taking advantage of the chromophore properties of cofactor PLP and PMP, we 
studied the absorption spectra of wild type Mtb KAPAS reaction with the substrates, L-
alanine and pimeloyl-CoA in the range of 300-600 nm. As shown in the figure 5.6 A, the 
absorption spectra of KAPAS shows two peaks at 345 nm and 425 nm, which are 
characteristic of the PLP form of the KAPAS (internal-aldimine) in non-coplanar and 
coplanar states, respectively. Addition of the first substrate, L-alanine shows an increase 
in the absorbance peak at 425 nm indicating the formation of external-aldimine complex 
of the enzyme with subsequent decrease in absorption at 345 nm (coplanar form of PLP). 
Further addition of pimeloyl-CoA to this enzyme-external-aldimine complex leads to the 
formation of the carbanion reaction-intermediate characterized by a third peak at 532 nm 
(Figure 5.6 B). 
To calculate the kinetic parameters of Mtb KAPAS for substrates L-alanine and 
pimeloyl-CoA, we performed the enzyme reaction with Ellman’s reagent (DTNB). 
Breakdown of pimeloyl-CoA to CoA-SH was monitored by measuring the increase in 
absorbance of resultant thiophenolate formation at 412 nm. The Km and Kcat values 
calculated for L-alanine were 400 μM and 7 x 10-3 /s and for pimeloyl-CoA were 4 μM 
and 9.1 x 10-3 /s, keeping the other substrate concentration constant, at room 
temperature. These values are quite similar to the values reported for Mtb enzyme by 
another group (194) but different from the values obtained for E. coli KAPAS (Km for L-
alanine is 900 μM and Km for pimeloyl-CoA is 70 μM). 
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FIGURE 5.6. Characterization of the KAPA synthase reaction intermediates. Absorbance spectra in the range of 300-600 
nm for (A) 10 μM KAPAS enzyme alone (blue) and a reaction mixture with 10 mM L-alanine after 30 sec (red) (B) 10 μM 
KAPAS + 10 mM L-alanine + 100 μM pimeloyl-CoA (0 sec-blue and 30 sec-pink). All the spectrophotometric experiments 
were conducted at room temperature.
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Conclusions 
In this chapter, we have described, in detail, the purification protocols for both 
His-tagged and wild type Mtb KAPAS, one of the interesting drug targets in the Mtb 
biotin biosynthetic pathway. We also tried to trouble-shoot some of the problems faced 
during the purification of this protein. To understand the catalytic behavior of this 
enzyme, preliminary biochemical characterization of KAPAS was carried out using 
spectroscopic methods. This analysis can be further utilized as an enzyme assay for 
inhibitor studies. Kinetic studies on Mtb KAPAS show that the Km values for the 
substrates L-alanine and pimeloyl-CoA are much lower than those of the E. coli enzyme. 
In addition, different crystallization trials of the apoenzyme and enzyme - 
substrate/product complexes were carried out for the determination of the three-
dimensional structures of this protein and we are awaiting the results. The active site in 
these KAPAS structures will further act as a template in virtual screening against the 
large compound libraries in search for a potent inhibitor. 
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CHAPTER VI 
CONCLUSIONS  
 
A better understanding of the physiology of Mycobacterium tuberculosis (Mtb) 
during its pathogenesis requires knowledge of the different metabolic pathways 
responsible for its survival. Research with Mtb is difficult because of its slow growth, 
clump formation in cultures due to its lipid-rich cell wall, biosafety level 3 work 
conditions, and the high cost of maintaining the animal models. However, the 
availability of the genome sequence of Mtb and the different genetic approaches to study 
them has paved our way towards the elimination of this organism. Different genetic 
methods have indicated the importance of various metabolic pathways, including the 
serine and biotin biosynthetic pathways, in the survival of Mtb during different stages of 
its pathogenesis. In this regard, we have studied the first enzyme of the serine and first 
three enzymes of the biotin biosynthetic pathways in Mtb. We had the opportunity to 
analyze three different classes of enzymes: oxido-reductase, transferase, and ligase, 
using different X-ray crystallographic techniques. 
In the first step of phosphorylated serine biosynthesis, D-3-phosphoglycerate 
dehydrogenase (PGDH) catalyzes the reversible oxidation of D-3-phosphoglycerate to 
hydroxypyruvic acid phosphate (HPAP), using NAD+ as a cofactor. Although this 
enzyme has been extensively studied in E. coli, Mtb PGDH has not been characterized to 
date. Mtb PGDH differs from E. coli PGDH in having an insertion of 130 amino acids 
near its C-terminus. In Chapter II of this dissertation, studies of the structure–function 
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relationship of PGDH in Mtb have been carried out in collaboration with Dr. Gregory A. 
Grant (Washington University School of Medicine, St. Louis, MO). Mtb PGDH was 
cloned, purified and further characterized, both structurally and biochemically. The 
three-dimensional structure of this 529-residue protein was determined in a nonstandard 
way. Since this protein lacked any methionine other than the starting one, this residue 
was introduced in the protein by mutating Ile514, located in the regulatory domain. This 
mutant was selected based on its sequence alignment with E. coli PGDH. We were able 
to obtain the phase information with only one selenomethionine residue in this 529 
amino acid protein, well below the theoretically estimated value of one methionine 
residue per 100 amino acids for phase determination (97). The reason we could get phase 
information with one selenomethionine might be a result of a highly redundant data (14-
fold) and a high symmetry space group (P6522) for this PGDH crystal. The resulting 2.3 
Å Mtb PGDH apostructure shows somewhat different domain organization in its 
monomer due to the presence of the insertion in comparison to E. coli PGDH. 
Superimposition of chain A on chain B in the asymmetric unit shows two different 
conformers. This conformational change between the adjacent subunits in the 
asymmetric unit is in the form of a 160º rotation and flipping of the nucleotide binding 
and substrate binding domains in relation to the intervening and regulatory domains. The 
pivot point for this change is located in a stretch of three glycine residues (316-318) on 
the long loop region, which connects both the nucleotide- and the substrate-binding 
domain to the intervening and the regulatory domain. Thus, the PGDH tetramer is 
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arranged in an asymmetric manner, generated by the heterodimer with a 
noncrystallographic two-fold axis.  
Because of the two different structural conformers, the cofactor-binding site in 
this dehydrogenase exists in two different environments: one inside a channel and the 
other as an open cleft. The presence of two different NADH-binding sites was further 
verified by stopped flow fluorescence spectroscopic experiments (78). Failure to trap the 
cofactor at the active site of Mtb PGDH structures was a result of the presence of the 
loop (203-213) blocking the cofactor-binding site in chain B due to the symmetry related 
molecule. Also, the causes for the weak cofactor binding were the high salt 
concentration (1 M NaK tartrate) present in the crystallization solution and the high ionic 
strength of the protein storage buffer (100 mM potassium phosphate). This fact is also 
supported by the stopped flow fluorescence analysis of NADH-binding in high ionic 
strength buffer (78).  
A 2.4 Å crystal structure of a binary complex of Mtb PGDH with the substrate 
HPAP pinpointed certain residues in the active site responsible for the enzyme activity. 
These residues (Arg 51, Arg132, and Arg233), which interact with HPAP, are mostly 
conserved in both E. coli and human PGDH. All the positively charged residues at the 
active site are oriented inwards to facilitate in the binding of the negatively charged 
substrates (HPAP and PGA). This structure also identified the His280 and Glu262 
residues at the active site which act as a catalytic dyad in dehydrogenases. In this 
complexed structure, we did not see the productive form of the enzyme due to the 
absence of a cofactor. However, comparison of this structure with the human truncated 
  
193
 
 
PGDH (with the bound substrate analog malate) provided us with a model for the 
resulting conformational changes at the active site cleft during hydride transfer. This 
change is in the form of a 15º rotation of the substrate-binding domain with respect to 
the nucleotide-binding domain which prevents solvent exposure during hydride transfer. 
Fluorimetric studies also indicate that the binding of NADH is facilitated by the presence 
of substrate in the active site, resulting in the conformational changes needed for 
catalysis. Thus, the order of substrate binding in Mtb PGDH is HPAP first and then 
NADH, which is the reverse of E. coli PGDH. 
Presence of tartrate bound to the intervening domain of Mtb PGDH provided us 
insights into a possible role for this domain (64). The role of tartrate as a physiological 
ligand is ruled out, as Mtb does not require tartrate in any metabolic reaction. However, 
this binding provided us a hint about the role of the intervening domain as a site for 
HPAP-binding due to its structural resemblance to tartrate. Mtb PGDH is 
uncompetitively inhibited at higher HPAP concentrations (250 μM) (128). This type of 
substrate inhibition has also been reported in rat liver PGDH which contains an 
intervening domain (29) but not in E. coli PGDH which lacks this domain. The HPAP-
binding site is termed an anion-binding site since all the positively charged residues from 
the intervening and regulatory domain interface converge to interact with HPAP. 
Mutational studies on these residues involved in HPAP binding (R446A, H447A, 
R451′A, R501′A, and L439′A) demonstrate reduced substrate inhibition (′ indicates the 
residue is from adjacent subunit). Triple mutation of the residues from one subunit 
(R451A, R501A, L439A) resulted in complete elimination of the substrate inhibition 
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(128). This kind of second substrate-binding site may be needed for additional regulation 
of this enzyme during Mtb infection of macrophages and can be used as a site for 
inhibitor design.  
Kinetic studies have also shown that Mtb PGDH is subject to feedback inhibition 
by the end product, L-serine, with an IC0.5 of ~30 μM. It exerts V-type inhibition and 
exhibits a mixed noncompetitive type of inhibition (64). This allosteric regulation shows 
cooperativity with a Hill coefficient of 2. In agreement with the kinetic data, the serine-
bound structure of Mtb PGDH revealed the presence of two serine molecules at the 
interface of the regulatory domains due to a non-crystallographic two-fold axis. This 
allosteric site is approximately 35 Å away from the active site. This structure also 
pinpointed the residues involved in the interaction with serine (Tyr461, Asp463, and 
Asn481′), which are not conserved in E. coli except for Asn481′. Mutation of any of 
these residues resulted in greatly reduced serine inhibition. Mutation of Asn481′ from 
the adjacent subunit (N481′A) also resulted in a loss of cooperativity for serine binding 
(78) which suggests that the hydrogen bonding of Asn481′ with serine strengthens the 
regulatory domain interface. There are no major conformational changes in the form of 
domain movements on serine binding in comparison to the apostructure. However, local 
changes at the allosteric site in the form of flipping of the side chains of Asp463 and 
Arg464 as well as change in side chain orientation of Asn481′ occurs with serine binding 
in contrast to the movement of a loop in E. coli PGDH. This flipping of the side chain 
results in the closure of the allosteric site channel present at the regulatory domain 
interface, resulting in hiding serine from solvent exposure. Finally, this structural 
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analysis also suggested that Mtb PGDH may not follow the same mechanism for serine 
inhibition as its E. coli counterpart. Thus, all this information gained from structural 
studies on serine feedback inhibition in Mtb PGDH will further assist in understanding 
the mechanism of allosteric regulation in other members of this extended form of PGDH 
as well as in other proteins which possess the ACT domain. Also, due to the human 
PGDH insensitivity to serine, this allosteric site in Mtb PGDH can act as a template for 
inhibitor design using fragment based library. 
Furthermore, these structural and kinetic studies of Mtb PGDH indicate that it is 
closely related to the mammalian PGDH (presence of intervening domain, substrate 
inhibition, etc). Nonetheless, Mtb PGDH is inhibited by L-serine which suggests that it 
also possesses metabolic properties similar to E. coli PGDH. These observations indicate 
that the Mtb PGDH is a link between the E. coli and the mammalian enzymes (64). The 
phylogenetic tree of PGDH from various organisms, generated by Ali et al., also 
supports this idea (22).  
Human PGDH is not inhibited by L-serine. Sequence alignment of human PGDH 
with Mtb PGDH shows a lot of variation in the two enzymes (sequence identity 33%) 
even though both belong to the same form of PGDH containing an intervening domain. 
Determination of the three-dimensional structure of human PGDH will elucidate the 
differences in domain and subunit organization in this enzyme in comparison to Mtb. 
This structure will also provide us a hint on the role of the C-terminal region, as this 
enzyme does not show regulatory properties. In this regard, we have discussed the 
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cloned, purified and set up crystallization trials in preparation for the structure 
determination. 
The focus of the second part of this dissertation was on the characterization of 
the enzymes participating in different steps of the biotin biosynthetic pathway using 
biochemical and X-ray crystallographic techniques. Biotin acts as a cofactor in various 
important metabolic pathways in Mtb. Various genetic studies have also indicated the 
importance of the enzymes of the biotin biosynthetic pathway in mycobacterium survival 
during infection in macrophages (8) as well as in mice (9). The fact that humans lack 
homologs of these enzymes makes them excellent targets for antibiotic development. 
Knockout studies on the bioF gene in the Mtb H37Rv strain show that absence of 
this gene, which codes for the first enzyme 7-keto, 8-aminopelargonic acid (KAPA) 
synthase (KAPAS) in the biotin biosynthetic pathway, results in complete clearance of 
mycobacterium in mice (9). This enzyme catalyzes the simultaneous decarboxylation 
and transamination of pimeloyl-CoA to KAPA, requiring pyridoxal 5′-phospahte (PLP) 
as a cofactor. We have discussed cloning and protein purification procedures as well as 
biochemical characterization of Mtb KAPAS in chapter V. This will further help in 
three-dimensional structure determination as well as in designing enzyme assays for 
inhibitor studies. Our studies show that this enzyme exists as a dimer of 80 kDa in 
solution and has a much higher substrate affinity than its E. coli counterpart. 
 In chapter III, examination of the 2.2 Å crystal structure of the second enzyme in 
biotin biosynthesis, 7, 8-diaminopelargonic acid (DAPA) synthase (DAPAS) in Mtb, 
revealed folds similar to those in E. coli DAPAS. This DAPAS structure was determined 
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using the molecular replacement technique. This enzyme catalyzes the transamination 
reaction of KAPA to DAPA. In this process, it requires PLP as a cofactor and utilizes a 
unique amino donor, SAM. Structural homology with other members of subclass II 
aminotransferases confirms its membership in this subclass. Despite the fact that the 
structure of E. coli DAPAS was known, its mode of dual-substrate (SAM and KAPA) 
recognition was a mystery to date. This question was answered by determining the 
structure of the ternary complex of Mtb DAPAS with PLP and the SAM analog 
sinefungin. Residues from both the subunits of the dimer contribute to the active site 
formation. Comparison of this structure with a model of KAPA complexed Mtb DAPAS 
provided us insights into the mechanism of substrate recognition in this particular 
aminotransferase enzyme, which is quite different from other enzymes of the subclass II. 
The substrate-bound structures identified the important active site residues involved in 
catalysis, also present in E. coli. Besides the residues Tyr157, Asp160, Arg400 involved 
in substrate binding at the active site, we recognized Tyr25 to be a key player in 
substrate recognition, both in positioning KAPA for amino group acceptance as well as 
in stabilizing the adenine ring of SAM by providing platform for stacking interactions. 
This fact was further confirmed by constructing the Y25A mutant, which did not show 
any DAPAS activity with the amino donor SAM. However, the reverse of the second 
half reaction of DAPAS with product DAPA showed only 70% activity. Furthermore, in 
an effort to identify potent inhibitors for Mtb DAPAS, virtual screening of large 
compound library has been attempted against the active site of a KAPA bound DAPAS 
model.  
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Certain Bacillus species as well as Brucella melitensis, Leptospira interrogans, 
and Aquifex aquenox lack this Tyr residue in the 25th position at the active site; instead, 
they have a Phe at a corresponding position in the protein sequence. This raises 
questions about the maintenance of the enzyme activity needed for the survival of these 
organisms, as it is evident from the previous paragraph that Tyr25 plays an important 
role in substrate recognition. The amino donor SAM can still bind at the active site since 
Phe can have stacking interactions with the adenine ring. However, an alternate binding 
mode for the substrate KAPA at the active site in the absence of the Tyr residue was 
unraveled on determination of the KAPA-bound B. subtilis DAPAS structure. The 
KAPA-bound form of DAPAS structure, as well as, the apoform and the PLP-enzyme 
complex structure in B. subtilis were solved using molecular replacement with Mtb 
DAPAS as the search model (sequence identity 32%). Interestingly, the active site in the 
apostructure as well as the PLP-bound structure contains a large peptide segment 
(Lys143-Glu172) which is disordered. The active site in Bacillus gets ordered only on 
the binding of the substrate KAPA, emphasizing the need for the hydrogen bond 
network of Tyr25:Tyr157:Asp160 (Mtb numbering) for the maintenance of the DAPAS 
active site.  
Chapter IV described the three-dimensional structure of the 1.85 Å Mtb 
dethiobiotin synthetase (DTBS) apoenzyme, the third enzyme in the biotin biosynthetic 
pathway. This enzyme catalyzes the formation of dethiobiotin from DAPA. This 
apoenzyme structure was determined using a single anomalous dispersion method with 
samarium at wavelength of 1.54 Å (Cu Kα). We utilized the strong anomalous behavior 
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of the Lanthanide metals at this wavelength. The differences in the local structural 
conformations of Mtb DTBS in comparison to E. coli and H. pylori DTBS were 
discussed in this chapter. The substrate and the product bound Mtb DTBS structures 
identified the key residues involved in catalysis, some of which are not conserved in the 
E. coli counterpart. These structures also illustrated that one of the substrates DAPA, as 
well as, the product DTB both bind in a hydrophobic pocket formed by residues from 
both the subunits of the dimer whereas the other substrate ATP binds in an open cleft 
made up of residues from a single subunit. The DAPA-bound Mtb DTBS structure 
further indicated the preference for carbamate formation at the N7 position of DAPA. 
Analyses of the substrate and the product complexed DTBS structures, and of the site 
directed mutagenesis of active site residue (D47A) have further helped us to elucidate a 
possible mechanism of enzyme action in a rather solvent exposed active site. 
With this knowledge of the active site architecture and biochemical 
characterization in these enzymes (KAPAS, DAPAS, and DTBS) in biotin biosynthesis 
and the mode of binding of substrates and natural inhibitors, we now have a starting 
point for designing new inhibitors against these enzymes, with the goal of eradication of 
Mycobacterium tuberculosis.  
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